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 Men ought to know that from the brain and from the brain only arise our pleasures, 
joys, laughter, and jests as well as our sorrows, pains, griefs and tears. ... It is the 
same thing which makes us mad or delirious, inspires us with dread and fear, whether 
by night or by day, brings us sleeplessness, inopportune mistakes, aimless anxieties, 
absent-mindedness and acts that are contrary to habit...    
         Hippocrates (Fifth century B.C.) 
 
Abstract  
Development of the human brain occurs in a number of complex pre- and 
postnatal stages which are governed by both genetic and environmental factors. 
Aberrant brain development due to inherited defects may result in a wide 
spectrum of neurological disorders which are commonly encountered in the 
clinical field of paediatric neurology. In the work for this thesis, I have 
investigated the molecular basis and defined the clinical features of three 
autosomal recessive neurological syndromes. I studied a cohort of children with 
early onset epileptic encephalopathy and, in one family, identified a novel 
homozygous pathogenic mutation of PLCB1. I have also utilised autozygosity 
mapping techniques to study consanguineous families with a complex motor 
disorder, infantile parkinsonism-dystonia, and identified loss-of-function 
mutations in the gene encoding the dopamine transporter (SLC6A3). 
Subsequent acquisition of a cohort of similarly affected children allowed detailed 
clinical and molecular characterisation of this novel disorder, dopamine 
transporter deficiency syndrome. Finally I have delineated the clinical and 
genetic features of PLA2G6-associated neurodegeneration. The identification of 
disease-causing genes contributes greatly to understanding the disease 
mechanisms underlying such early-onset disorders, and also provides novel 
insights into normal human neurodevelopment. 
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1.1 Introduction and overview 
„The task of neural science is to explain behaviour in terms of the activities of the brain. 
How does the brain marshal its millions of individual nerve cells to produce behaviour, 
and how are these cells influenced by the environment...? The last frontier of the 
biological sciences – their ultimate challenge – is to understand the biological basis of 
consciousness and the mental processes by which we, perceive, move, think and 
remember‟ 
   Eric Kandel (Recipient of the Nobel Prize for Medicine, 2000) 
 
  
 
Molecular biology has provided important insights into human brain function, 
predominantly by expanding knowledge on how the brain develops, how nerve 
cell communicate, how different patterns of neural interconnections give rise to 
a variety of motor acts and human perceptions, and how communication 
between neurons are modified by human experiences and diseases. 
At a molecular level, advances in neural science have been achieved in a 
number of ways (Kandel et al., 2000a). The characterisation of ion channel 
structure and function has greatly facilitated the analysis of neurobiological 
problems. Structural studies have also deepened the understanding of 
membrane receptors coupled to intracellular secondary messenger systems, 
and the role of these systems in modulating the physiological responses of 
nerve cells.  
With the possible exception of trauma, it is quite possible that every disease 
affecting the human nervous system has some inherited component, ranging 
from monogenic inheritance to genetic susceptibility. Advances in molecular 
biology, (such as the Human Genome Project and whole genome sequencing) 
have certainly facilitated the identification of genes contributing to specific 
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neurological disorders. Characterisation of genes encoding ion channels, 
membrane proteins/receptors, growth factors, transcriptional regulatory factors 
and cell/substrate adhesion molecules have transformed the study of 
neuroscience from a descriptive discipline into a mechanistic one. Indeed, the 
molecular mechanisms underlying the assembly of functional neuronal circuitry 
(including the specification of cell fate, cell migration, axonal growth, target 
recognition and synapse formation) are increasingly understood. The ability to 
develop genetically modified organisms (such as zebrafish, mice and primates) 
has additionally allowed us to elucidate how single gene defects may cause 
neurological abnormalities at both a gross phenotypic and cellular/molecular 
level. Such animal models have also greatly contributed to understanding the 
pathogenic mechanisms underlying human neurological diseases. 
For the work described in this thesis, I have utilised my skills as a paediatric 
neurologist to accurately phenotype and categorise children with complex 
neurological disorders. I have subsequently undertaken molecular genetic 
investigation in order to identify disease-causing genes and define the clinical 
spectrum of such genetic disorders. I will describe one epilepsy syndrome 
(PLCB1-infantile epileptic encephalopathy) and two predominantly 
extrapyramidal syndromes affecting the basal ganglia (dopamine transporter 
deficiency syndrome and PLA2G6-associated neurodegeneration). 
Understanding the molecular and cellular mechanisms underlying the 
pathophysiology of these neurological syndromes will enhance the knowledge 
of brain development and neural function, and can also facilitate the future 
development of novel therapeutic strategies. 
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In this introductory chapter, I will briefly describe the salient features of normal 
and abnormal brain development (and the wide variety of associated 
monogenic neurological diseases). I will also summarise the evolution of 
paediatric neurology as a distinct clinical specialty, and provide an overview of 
the breadth of neurological disorders encountered in this field, with a focus on 
epilepsy and movement disorders (relating directly to diseases investigated in 
this thesis). The general principles of gene mapping will also be discussed. 
1.2 Normal and abnormal brain development 
Monogenic defects may affect the developing brain at any stage of pre- and 
postnatal neural development, leading to a wide spectrum of neurological 
disorders. The major stages of normal brain development and some examples 
of genetic defects causing aberrant brain development are summarised in Table 
1-1. Each developmental phase is also briefly discussed below (Volpe, 2008a; 
Volpe, 2008b).  
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Table 1-1 
Major events in development of the human brain (adapted with data from Volpe 2008a; Volpe, 2008b), and some 
examples of single gene defects causing aberrant brain development 
Developmental Phase Single gene defects References 
Primary neurulation  
(Peak time 3-4 weeks gestation) 
 
 
 
 
Craniorachischisis totalis   A variety of neural tube defects may be caused by:-  
Anencephaly   Variants in genes MTHFR, MTRR, MTHFD1 Greene et al., 2009 
Myeloschisis   VANGL1,VANGL2 Lei et al., 2010; Kibar et al., 2007, 2009 
Encephalocoele   COL18A1 (Knobloch syndrome) Sertie et al., 2000 
Myelomeningocoele   MKS1, RPGRIP1L (Meckel syndrome) Kyttala  et al., 2006; Delous et al., 2007 
Prosencephalic development 
(Peak time 2-3 months gestation) 
 
 
 
 
Atelencephaly SIX3 Wallis et al., 1999 
Holoprosencephaly SIX3, SHH, TGIF, ZIC2 PTCH1,TGDF1, FAST1, GLI2 Wallis and Muenke, 2000 
Agenesis of the corpus callosum Many syndromes e.g. ARX (XLAG), L1CAM (CRASH) Paul et al., 2007 
Septo-optic dysplasia HESX1 Thomas et al., 2001 
Development of the cerebellum  
(Peak time 2-3 months gestation) 
Many diseases, examples including:- 
 
 
Dandy Walker malformation ZIC1, ZIC4 Grinberg et al., 2004 
Joubert syndrome NPHP1, CEP290, AHI1,TMEM67 Parisi et al., 2008 
Neuronal proliferation 
(Peak time 2-4 months gestation) 
 
 
 
 
Primary microcephaly MCPH1, CDK5RAP2, ASPM, CENPJ, STIL Thornton et al., 2009 
Macrocephaly PTEN, VG5Q, NSD1, FMR1, Williams et al., 2008 
Neurocutaneous syndromes NF1  Williams et al., 2008 
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Neuronal migration  
(Peak time 3-5 months gestation) 
 
 
 
 
Schizencephaly EMX2 Brunelli et al., 1996 
Lissencephaly 
Type I: PAFAH1B1, RELN, TUBA1A, VLDLR, DCX, ARX  
Type II:POMT1, POMT2, FKRP, LARGE  
Spalice et al., 2009 
Vajsar et al., 2006 
Pachygyria TUBA1A Poirier et al., 2007 
Band heterotopias PAFAH1B1, FLNA, ARFGEF2 Spalice et al., 2009 
Polymicrogyria SRPX2, PAX6, TBR2, KIAA1279, RAB3GAP1, COL18A1 Spalice et al., 2009 
Focal cerebrocortical dysgenesis ?Variants of TSC1 Spalice et al., 2009 
Organisation  
(Peak time 5 months gestation-postnatal) 
Spectrum of disorders including:- 
 
 
Mental retardation (with/ without seizures)  
Many, including ARX 
ARHGEF6, OPHN1, PAK3 
Bienvenu et al., 2002  
Chechlacz and Gleeson 2003 
Rett syndrome  MECP2 Amir et al., 1999 
Angelmans syndrome UBE3A Kishino et al., 1997 
Myelination  
(Peak time Birth-several years postnatal) 
Disorders of dysmyelination include:- 
 
 
Perlizaeus-Merzbacher disease PLP1 Hodes et al., 1993 
Perlizaeus-Merzbacher like disease GJC2 Bugiani et al., 2006 
Krabbe‘s disease GALC Sakai et al., 1994 
Metachromatic leukodystrophy  ARSA Polten et al., 1991 
Canavan disease ASPA Kaul et al., 1993 
Alexander disease GFAP Brenner et al., 2001 
Vanishing white matter disease EIF2B1, EIF2B2, EIF2B3, EIF2B, EIF3B5 Van der Knaap et al., 2002 
Megalencephalic leukoencephalopathy with 
subcortical cysts 
MLC1 Ilja Boor et al., 2006 
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1.2.1 Primary neurulation 
Primary neurulation refers to the formation of the neural tube at week 3-4 of 
gestation (Volpe, 2008a). The nervous system originates from the dorsal aspect 
of the embryo as a plate of tissue differentiating from the central ectoderm. The 
underlying notochord and chordal mesoderm induce formation of the neural 
plate (~ day 18). The chordal mesoderm then induces dorsal invagination of the 
lateral margins of the neural plate, thus forming the neural tube, which gives 
rise to the central nervous system (CNS). At a molecular level, surface 
glycoproteins, cell-cell recognition and adhesive interactions with the 
extracellular matrix are believed to play an important role in adhesion of the 
neural folds. The action of specific regional patterning genes (bone 
morphogenetic proteins and sonic hedgehog) homeobox genes, surface 
receptors and transcription factors is also contributory. Animal studies have 
recently demonstrated an essential role for the planar cell polarity pathway in 
mediating a morphogenetic process called convergent extension during neural 
tube formation (Kibar et al., 2007). During neural tube closure, neural crest cells 
form and give rise to dorsal root ganglia, sensory ganglia of the cranial nerves, 
autonomic ganglia, Schwann cells and cells of the pia and arachnoid.  
Interaction of the neural tube with the surrounding mesoderm gives rise to the 
dura and axial skeleton (skull and verterbrae).  
Disturbance of primary neurulation is associated with a number of brain 
malformations (Table 1-1). The underlying aetiology is often complex and 
multifactorial. Environmental components (such as folate deficiency and 
teratogens such as thalidomide and anti-epileptic agents) may play a role. 
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Single gene defects (Table 1-1) and chromosomal abnormalities (such as 
chromosomal trisomies and duplications) are also reported (Volpe, 2008a). 
1.2.2 Prosencephalic development 
Prosencephalic development begins at 5-6 of gestation and occurs in three 
sequential stages which result in formation of much of the face and forebrain 
(Volpe, 2008a):- 
a. Prosencephalic formation (week 5-6) from the rostral end of the neural tube.  
b. Prosencephalic cleavage (week 5-6) involves horizontal cleavage (forming the 
paired optic vesicles, olfactory bulbs and tracts), transverse cleavage (to 
separate the telencephalon from the diencephalon) and sagittal cleavage (to 
form the paired cerebral hemispheres, lateral ventricles and basal ganglia from 
the telencephalon). 
c. Midline prosencephalic development (month 2-3), with formation of the 
commissural, chiasmatic and hypothalamic plates. These structures form the 
corpus callosum/septum pellucidum, optic nerve chiasm and hypothalamus 
respectively. 
 
Forebrain development is governed by dorsoventral patterning molecular 
pathways, including the sonic hedgehog signalling pathway and the nodal 
pathway. Aberrant prosencephalic development may arise from a number of 
genetic defects (Table 1-1). 
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1.2.3 Development of the cerebellum 
Development of the cerebellum will be discussed in this section as the critical 
embryonic time period is in parallel with prosencephalic development. The 
primordia of the cerebellar hemispheres appear in week 5 as bilateral 
thickenings of the dorsal surface of the rhombencephalon (Ten Donkelaar and 
Lammens, 2009). By continued growth of this region, the primitive vermis and 
cerebellar hemispheres become apparent. Progenitor cells in the subependymal 
germinative zones of the rhombic lip generate neurons that migrate radically (to 
form the dentate nucleus, other nuclei and the Purkinje cells) and migrate 
tangentially over the surface of the cerebellum to produce the external granule 
cell layer. Cells from this external granular layer will then migrate inward 
through the Purkinje cells and form the internal granule cells of the mature 
cerebellum.  
 
Inherited cerebellar malformations are diverse and extensive and include 
disorders of the vermis (such as Joubert syndrome, Table 1-1) as well as those 
primarily involving the cerebellar hemispheres (such as lissencephalies with 
cerebellar hypoplasia, congenital muscular dystrophies and metabolic 
disorders). 
 
1.2.4 Neuronal proliferation 
Major proliferative events occur between 2-4 months of gestation (Volpe, 
2008b). All neuronal glia are derived from the ventricular and subventricular 
zones, present in the subependymal location at every level of the developing 
nervous system. Phase 1 (between 2-4 months) is concerned with the 
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generation of radial glia and neuronal proliferation. Phase 2 (from 5 months 
gestation to ~11 months after birth) is associated primarily with glial 
proliferation. The proliferative events (involving the radial glial cells as neuronal 
progenitor cells) are modulated by several key signalling pathways involving the 
Notch receptor, the ErbB receptor (through the ligand neuregulin) and the 
fibroblast growth factor receptor (Ever and Gaiano, 2005). Other critical 
molecular determinants include beta-catenin, a protein that functions in the 
decision of progenitors to proliferate or differentiate (Chenn and Walsh, 2002). 
Radial glial cells are progenitors for many neuronal cell types (cortical neurons, 
astrocytes, oligodendrocytes and neural stem cells) and also guide for neuronal 
migration. Genetic disorders of neuronal proliferation include the primary 
microcephaly syndromes as well as disorders of macrocephaly and 
neurocutaneous syndromes (Table 1-1). 
 
1.2.5 Neuronal migration 
Neuronal migration refers to the process by which millions of nerve cells move 
from their sites of origin in the ventricular and subventricular zones to other loci 
within the CNS (Valiente and Marín, 2010). The peak time period is from 3-5 
months gestation. Within the cerebrum, radial migration results in formation of 
the projection neurons of the cortex. Tangenital migration form GABA (γ-
aminobutyric acid)-expressing interneurons of the cerebral cortex. Radial glial 
cells guide this process of migration. There are a number of key molecular 
determinants of neuronal migration, summarised in Table 1-2. 
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A wide variety of neuronal migration disorders are caused by single gene 
defects including schizencephaly, lissencephaly, pachygyria, polymicrogyria, 
heterotopias and focal cerebrocortical dysgenesis (Table 1-1). In the more 
severe disorders of neuronal migration, seizures may be a prominent early 
clinical feature. 
 
Table 1-2 
Molecular determinants of neuronal migration (adapted from Volpe, 2008b) 
 
 
 
 
1.2.6 Organisation 
Organisational events occur from about 5 months gestation to several years into 
postnatal life. During organisation, there is establishment and differentiation of 
the subplate neurons (SPN) (Kanold and Luhmann, 2010). These SPNs 
function as the site of synaptic contact for ‗waiting‘ thalamocortical and 
corticocortical afferents before formation of the cortical plate. SPNs provide a 
functional link between ‗waiting afferents‘ and cortical targets, have a role in 
Preplate neurons and extracellular matrix Fibronectin 
 Chondroitin 
 Heparan sulphate 
 Fukutin proteoglycans 
 GABA receptors 
 Integrins 
 Laminin 
 Reelin 
Radial Glia Erb B4 receptors 
 Brain lipid binding protein (BLBP) 
Migrating Neurons Notch receptors 
 Neuregulin 
 Astrotactin 
 Doublecortin 
 Platelet activating factor acetohydrolase subunit 1 
 Filamin 1 
 Cyclin dependent kinase 5 
 Neural cell adhesion molecule (NCAM) 
 N-methyl-D-aspartate (NMDA receptors) 
 Calcium channels 
 GABA receptors 
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axonal guidance into the cerebral cortex for ascending afferents and are also 
involved in cerebral cortical organisation and synaptic development. The next 
phases of organisation involve lamination (attainment of proper alignment, 
orientation and layering of cortical neurons), elaboration of dendritic and axonal 
ramifications and synaptogenesis. The factors that stimulate synaptic formation 
initially include activity-independent events (molecular mechanisms involved in 
targeting), followed by activity-dependent events (Klintsova and Greenough, 
1999). Modulation of ion channels (especially calcium-permeable channels by 
neurotransmitters such as glutamate) and modulation of cell surface receptors 
(by a variety of ligands) play an important role in this process. Selective 
apoptosis (programmed cell death) of neuronal process and synapses then 
occurs, mediated by the action of specific genes and their transcription factors 
(Bergeron and Yuan, 1998).  During this phase of brain development, glial 
proliferation and differentiation result in the formation of astrocytes, 
oligodendrocytes and microglia (Volpe, 2008b). 
 
Disorders resulting from abnormal neural organisation are less well understood. 
A primary disturbance of neural organisation is thought to be involved in a 
number of disorders resulting from monogenic defects (Table 1-1) and other 
aetiologies. Diseases include mental retardation with/without seizures, Rett 
syndrome, Down syndrome, Fragile X syndrome, Angelmans syndrome and 
Duchenne muscular dystrophy. Disrupted organisation may also contribute to 
the pathophysiology of brain abnormalities observed in prematurity and 
perinatal injury. 
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1.2.7 Myelination 
Myelination is a process by which axons develop a surrounding myelin 
membrane, creating an insulating layer that promotes fast conduction of nerve 
impulses (Thaxton and Bhat, 2009). The time period for myelination is long, 
beginning in the 2nd trimester of pregnancy and continuing into adult life. The 
fastest changes in myelination occur with the first 8 postnatal months. 
Myelination is nearly completed by 2 years of age. Initial proliferation and 
differentiation of oligodendroglial cells is followed by elaboration of the cell 
membrane to form the myelin sheath. Myelination is determined at a molecular 
level by a variety of growth factors, hormones cytokines, surface receptors and 
secreted ligands (Thaxton and Bhat, 2009). 
Aberrant myelination is seen in a wide variety of neurological disorders 
including demyelinating disorders (such as multiple sclerosis) and white matter 
diseases of dysmyelination. Examples of monogenic leukodystrophies include 
Perlizaeus-Merzbacher disease, Canavan disease, Alexander disease, 
metachromatic leukodystrophy and Krabbe‘s disease (Table 1-1). 
1.2.8 Summary 
As illustrated in Chapter 1.2, genetic defects impacting on brain development 
account for a variety of early-onset neurodevelopmental disorders. These 
conditions are associated with a wide spectrum of neurological symptoms and 
signs. From a practical perspective, the diagnosis and management of children 
affected with such disorders involves clinicians with an expertise in paediatric 
neurology.  
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1.3 Paediatric neurology 
‘Without patients, knowledge is only knowledge‟  Takasha Shiihara (2009) 
More than 100 years ago, long before paediatric neurology was established as 
a distinct clinical specialty, physicians from many different disciplines 
contributed to the evolution of this field (Millichap and Millichap, 2009). The 
biographies of most of these founders of paediatric neurology are included in 
books by Ashwal (1990) and Aird (1994). Obstetricians also contributed to this 
field by recognising the causal role of birth difficulties and prematurity in 
neonatal asphyxia and cerebral palsy (Little, 1862). Among the earliest 
contributors, Sigmund Freud, the psychiatrist, directed a clinic for such children 
with cerebral palsy and published on the definition and nature of this disorder in 
1897. Bernard Sachs, a neuropsychiatrist, wrote a landmark textbook of 
paediatric neurology in 1895, and also further contributed to the classification of 
cerebral palsy in 1926. In the 1930s, Ford, a neurologist, is remembered for his 
classic book, Diseases of the Nervous System in Infancy, Childhood and 
Adolescence which, in context, was an incredible achievement, written almost 
quarter of a century before the formal evolution of the clinical specialty. In the 
1950s, several academics and clinicians developed specialty clinics for children 
with neurological disorders and wrote extensively on childhood epilepsy, 
cerebral palsy, and meningitis. In the 1960s paediatric neurology was 
recognised as a distinct subspecialty within the field of neurology. 
The field of paediatric neurology has rapidly expanded over the last 50 years. In 
the UK, there are ~90 consultant paediatric neurologists [British Paediatric 
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Neurology Association (BPNA) secretariat, personal communication, 2010]. 
Paediatric neurology involves the care of children and adolescents with acute, 
recurrent and chronic disorders of the nervous system. Clinical fields include 
neonatal neurology, cerebral palsy, neurometabolic disorders, neurocutaneous 
syndromes, epilepsy, disorders of balance and movement, grey and white 
matter diseases, brain injury, tumours, vascular diseases, neuromuscular 
disorders and neurological impairment in systemic diseases. In Chapter 1.4 and 
1.5, I will focus on the features of two specific areas of paediatric neurology 
pertaining to the disease described in this thesis: (i) epilepsy and (ii) movement 
disorders associated with basal ganglia dysfunction. 
1.4 Epilepsy 
1.4.1 Epidemiology 
Epilepsy is one of the oldest conditions known to mankind and it is still the most 
common neurological disorder – at any given time it is estimated that 50 million 
people worldwide have a diagnosis of epilepsy (WHO, 2001b). The worldwide 
prevalence is estimated at 2.7—17.6 per 1000, with the highest incidence in 
infancy/early childhood and old age (Banerjee et al., 2009). 
1.4.2 Definitions 
The epilepsies: a group of neurological disorders characterised by recurrent 
epileptic seizures which are unprovoked by any immediate identified cause 
(ILAE, 1993). 
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Epileptic seizure: a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain. (Fisher et al. 
2005). 
Electroencephalogram (EEG): a graphical record of the electrical activity of 
the brain (usually taken from surface scalp electrodes) produced by an 
electroencephalograph. EEG recordings may be ictal (when electrical activity 
during a seizure event is captured on EEG) or interictal (EEG recording 
undertaken between seizures). The EEG may be helpful towards diagnosing 
epilepsy or an epilepsy syndrome and may also give a crude insight into overall 
brain function. A sleep EEG recording may also be useful for the diagnosis of 
certain epilepsy syndromes (El Shakankiry, 2010). 
Epilepsy syndrome: an electroclinical syndrome characterised by clinical 
features, signs, and symptoms that together define a distinctive, recognizable 
clinical disorder. These often become the focus of treatment trials as well as of 
genetic, neuropsychological, and neuroimaging investigations. These are 
distinctive disorders identifiable on the basis of a typical age of onset, specific 
EEG characteristics, seizure types, and often other features which, when taken 
together, permit a specific diagnosis. The diagnosis in turn often has 
implications for treatment, management, and prognosis (Berg et al., 2010). 
Epileptic encephalopathy: a group of conditions where the epileptic activity 
itself may contribute to severe cognitive and behavioural impairments above 
and beyond what might be expected from the underlying pathology alone and 
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that these can worsen over time. These impairments may be global or more 
selective and they may occur along a spectrum of severity (Berg et al., 2010). 
1.4.3 Classification of epileptic seizures 
Seizures are mainly classified as either generalised or focal events (Berg et al., 
2010), as summarised in Table 1-3. 
 
Table 1-3 
Classification of the epilepsies (adapted from Berg et al., 2010) 
 
Generalised Tonic-clonic (in any combination) 
 Absence: 
Typical 
 Atypical 
 Absence with special features:  
Myoclonic absence 
Eyelid myoclonia 
 Myoclonic 
 Myoclonic-tonic 
 Myoclonic-atonic 
 Clonic 
 Tonic 
 Atonic 
Focal  
Unknown Epileptic spasms 
 
 
Generalised epileptic seizures are conceptualized as originating at some 
point within, and rapidly engaging, bilaterally distributed networks. Such bilateral 
networks can include cortical and subcortical structures, but do not necessarily 
involve the entire cortex.  
Focal epileptic seizures are conceptualized as originating within networks 
limited to one hemisphere. They may be discretely localized or more widely 
distributed. Focal seizures may originate in subcortical structures. For each 
seizure type, ictal onset is consistent from one seizure to another, with 
preferential propagation patterns that can involve the contralateral hemisphere. 
In some cases, however, there is more than one network, and more than one 
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seizure type, but each individual seizure type has a consistent site of onset. 
Focal seizures may be described and classified by whether they are (i) motor or 
sensory events or (ii) according to the region of the brain from which they 
originate (Figure 1-1), or (iii) whether they are accompanied by impairment of 
consciousness (Berg et al., 2010). 
 
Figure 1-1 
Schematic representation of the brain illustrating the possible origins and 
clinical symptoms of focal seizures 
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1.4.4 Classification of epilepsy syndromes  
A pragmatic classification of the various epilepsy disorders was proposed by the 
Task Force on Classification and Terminology (Engel, 2006) according to level 
of specificity and within those designations, by age where meaningful. An 
overview of epilepsy syndromes is given in Table 1-4. The specific epileptic 
encephalopathy syndromes occurring in children under <1 year of age are 
discussed in more detail in Chapter 3 (Table 1-4, boxed in red). No reference to 
aetiology is made in this classification system and indeed the same aetiology 
may give rise to a number of electroclinical syndromes (see Chapter 3). The 
classification is thus helpful for the diagnosis of age-dependent electroclinical 
syndromes and although it may direct further diagnostic investigations and 
management strategies, it is not an aetiological classification system reflecting 
the underlying basis of disease.  
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Table 1-4 
Classification of epilepsy (adapted from Engel, 2006) 
Neonatal period (< 4 weeks) Benign familial neonatal epilepsy (BFNE) 
 Early myoclonic encephalopathy (EME) 
 Ohtahara syndrome 
Infancy (<1 year) Epilepsy of infancy with migrating focal seizures 
 West syndrome 
 Myoclonic epilepsy in infancy (MEI) 
 Benign infantile epilepsy 
 Benign familial infantile epilepsy 
 Dravet syndrome 
 Myoclonic encephalopathy in non-progressive disorders 
Childhood (1-12 years) Febrile seizures plus (FS+) (can start in infancy) 
 Panayiotopoulos syndrome 
 Epilepsy with myoclonic atonic (previously astatic) seizures 
 Benign epilepsy with centrotemporal spikes (BECTS) 
 Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) 
 Late onset childhood occipital epilepsy (Gastaut type) 
 Epilepsy with myoclonic absences 
 Lennox-Gastaut syndrome 
 Epileptic encephalopathy with CSWS 
 Landau-Kleffner syndrome (LKS) 
 Childhood absence epilepsy (CAE) 
Adolescence–Adult (>12 years) Juvenile absence epilepsy (JAE) 
 Juvenile myoclonic epilepsy (JME) 
 Epilepsy with generalized tonic–clonic seizures alone 
 Progressive myoclonus epilepsies (PME) 
 Autosomal dominant epilepsy with auditory features (ADEAF) 
 Other familial temporal lobe epilepsies 
Less specific age relationship Familial focal epilepsy with variable foci (childhood to adult) 
 Reflex epilepsies 
Distinctive constellations Mesial temporal lobe epilepsy with hippocampal sclerosis  
 Rasmussen syndrome 
 Gelastic seizures with hypothalamic hamartoma 
 Hemiconvulsion–hemiplegia–epilepsy 
 Epilepsies that do not fit into any of these diagnostic categories 
can be distinguished first on the basis of the presence or 
absence of a known structural or metabolic condition (presumed 
cause) and then on the basis of the primary mode of seizure 
onset (generalized vs. focal) 
Structural-metabolic epilepsies Malformations of cortical development  
 Neurocutaneous syndromes 
 Tumour 
 Infection 
 Trauma 
 Angioma 
 Perinatal insults 
 Stroke 
 Etc. 
Conditions with epileptic seizures 
traditionally not given a diagnosis 
of epilepsy 
Benign neonatal seizures (BNS) 
 
 Febrile seizures (FS) 
Epilepsies of unknown cause  
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1.4.5 Mechanisms of epileptogenesis in the immature brain 
Epileptogenesis is defined as the process whereby a neuronal network 
develops recurrent epileptic seizures de novo or following an insult, and is also 
the process whereby seizures become more severe and frequent in chronic 
epilepsy (Rakhade and Jensen, 2009). Animal models of epilepsy and human 
tissue studies suggest that epileptogenesis involves a cascade of molecular, 
cellular and neuronal network alterations. 
1.4.5.1 Seizure susceptibility factors 
A number of factors regulating neuronal excitability have been implicated in the 
increased seizure susceptibility of the immature brain (Rakhade and Jensen, 
2009). 
(i) Enhanced excitation of the immature brain 
During synaptogenesis and brain development, excitation predominates over 
inhibition within neuronal networks of the cerebral cortex and limbic structures in 
the neonatal period and during the first few years of life (Sanchez and Jensen, 
2001). Excitatory ion channels and transporters are expressed at levels that 
promote excitation, whereas inhibition is relatively underdeveloped compared 
with later life. 
Glutamate is the predominant excitatory amino acid neurotransmitter in 
neurons. Glutamate receptors (GluRs) are developmentally regulated in 
neurons and glia (Silverstein and Jensen, 2007). Ionotropic GluRs (iGluRs) are 
ligand-gated ion channels that permit the flux of sodium, potassium and calcium 
ions to varying degrees, depending on their subunit make-up (Lau and Zukin, 
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2007). The main iGluR subtypes are N-methyl-D-aspartate receptors 
(NMDARs), α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors 
(AMPARs) and kainate receptors. The characteristic patterns of NMDAR and 
AMPAR subunit expression in the developing brain lead to increased calcium 
influx and extended current decay times (Lau & Zukin, 2007, Kumar et al., 
2002) which enhance excitability. This excitability is implicated in rapid 
physiological synaptogenesis that occurs during brain development, but also 
lowers the threshold for seizures in the immature brain.  
Glutamate also activates metabotropic GluRs (mGluRs), the G-protein-coupled 
receptors that mediate slow synaptic responses (Nakanishi, 1994). Compared 
with the iGluRs, less information is available regarding developmental 
regulation of mGluRs. Results from a study in rodents, however, showed that 
mGluR1 expression might peak in the first postnatal week, whereas mGluR2, 
mGluR3 and mGluR5 levels mature by the second postnatal week (Avallone et 
al., 2006). Agonists of group I mGluRs exert proconvulsant effects, suggesting 
that elevated levels of receptors from this group might have a role in early 
excitability. 
(ii) Diminished GABAergic inhibition in early life 
While the major inhibitory neurotransmitter γ-aminobutyric acid (GABA) is 
inhibitory and hyperpolarizing in the mature brain, it may be excitatory and 
depolarizing in the immature brain (Loturco et al., 1995). GABA release can 
activate GABAA receptors (GABAARs), which are ligand-gated chloride 
channels. In immature neurons, the intracellular chloride concentration is higher 
than the extracellular concentration, so GABAAR activation leads to an efflux of 
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such ions, thereby depolarizing the cell. This depolarizing effect is largely 
attributable to differences in expression of the chloride transporters in the 
immature brain (Dzhala et al., 2005). 
(iii) Excitability and ion channels 
Like ligand-gated receptors, voltage-gated ion channels affect neuronal 
excitability, and their expression is developmentally regulated. Mutations in 
genes coding for voltage-gated potassium, calcium and sodium channels are 
linked to early onset epilepsy disorders (see Chapter 1.4.6). 
1.4.5.2 The epileptogenic cascade 
It is postulated that epileptogenesis occurs via a number of major stages known 
as the ‗epileptogenesis cascade‘ (Rakhade and Jensen, 2009). Early acute 
changes include rapid alterations in ion channel activity, post-translational 
changes to existing proteins (for example, neurotransmitter receptors) and 
activation of immediate early genes (including Fos, Jun, Egr1, Egr4, Homer1, 
Nurr77, and Arc, Herdegen and Leah, 1998). The subacute period of hours to 
weeks can include processes such as activation of transcription, neuronal death 
and inflammation. Chronic changes that occur over weeks to months include 
anatomical alterations such as neurogenesis, mossy fibre sprouting, network 
reorganization, and gliosis. 
 
1.4.6 Genetics and epilepsy 
Since antiquity, it has been recognised that many types of epilepsy have an 
inherited component, as demonstrated by numerous twin studies, family 
aggregation studies and multiplex family studies (Helbig et al., 2008). Epilepsies 
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associated with a heritable component may be classified as either idiopathic 
epilepsies (absence of neurological deficits, intellectual disability, or brain 
lesions with no known/suspected external cause and suspected to have a 
genetic component) or symptomatic epilepsies (mainly secondary to 
neurodevelopmental defects). The symptomatic epilepsies of genetic origin are 
associated with a wide variety of neurodevelopmental genetic defects, including 
those causing defects in primary neurulation, prosencephalic development, 
neuronal proliferation, neuronal migration, organisation and myelination (as 
discussed in Chapter 1.2 and Table 1-1). In contrast, the idiopathic epilepsies 
are mainly associated with genetic defects of ion channels, the so-called 
‗channelopathies‘ (Mulley et al., 2003). The genes associated with idiopathic 
epilepsy syndromes are summarised in Table 1-5. 
Table 1-5 
Genes associated with the idiopathic epilepsies  
(adapted from Mulley et al., 2003) 
 
Epilepsy syndrome Gene Reference 
Benign familial neonatal seizures KCNQ2 Biervert et al., 1998 
Singh et al., 1998 
Dedek et al., 2001 
 KCNQ3 Charlier et al., 1998 
Benign familial neonatal-infantile seizures SCN2A Heron et al., 2002 
Generalised epilepsy, febrile seizures plus  
(Severe myoclonic epilepsy of infancy) 
SCN1A Escayg et al., 2000 
(Claes et al., 2001) 
 SCN1B Wallace et al., 1998 
 SCN2A Sugawara et al., 2001 
Autosomal dominant nocturnal frontal lobe epilepsy CHRNA4 Steinlein et al., 1995 
 CHRNB2 De Fusco et al., 2000 
 GABRG2 Baulac et al., 2001 
Autosomal dominant juvenile myoclonic epilepsy GABRA1 Cossette et al., 2002 
Autosomal dominant partial epilepsy with auditory features LGI1 Kalachikov et al., 2002 
Childhood absence epilepsy GABRG2 Wallace et al., 2001 
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Mutations of voltage-gated potassium channels interfere with the normal 
hyperpolarizing potassium ion current and promote repetitive action potential 
firing (Castaldo et al., 2002). Voltage-gated sodium channel abnormalities have 
also been implicated in a number of epilepsy syndromes (Table 1-5). To date, 
more than 300 mutations in SCN1A have been identified. Gain-of-function 
mutations are a primary cause of generalized epilepsy with febrile seizures-plus 
(GEFS+). Lossin et al. (2002) analysed the functional effects of three SCN1A 
mutations. The mutant forms affected channel inactivation leading to a 
persistent inward sodium current, suggesting the likely basis for in-vivo 
hyperexcitability. In contrast, most cases of severe myoclonic epilepsy of 
infancy (SMEI) result from loss-of-function SCN1A mutations and studies using 
mouse models suggest that there is selective loss of sodium ion currents and 
reduced excitability of GABAergic inhibitory interneurons, which leads to 
hyperexcitability, epilepsy and ataxia. (Escayg and Goldin, 2010). 
1.4.7 Summary 
From Chapter 1.2 and 1.4 it is evident that epilepsy may arise in association 
with a number of genetic defects. In Chapter 3, I will describe a patient with an 
infantile epileptic encephalopathy associated with a novel deletion of the gene 
PLCB1. PLCB1 is postulated to disrupt muscarinic acetylcholine receptor 
signalling, thereby affecting normal inhibitory neuronal circuitry and increasing 
seizure susceptibility. 
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1.5 Movement disorders and the basal ganglia 
1.5.1 Introduction 
Clinical observations first suggested the involvement of the basal ganglia in the 
control of movement and pathophysiology of movement disorders (Kandel et al., 
2000b). Post-mortem brain examinations of patients with Parkinson disease, 
Huntington‘s chorea and hemiballismus revealed pathological changes in these 
subcortical nuclei. This led to the conclusion that dysfunction of the basal 
ganglia could result in both hyperkinetic and hypokinetic movement disorders.  
Within the field of paediatric neurology, a number of movement disorders are 
encountered, in which the origin of disease is believed to be within the basal 
ganglia. Such diseases may clinically manifest as abnormal involuntary 
hyperkinetic disorders (including chorea, athetosis, ballismus, dystonia, 
myoclonus, tics and tremor) and also as hypokinetic phenotypes (such as 
bradykinesia in parkinsonism). Normal motor function may be significantly 
affected. The underlying causal factors of basal ganglia-related disorders are 
diverse, and include genetic defects, neurotransmitter imbalance, infection, 
post-infective phenomena and metabolic diseases, as well as a plethora of 
unexplained conditions. 
In clinical practice, the generic term ‗extrapyramidal disorders‘ is commonly 
used to describe this group of disorders. In this context, ‗extrapyramidal‘ refers 
to the concept that the dysfunctional system predominantly originates outside 
the pyramidal tract. This term, although didactically useful, is actually not wholly 
accurate. Indeed the pyramidal and extrapyramidal components interact and 
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share common pathways for the control of voluntary movement. The motor 
actions of the basal ganglia are mediated in large part through the 
supplementary, premotor and motor cortices via the pyramidal system. Indeed, 
complex interrelationships between the basal ganglia, cerebellum, thalamus 
and cerebral cortex (Figure 1-2) render the classification of ‗basal ganglia 
disease‘, although perhaps clinically useful, somewhat arbitrary.  
 
Figure 1-2 
Schematic representation of the major input and output connections of the basal 
ganglia (Adapted from Kandel, 2000b) 
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1.5.2 Neuroanatomy of the basal ganglia 
The basal ganglia consist of several interconnected subcortical nuclei with 
major projections to the cerebral cortex, thalamus and certain brainstem nuclei. 
They receive major input from the cerebral cortex and thalamus and send their 
output back to the cortex (via the thalamus) and to the brainstem (Figure 1-2). 
The four principal nuclei of the basal ganglia (illustrated in Figure 1-3) are (i) the 
striatum - caudate nucleus and putamen, separated by the internal capsule and 
ventral striatum which includes the nucleus accumbens (ii) the globus pallidus - 
internal segment, GPi, and external segment, GPe (iii) the substantia nigra pars 
reticulara and pars compacta and (iv) subthalamic nuclei. 
 
Figure 1-3 
Coronal section of the brain illustrating a schematic representation of the basal 
ganglia structures 
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1.5.3 Functional aspects of the basal ganglia  
Connections of the basal ganglia may be summarised as follows:- 
1.5.3.1 Input connections to the basal ganglia  
The major input to the basal ganglia is from excitatory glutaminergic projections 
from the cortex to the striatum. The striatum also receives excitatory projections 
from the thalamus, dopaminergic projections from the midbrain and 
serotonergic input from the raphe nuclei (Kandel, 2000b).  
The subthalamic nuclei receive direct cortical inputs, so is therefore considered 
another input station of the basal ganglia, in addition to the striatum. This 
‗hyperdirect‘ pathway (Figure 1-4) conveys strong excitatory signals from the 
cortex to the globus pallidus with faster conduction velocity than the striatal 
pathways. 
1.5.3.2 Output connections from the basal ganglia 
The two major basal ganglia output pathways are from the internal segment of 
the globus pallidus and from the substantia nigra. This inhibitory output is 
modulated by the direct and indirect pathway (Alexander and Crutcher, 1990; 
Nambu, 2008), which run from the striatum to the output nuclei (Figure 1-4). 
Dopaminergic projections from the substantia nigra pars compacta differentially 
modulate the activity of striatal projection neurons in the direct and indirect 
pathways. Dopamine excites striatal neurons in the direct pathway through 
dopamine D1 receptors while it inhibits striatal neurons in the indirect pathway 
through dopamine D2 receptors. 
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Figure 1-4 
Schematic representation of the hyperdirect, direct and indirect pathways of the 
basal ganglia 
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The direct pathway arises from GABAergic striatal neurons containing 
substance P and dynorphin. When the direct pathway is activated by phasic 
excitatory inputs (Figure 1-4), the tonically active neurons in the pallidum are 
suppressed, thus allowing the cortex to be activated. The direct pathway thus 
provides positive feedback in the circuit between the basal ganglia and 
thalamus by disinhibiting the thalamus and increasing thalamocortical activity, 
thereby facilitating movement. 
The indirect pathway arises from GABAergic striatal neurons containing 
enkephalin and neurotensin. In contrast to direct pathway, the indirect pathway 
increases inhibition of the thalamus as can be seen by considering the polarity 
of the connections between the striatum and the external pallidal segment, 
between the external segment and the subthalamic nucleus and between the 
subthalamic nucleus and the internal pallidal segment (Figure 1-4). The indirect 
pathway thus provides negative feedback in the circuit between the basal 
ganglia and the thalamus by inhibiting thalamocortical neurons and thereby 
inhibiting movement. 
This direct/indirect pathway model of basal ganglia circuitry is widely accepted. 
However it is most certainly oversimplified and interconnections of the cortico-
basal ganglia loop are in reality much more complex (Nambu, 2008). 
Nevertheless, this basic model does still provide a decent insight into the 
functions of the basal ganglia (Nambu, 2008). In simple terms, disinhibition via 
the direct pathway releases a selected motor program. Signals through the 
hyperdirect and indirect pathways make clear the initiation and termination of a 
selected motor program. In addition to a temporal aspect, the enhancement by 
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differential inputs through the hyperdirect, direct, and indirect pathways may 
work spatially as well. Signals through the hyperdirect and indirect pathways 
activate the pallidum and substantia nigra neurons extensively, thereby 
inhibiting large areas of the thalamus. Signals through the direct pathway, 
however, disinhibit thalamic neurons centrally. However the hyperdirect and 
indirect pathways inhibit thalamic neurons in the more extensive surrounding 
area, which are involved in other competing motor programs. Thus the 
hyperdirect, direct, and indirect pathways ensure that only the selected motor 
program is executed at the selected time, and other competing motor programs 
are cancelled. The oculomotor, prefrontal, and limbic loops seem to control the 
activity of corresponding cortical areas in a similar manner to the motor loop. 
There is also evidence implicating basal ganglia circuits in non-motor function, 
such as cognition, attention, learning (especially motor learning), potentiation of 
behaviour-guiding rules and mood (Salinas et al., 2000). These circuits originate 
in the prefrontal and limbic regions of the cortex and engage with specific areas 
of the striatum, pallidum and substantia nigra (Kandel, 2000b). The 
neurotransmitters serotonin and dopamine are thought to play an important role 
in these non-motor functions. 
 
1.5.4 Basal ganglia disease mechanisms in motor disease 
From Chapter 1.5.2 and 1.5.3, it can be postulated that movement disorders of 
the basal ganglia may be associated with structural or biochemical disruption of 
the basal ganglia pathways. Two disease models are proposed and although 
they provide some useful insights, the mechanisms of disease are far from fully 
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elucidated. These theories may explain some, but not all, of the clinical 
semiology observed in these disorders (Nambu, 2008):- 
1.5.4.1 The firing rate model 
It has been proposed that activity imbalance between the direct and indirect 
pathways may affect the mean firing rate of the output nuclei of the basal 
ganglia, thereby inducing hypokinetic or hyperkinetic disorders (De Long, 1990).  
In states of dopamine depletion, such as Parkinson‘s disease (Obeso et al., 
2008) a decrease in tonic excitation of the direct pathway and increase in tonic 
inhibition in the indirect pathway result in overall increased activity in globus 
pallidus interna/substantia nigra pars reticulara. The ensuing inhibition of 
thalamic and cortical neurons results in hypokinesia/akinesia. On the other 
hand, in hyperkinetic disorders, excessive inhibition in the GPi through the 
hyperdirect, direct, and indirect pathways may induce uncontrollable 
disinhibition in the thalamus and cortex, leading to involuntary movements. 
Electrophysiological studies using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced parkinsonian monkeys have failed to corroborate this 
postulated increase in GPi activity (Wichmann, 1999). In contrast, decreased 
GPi activity has been reported in hyperkinetic animal models (such as the DYT1 
mouse model) which supports this firing rate model (Chiken et al., 2008). 
1.5.4.2 Firing pattern model 
In both affected patients and animal models of movement disorders disturbed 
information processing is a postulated disease mechanism, as oscillatory and/or 
synchronised activity is observed (Bergmann et al., 1998). The measured 
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frequency bands include the frequency of resting tremor (4–9 Hz) and the beta 
band (10–30 Hz) (Brown, 2007). The significance beta band oscillation is not 
entirely clear, but it may be associated with akinesia. Indeed, treatment for 
akinesia (with drugs/ stereotaxic surgery) has been shown to suppress this beta 
band oscillation. However, in the course of MPTP treatment of primates, the 
appearance of parkinsonian motor symptoms precedes that of oscillatory 
activity which does not support the firing pattern model (Leblois et al., 2007).  
 
1.5.5 Summary 
In Chapter 1.5, I have outlined the anatomical and functional aspects of the 
basal ganglia and its postulated role in disease. Disorders of the basal ganglia 
may thus arise from a wide variety of causes. These include hypoxic-ischaemic 
events involving the basal ganglia, tumours, infection, CNS autoimmune 
diseases, post-infectious disorders, neurodegeneration with brain iron 
accumulation, inborn errors of metabolism, genetic syndromes and disorders of 
neurotransmitter imbalance.  In Chapters 4 and 5, I will describe identification of 
a novel gene (SLC6A3) postulated to disrupt dopamine regulation in the basal 
ganglia, thereby resulting in a complex (primarily extrapyramidal) infantile-onset 
movement disorder. In Chapter 6, the clinical and genetic delineation of children 
with an infantile-onset disorder of brain iron accumulation in the basal ganglia 
will be described (PLA2G6-associated neurodegeneration).  
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1.6 Gene identification 
1.6.1 Why study rare recessive neurological diseases? 
The research described in this thesis has primarily focused on the mapping and 
identification of genes causing rare autosomal recessive neurological disorders. 
As described in the previous sections of this chapter, the molecular 
mechanisms accounting for a great number of neurological disorders remain yet 
to be elucidated. Although it may be argued that the time and effort spent in the 
study of such rare diseases greatly exceeds their relative contribution to 
improving the morbidity of the general population, often such studies will have 
implications for more common diseases and disease susceptibility.  
This is exemplified by the glucocerebrosidase gene GBA. While loss of function 
of both alleles causes the relatively rare autosomal recessive syndrome Type 1 
Gaucher‘s disease, its heterozygous loss of function has been shown to 
increase the risk of developing Parkinson‘s disease more than five-fold (Lees et 
al., 2009). 
Another example is Aicardi-Goutieres syndrome (AGS), a (mainly) autosomal 
recessive encephalopathy. In its most classical form, the clinical phenotype is 
considered to be the Mendelian mimic of in utero congenital viral infection 
(Crow and Livingston, 2008). In AGS, altered alpha interferon function is a 
major pathological feature, which is also seen in systemic lupus erythematosis 
(SLE). Interestingly (i) some children with AGS develop early onset SLE, (ii) 
heterozygous mutations in AGS1 (TREX1) cause a cutaneous form of SLE and 
(iii) pathogenic mutations in TREX1 are the single most common monogenic 
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cause of SLE (Crow and Rehwinkel, 2009). In AGS, endogenous nucleic acids 
accumulate and are sensed as ‗non-self‘, leading to an interferon-mediated 
immune response. By defining the precise mechanisms involved in this 
disorder, future targeted interruption of specific stages of the molecular pathway 
may lead to the development of novel therapeutic strategies. Identification of 
genes causing rare recessive neurological disorders may, as illustrated here, 
provide novel insights into normal biology, disease pathophysiology, disease 
susceptibility and potential therapeutic targets.     
The impact of gene identification for a family must also not be underestimated. 
In my clinical experience as a paediatric neurologist, parents of children with 
complex neurological disorders are almost invariably keen to pursue 
investigations in order to determine an underlying diagnosis. This may often 
require invasive neurological tests, such as a lumbar puncture (LP) and tissue 
biopsy. Identification of disease-causing gene mutations will allow accurate 
diagnosis for an affected patient. This can often give parents ‗closure‘ and will 
negate the need for further diagnostic investigations. It will also facilitate genetic 
counselling, carrier testing and prenatal diagnosis for other at-risk family 
members.  
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1.6.2 Approaches to gene identification 
There are essentially two approaches that can be used to identify a disease-
causing gene. Firstly suitable candidate genes may be selected, independent of 
chromosomal location (functional cloning). Secondly, a chromosomal region 
may be pinpointed and candidate genes within the region are subsequently 
selected (positional cloning) (Wicking and Williamson, 1991). In practical terms, 
the most efficient and effective way to identify genes is by utilising both 
strategies, the positional-candidate approach (Deloukas et al., 1998). 
1.6.2.1 Functional cloning 
Functional cloning requires a detailed knowledge of a particular disease 
phenotype and the biological defect causing it. A classical example of functional 
cloning was in the identification of mutations in the gene coding for 
phenylalanine hydroxylase (PAH) which causes phenylketonuria (DiLella et al., 
1987). Prior to genetic mapping, this was the main approach for the 
identification of disease causing genes. 
The approach is still being today, for example when there are potentially 
suitable candidate genes for a specific disorder. For example, the genetic 
investigation of patients with attention deficit hyperactivity disorder (ADHD) has 
involved extensive screening of genes affecting the catecholaminergic and 
serotonergic pathways (Faraone and Mick, 2010). Once gene identification has 
linked a specific phenotype to a particular biological pathway, this approach of 
functional cloning allows selection of further candidate genes from the same 
pathway that may cause identical or related conditions. This is exemplified by 
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the identification of RAB3GAP2 mutations in Martsolf syndrome (Aligianis et al., 
2006) following the identification of RAB3GAP1 mutations in Micro syndrome 
(Aligianis et al., 2005). 
Functional cloning has been greatly aided by analysis of mouse mutants which 
have been generated by systematic mutagenesis programs. Completion of the 
mouse genome project has aided this approach (Waterston et al., 2002). As 
discussed in Chapter 3, human-mouse homologies may be particularly 
valuable, as mutations in specific genes may often cause similar phenotypes. 
1.6.2.2. Positional cloning 
Positional cloning aims to define a chromosomal segment within which a 
disease-causing gene is located. The Human Genome Project (Venter et al., 
2001) has greatly facilitated this approach to gene identification, by providing 
physical and genetic maps enabling one to locate markers and genes within a 
specific chromosomal region. The resources provided by public databases such 
as ‗NCBI‘, ‗Ensembl‘ and ‗UCSC Genome Bioinformatics site‘ include detailed 
information about numerous polymorphic markers spread throughout the 
genome, genetic maps based on these markers, a physical map based on latest 
genomic sequence information, a rapidly expanding map of expressed 
sequences and information management and search tools. Direct mapping of 
Mendelian disorders is achieved by linkage analysis which allows the 
localisation of a gene to a chromosomal region (or locus). Once the disease 
locus is established, then candidate genes may be selected for screening, 
based on information about the gene function, tissue expression pattern and 
homologies to other genes or animal models. 
Chapter 1   General Introduction 
 
39 
 
1.6.3 Haplotypes and genetic markers 
A haplotype is a set of closely linked alleles (either genes or DNA 
polymorphisms) which are inherited as a unit. The word originates from ‗haploid 
genotype‘. Haplotypes are used extensively in genetic mapping and population 
studies. The original haplotypes were constructed on the basis of blood groups 
(Morton, 1955). Progress in genetic mapping has been greatly aided by the 
development of more widespread polymorphic markers such as Restriction 
Fragment Length Polymorphisms (RFLPs), microsatellite markers (Weber and 
May, 1989) and single nucleotide polymorphisms. In this thesis, I have utilised 
microsatellite markers and single nucleotide polymorphisms (SNPs) as markers 
in genetic mapping. 
Microsatellite markers (or short tandem repeat polymorphisms) are multiple 
repeats of 2, 3 or 4 bases. They are extremely polymorphic, may be analysed 
by polymerase chain reaction (PCR) and are present approximately every 
30,000 bases in the genomic sequence (Stallings et al., 1991). Many successful 
mapping projects have been achieved by the use of microsatellites to conduct 
genome-wide scans (for example, Aligianis et al., 2005).  
SNPs are now much more widely used in genetic mapping studies in the study 
of complex multifactorial diseases, diseases with Mendelian inheritance and 
copy number variants (CNVs). The first SNP array for genome wide scan was 
produced by Affymetrix GeneChip® 10K Xba Array containing 11,555 SNP 
markers (Affymetrix Inc, Santa Clara, CA). Since 2004, several successful 
mapping projects have been accomplished using this 10K array (for example 
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Gissen et al., 2004). SNPs are biallelic so they are almost invariably less 
polymorphic (and thus less informative) than microsatellite markers. However, 
the great advantage is that the density of SNPs in the human genome allows 
the researcher to obtain higher resolution mapping information. Currently, the 
Affymetrix® Genome-Wide Human SNP Array 6.0 contains more than 906,600 
SNPs and more than 946,000 probes for the detection of copy number 
variation. Recent advances in SNP genotyping have also facilitated the 
construction of a detailed human haplotype map of over 3.1 million SNPs 
(International HapMap consortium 2007). 
1.6.4 Informativeness of markers 
For a marker to be useful in linkage analysis of inherited disorders, its state 
needs to be known for at least one parent (who is a heterozygote). 
Heterozygosity of the marker in the study population is a measure of its 
informativity. Heterozygosity (H) is calculated by the following equation: 
H = 1 – Σpi 2 
                    
where pi is the population frequency of the ith allele (Ott, 1991). In 
consanguineous populations, the members of the kindred are more likely to be 
homozygous for markers by descent and H is therefore reduced and is (1-F)H, 
where F is the inbreeding coefficient.  
The term polymorphism information content (PIC) is also used for the 
assessment of marker informativity. PIC defines the probability that one could 
identify which allele of a given parent was transmitted to a given offspring, the 
i 
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other parent being genotyped as well (Botstein et al., 1980). This is equal to the 
marker heterozygosity, less the frequency for which the other parent is 
heterozygous for the same marker alleles: 
PIC = 1 – Σpi 2 _ ΣΣ 2pi 2 pj 2 
1.6.5 Maps 
A number of genetic and physical maps of the genome have been developed, 
and these maps are fundamental tools for mapping and gene identification. 
Genetic maps were developed by tracing the inheritance of phenotypes and/or 
polymorphic markers through successive generations. Polymorphic loci are 
positioned relative to one another on the basis of the frequency at which they 
recombine during meiosis. The unit of distance is the centiMorgan (cM) and 
1cM denoted a 1% chance of recombination.  
Examples of genetic maps that have been constructed over the last two 
decades include the Généthon map (a microsatellite marker-based linkage 
map, Weisssenbach et al., 1992; Dib et al., 1996) and the Marshfield map. The 
Marshfield map was based on the genotyping of around 8,000 microsatellite 
markers in eight  large, three generation families from the Centre d‘Etude du 
Polymorphisme Human (CEPH) collection containing 188 meioses (Broman et 
al., 1998). More recent maps include those generated by deCODE Genetics in 
Iceland, with substantially improved resolution of up to five times the resolution 
of previous maps (Kong et al., 2002). This map was based on the genotyping of 
5,136 microsatellite markers, in 146 nuclear families containing 1,257 meioses.  
        i=1                  i=1   j=i+1 
 
 
                  n-1    n 
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The construction of these genetic maps and intermediate physical maps has 
significantly contributed to sequencing the entire human genome in the Human 
Genome Project (Venter et al., 2001). In the human genome, 1cM corresponds, 
on average, to roughly a physical map distance of 1Mb, although the 
relationship varies across the genome. 
1.6.6 Linkage 
In 1911, Morgan reported that meiotic recombination events were less likely to 
occur between two loci that are close together on a chromosome than between 
two loci which are widely separated or on different chromosomes (Morgan, 
1911). Linkage between two markers is defined as occurring when 
recombination events occur less that 50% of the time, with a resultant 
recombination fraction of <0.5 (Ott, 1999). This indicates that the loci are on the 
same chromosome and close to each other. 
1.6.7 Recombination fraction 
The recombination fraction (θ) represents the proportion of offspring who are 
recombinant (R) (as opposed to non recombinant, NR) between two given loci. 
It is calculated as follows: 
θ =       R  
       (R + NR) 
 
When two loci are syntenic (physical, co-localised), there is a much greater 
chance that they will co-segregate if they are close together, resulting in a lower 
recombination fraction. If two loci coincide, θ is 0. When they are further apart, 
there is a higher chance of crossover and θ increases. The maximum value for 
θ is 0.5, which signifies that that the two loci are not linked. The distance 
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between two markers on a genetic map is expressed as θ and measured in cM. 
One cM denotes a 1% of recombination and, as previously discussed in 
Chapter 1.6.5, roughly corresponds to a physical distance of 1Mb. The 
relationship between physical distance and genetic distance is however non-
linear, and it appears that certain chromosomal regions are particularly prone to 
recombination (recombination ‗hot-spots‘), for example, between regions of 
homologous repetitive sequence. Recombination events are relatively more 
common in telomeric regions, and less common near the centromere. They are 
also more common in females. 
1.6.8 LOD scores and critical values 
Linkage analysis essentially determines whether θ observed between two 
markers significantly differs from 0.5.  
When phase is known, (alleles for both markers can be unequivocally 
assigned), θ can be calculated by counting up all the recombinations. Where 
parental phase and genotypes are not known for the studied meiosis, this is not 
possible. Thus, likelihood ratio testing has been employed for human linkage 
analysis (Ott, 1999). The probability of linkage is calculated as the LOD score, 
Z(θ) (Morton, 1955). The LOD score is the logarithm of the odds that the 
pedigree is linked (H1) as opposed to being unlinked (H0) and is expressed as 
follows: 
Z(θ)= log10 L(H1)      = log10       L(θ) 
  L(H0)         L(θ =0.5) 
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For each pedigree, the LOD score is calculated at a range of θ values. The 
most likely recombination fraction is the value at which the LOD score is 
highest. In a set of families, the overall probability is the product of the 
probabilities in each family, therefore LOD scores (being logarithms) can be 
added up across families (see Chapter 4).  
In 1955, Morton proposed criteria for linkage that are still in use today. Linkage 
is accepted when Zmax>3 for autosomal loci (or Zmax>2 for X-linked loci) and 
linkage is rejected when Zmax<-2. These values correspond to significance 
levels not exceeding 0.001 (Zmax>3), and 0.01 (Zmax>2). Because of the prior 
probability of a chance linkage between two traits, the p-value associated with a 
LOD score of 3.0 is approximately 0.04 (i.e. consistent with a false-positive rate 
of 1 in 25). 
In order to obtain statistical proof of linkage of a disease locus to a particular 
marker locus, it is necessary to calculate a LOD score by using two-point or 
multipoint linkage analysis. Two-point linkage analysis is used to establish 
whether there is linkage between one marker locus and one disease locus. It is 
often seen as a rough or ‗coarse‘ indication of the location of the disease locus. 
Multipoint linkage analysis is essentially an extension of two-point analysis in 
which, instead of finding the recombination fraction between a single marker 
and a disease locus, the disease locus is mapped against several markers 
simultaneously. In contrast to two-point linkage analysis multipoint linkage 
therefore extracts more information from the genotyping data and can give an 
indication of the likely position of the disease locus relative to the markers. 
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Generally multipoint linkage gives higher LOD-scores than those achieved with 
two-point analysis. 
1.6.9 Autozygosity mapping 
1.6.9.1 Introduction 
In 1953, Smith recognised that searching for homozygous regions by descent in 
consanguineous families offered a powerful strategy for mapping autosomal 
recessive disorders. Almost 35 years later, advances in molecular techniques 
(such as the development of genetic maps) allowed Lander and Botstein (1987) 
to reintroduce this concept and formulate a technique called ‗homozygosity 
mapping‘ for the mapping of autosomal recessive disorders in consanguineous 
kindreds. As a locus can be homozygous by virtue of parental descent from a 
common ancestor, and thus autozygous, this methodology is also termed 
autozygosity mapping (Mueller and Bishop, 1993). One of the first disorders to 
be mapping this way was alkaptonuria (Pollak et al., 1993) and over the last 17 
years a multitude of disorders have been successfully mapped this way 
(examples of such mapping in neurological diseases include publications by 
Aligianis et al., 2005, Morgan et al., 2006, Bockenhauer et al., 2009). 
1.6.9.2 Consanguinity and the UK Pakistani population 
Successful autozygosity mapping relies on the identification of consanguineous 
kindreds in which there are multiple affected children with an identical disorder. 
Consanguinity is defined as a union between couples who are related as 
second cousins or closer, equivalent to a coefficient of inbreeding (F) in their 
offspring of ≥ 0.156. A 2nd cousin couple share 1/32 of their autosomal genes. 
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Their children have identical gene copies at 1/64 of all loci. F thus relates to a 
child of a consanguineous relationship and indicates the probability that the 
child will be homozygous for a specific gene/marker (at a specific locus) derived 
from a common ancestor. The coefficient of relationship (R) relates to a 
consanguineous couple and represents the proportion of genes that they would 
expect to share by descent from a common ancestor (Table 1-6). 
 
Table 1-6  
Degrees of consanguinity and its effect on F and R and risk of autosomal 
recessive disease in offspring (Adapted from Young, 1999) 
Parental relationship R F 
Autosomal recessive 
disease risk in progeny 
Siblings 1/2 1/4 1/8 
Half siblings 1/4 1/8 1/16 
Uncle-niece/aunt-nephew 1/4 1/8 1/16 
Double 1
st
 cousins 1/4 1/8 1/16 
1
st
 cousins 1/8 1/16 1/32 
Double 2
nd
 cousins 1/16 1/32 1/64 
2
nd
 cousins 1/32 1/64 1/128 
 
Consanguineous marriages are common practice in a number of communities 
worldwide. In Arab populations the most common type of consanguineous 
marriage occurs between first cousins who are children of two brothers, 
whereas in the Indian subcontinent uncle-niece marriages are the most 
commonly encountered form of consanguineous relationship. Although the 
potential genetic risks are recognised within these communities, this risk if often 
outweighed by the perceived social advantages of greater family and marital 
stability. A consanguineous marriage is believed to strengthen family ties and 
avoid health or financial uncertainties that arise through marriage to a spouse 
external to the family or community. Economic reasons are also considered 
important in consanguineous marriages. In countries where dowry payments 
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are usual, these costs are minimised or completely removed (Bittles, 2001; 
Modell and Darr, 2002). Within certain communities, consanguineous couples 
will often marry and have children earlier, and may have increased family sizes, 
further increasing the likelihood of expression of a recessive disorder. 
At the population level, the effect of customary consanguineous marriage 
depends on the frequency and nature of all recessive diseases in the population 
and on the population structure. Documented effects include increased infant 
mortality, congenital malformations, learning difficulties, blindness, hearing 
difficulties and metabolic disorders. A meta-analysis of 38 studies (mainly from 
developing countries) showed an average increase of infant mortality by 4.4% 
amongst offspring of first cousins compared with unrelated controls (Bittles and 
Neel, 1994). It is however important to remember that disorders that lead to 
death in countries with poor medical resources may otherwise be successfully 
treated in developed countries.  
In unrelated parents, the prevalence of serious congenital abnormalities and 
genetic disorders is 2 - 2.5% (Congenital Anomalies Register) and around 4% in 
some longer term studies. These risks are doubled for children from 1st cousin 
relationships. A Birmingham study (Bundey and Alam, 1993) found 0.4% of the 
North European couples to be related, whereas among British Pakistanis, 69% 
of couples were related and 57% were first cousins. Amongst the British 
Pakistani children the birth prevalence of all congenital and genetic disorders 
was 7.9%, almost double that of Northern European children (4.3%). The 
prevalence of (definite, probable or possible) recessive disorders was 3.0–3.3% 
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in the British Pakistani children, ~10 times higher than in the North European 
children (0.28%). 
Because of the complex social aspects involved, the clinical approach has to be 
to offer improved access to genetic counselling, rather than to discourage 
consanguinity, which can often be a fundamental part of tradition in these 
communities. This includes carrier testing for at-risk couples (sometimes even 
prior to marriage and having children) as well as prenatal diagnosis. Prenatal 
diagnosis by chorionic villus sampling in the first trimester for severe disorders 
(such as thalassaemia) is becoming increasingly acceptable to such 
communities (Darr and Modell, 1988). 
1.6.9.3 Principles of autozygosity mapping 
Figure 1-5 illustrates the family tree of a hypothetical consanguineous family in 
which two children are affected with an autosomal recessive condition. The 
disease allele has been passed down through successive generations from the 
common ancestor (CA). The affected children have thus inherited both copies of 
this disease allele from their parents, and are thus homozygous-by-descent for 
this gene. In addition, the chromosomal segment surrounding the gene is also 
homozygous (shaded in red). Recombination events during meiosis lead to a 
reduction in the size of the autozygous (red) chromosomal segment over 
successive generations. Disease loci in consanguineous kindreds are thus 
normally (but not always) located in such homozygous regions of the genome. 
These homozygous regions can thus be identified using genome-wide SNP 
arrays and microsatellite markers. Once homozygous regions are identified, the 
region of interest can be examined for candidate genes for sequencing.  
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Figure 1.5  
The principle of autozygosity mapping, in which the specific mutation of a disease 
gene (indicated by the black arrow) can be passed on from a common ancestor 
(CA) to offspring and the product of a consanguineous marriage, can result in 
affected offspring 
 
   
1.6.9.4 Mathematical model for autozygosity mapping 
The mathematical model of homozygosity mapping was formalised by Lander 
and Botstein (1987). For a child from a consanguineous union, the probability of 
being homozygous-by-descent Fq is equal to the disease allele frequency (q) 
multiplied by F (the coefficient of inbreeding), assuming that the disease is in 
Hardy Weinberg equilibrium (HWE). The probability that the child is not 
homozygous as there has been random meeting of 2 alleles is: 
(1-F)q2 
CA 
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If the disease gene is in HWE in the population, then the proportion of affected 
individuals homozygous by descent (α) is: 
α = Fq 
 
      Fq +(1-F)q2 
 
If q is small, then it is more likely that α~1. This equation thus demonstrates the 
validity of the assumption that for a rare recessive disorder, the disease gene 
will lie within a homozygous region. On the converse, parents of children with 
recessive disorders are more likely to be related. 
1.6.9.5 The power of autozygosity mapping 
A LOD score can be constructed on the basis of α and F. The region around a 
disease gene will be homozygous by descent with a probability α, while 
unlinked region will have a probability of homozygosity by descent of F. Thus 
the ratio of α:F is the odds in favour of linkage (assuming that the genotyping is 
fully informative. In a 1st cousin union (F=1/16) with a region that is definitely 
homozygous by descent, there is an odds ratio of 16:1 in favour of linkage, i.e. a 
LOD score of 1.204. Through detecting common regions of homozygosity in 3 
separate 1st cousin unions (all with one child affected with a common 
phenotype), a significant LOD score of 3.61 would be obtained (providing 
markers are informative and α~1).  
Using more distally related families for mapping will increase the power to 
detect linkage. An affected child of 2nd cousin parents could derive a maximum 
LOD score of 2.41. This concept is illustrated in Chapter 4, where linkage to a 
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disease locus (and a significant LOD score of >5) was established using 2 
separate families (with a total of only 3 affected children). 
1.6.9.6 Pitfalls of autozygosity mapping 
It is important to note that autozygosity mapping has a number of pitfalls which 
need to be carefully considered when embarking on mapping studies.   
The majority of these recessively inherited diseases are rare and it can be often 
very difficult to ascertain a sufficient number of patients with the same/ related 
phenotypes to embark on autozygosity mapping studies. Another problem is that 
in many parts of the world family sizes tend to be smaller, often no more than 
three to four children, making it unusual for there to be more than two affected 
siblings within a sibship (Mueller and Bishop, 1993). As discussed in Chapters 3-6 
of this thesis, a potential solution to this problem is by setting up collaborative 
projects and pooling clinical resources. 
Investigating rare diseases within isolated communities also has other problems. 
A number of families will harbour a ‗private mutation‘ for an inherited disorder. In 
such cases it may prove difficult to find other families (even with similar 
phenotypes) who have mutations in the same gene. Proof of pathogenesis can 
thus be very difficult in these isolated cases.  
Rarely, autosomal recessive disease in consanguineous kindreds may be caused 
by compound heterozygous mutations. In such cases, the disease locus may not 
be within a region of homozygosity, and thus will not be detected when performing 
a genome-wide scan for homozygous regions. This is evident in Karak syndrome. 
In the original report of this syndrome, described by Mubaidin et al., (2003), the 
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two affected boys were born to first cousin parents from an inbred Jordanian 
family. The family structure was suggestive of autosomal recessive (or X-linked) 
inheritance. However, phenotypic similarity with other patients  with mutations in 
PLA2G6 prompted screening of this gene, and compound heterozygous PLA2G6 
mutations were identified in both boys (Morgan et al., 2006). Microsatellite marker 
analysis of the region on chromosome 22 revealed that both boys shared a 
common heterozygous haplotype that was different to their parents. Thus, in this 
family, if mapping studies had been undertaken, the disease locus would have 
been missed as it was not contained within a homozygous region in the affected 
individuals. 
Miano et al., (2000) found that allelic heterogeneity may occur even within single 
consanguineous kindred, which results in loss of homozygosity in flanking 
markers and failure to detect linkage with a false-negative result. In their cited 
example, the true locus for enhanced S-cone syndrome was missed as one of the 
four affected individuals from one kindred was found to be a compound 
heterozygote for the disorder. The other three were homozygous for one of these 
detected mutations. Miano et al., also reported that autozygosity can be detected 
in families that are unrelated to the disease, an explanation being that ―hidden‖ 
consanguinity in pedigree founders may add to the likelihood of detection of such 
regions. Another pitfall is in underestimating the extent of inbreeding which can 
potentially inflate the LOD scores, increasing the chance of a false-positive 
linkage. 
Locus heterogeneity describes the situation where the same clinical phenotype 
can result from mutations at any one of several genetic loci. Autosomal recessive 
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diseases can be extremely heterogeneous, as has been shown for autosomal 
recessive microcephaly in the Pakistani community (Woods et al., 2005). Before 
undertaking linkage analysis for a particular genetic disease, it is important to 
investigate whether any previous data has already mapped any disease loci, or at 
least suggested genetic heterogeneity. Ideally, if possible, linkage studies should 
be performed in one large consanguineous family with multiple affected 
individuals (for example, Morgan et al., 2006), as this can be much more powerful 
than using several different families with one or two affected individuals. Once 
linkage is established in the large family, other smaller consanguineous families 
can be investigated for linkage to the same region. Such approaches are not 
always possible, but if they are, they can overcome this problem of locus 
heterogeneity.  
1.7 Conclusion 
In this chapter, I have given a broad overview of inherited neurological disorders 
and methods by which disease-causing genes may be identified. From my 
perspective as a paediatric neurologist, it is striking that, for the majority of these 
neurological disorders, there is no curative treatment and therapeutic strategies to 
date are generally supportive or palliative. One hopes that future advances in 
molecular biology and identification of further single gene disorders will not only 
help elucidate pathophysiological processes (thereby enhancing understanding of 
normal physiology and disease mechanisms), but also facilitate the development 
of therapeutic targets for future possibly curative treatments for neurological 
diseases. Promising work in such treatment of inherited neurological disorders is 
already underway (Kinali et al., 2009; Zeng et al., 2010). 
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This chapter describes the general procedures used widely in this thesis. 
Specific methodologies pertaining to individual chapters are contained therein. 
 
2.1 Ascertainment of patients and control subjects 
2.1.1 Patient recruitment 
In this thesis, molecular genetic investigations were undertaken in 
consanguineous kindreds containing children affected with undiagnosed, early-
onset, complex neurological disorders. The families originated from a variety of 
ethnic backgrounds (Pakistani, North Indian, Bangladeshi and mixed European 
descent). For each neurological condition, a cohort of patients (with a similar 
clinical phenotype) from non-consanguineous families was also established. 
Autozygosity mapping strategies were utilised to establish disease loci and 
identify novel disease-causing genes in consanguineous families. Sequencing 
of these genes was subsequently undertaken in the relevant cohort of sporadic 
cases in order to establish mutation frequency. 
Consanguineous families and sporadic cases with the following neurological 
conditions were recruited:-  
 Infantile spasms (West syndrome) 
 Infantile parkinsonism-dystonia (dopamine transporter deficiency syndrome)  
 PLA2G6-associated neurodegeneration (PLAN) 
Patients were recruited through the NAMR (National Autozygosity Mapping 
Resource) from:- 
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 UK NHS (National Health Service) regional genetics services 
 UK NHS tertiary paediatric neurology departments  
 The British Paediatric Neurology Association  Surveillance Unit (BPNSU) 
 Worldwide collaboration with internationally-based paediatric neurologists 
 
2.1.2 Consent and ethics approval 
Informed consent was obtained from all participants and the study was 
approved by the LREC (Local Research Ethics Committee). All clinical research 
adhered to principles outlined by the Declaration of Helsinki. 
 
2.1.3 Patient assessment and acquisition of blood samples 
For most UK-based families, I performed a detailed clinical assessment 
including a full medical history and systemic/neurological examination. Blood 
samples were taken from all affected individuals, both parents and any 
unaffected siblings. For families based outside the UK, clinical data was 
acquired by liaising with the referring clinician. Questionnaires were used to 
gather clinical data and extensive video footage of affected children was 
analysed for accurate neurological phenotyping. For such internationally 
acquired cases, the referring clinician sent either DNA or fresh blood samples 
(in EDTA tubes) for DNA and RNA extraction by the West Midlands Regional 
Genetics Laboratory.  
2.1.4 DNA from control subjects  
Control DNA samples were kindly donated by the West Midlands Regional 
Genetics Laboratory for assessing population frequencies of identified genomic 
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variants. The surnames of the families were used to select which control panel 
they fitted into, after which they were anonymised. 
 
2.2 Materials 
2.2.1 Chemical reagents 
Acetamide        Sigma 
Agarose        Bioline 
2X BiomixTM Red       Bioline 
dNTPs (diluted from 100mM to a working stock of 2mM) Bioline 
EDTA (ethylenediaminetetraacetic acid)    Sigma 
ExoSaP-IT®         USB Corporation, USA 
Ethanol        Fisher Scientific 
Ethidium bromide       Sigma 
GC rich solution of FastStart Taq DNA Polymerase Kit Roche  
Genescan-500 LIZ Size Standard     Applied biosystems 
Hi-Di Formamide       Applied biosystems 
HyperladderTM I (Separation range 200 – 10000bp)  Bioline 
HyperladderTM VI (Separation range 10090 – 48000bp) Bioline  
MicroCLEAN®       Web Scientific 
Primers        Sigma 
10X TBE Electrophoresis Buffer (diluted to 1X)   Geneflow 
Water (distilled-RNase/DNase free, dH2O)   Invitrogen 
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2.2.2 Kits 
Affymetrix Genome-Wide 250K SNP Array    Affymetrix Ltd 
BigDye Terminator Cycle Sequencing Kit version 3.1   Applied biosystems 
BigDye 5X Sequencing Buffer (25nM Tris pH 8.7, 4mM MgCl2) Applied biosystems 
PCR Extender System (5 Prime for Long Range PCR)  Flowgen Bioscience 
Puregene Genomic DNA Purification Kit     Gentra systems 
QIAquick Gel Extraction kit       Qiagen 
Reverse transcription system A3500     Promega 
2.3 DNA analysis 
2.3.1 DNA extraction 
DNA extraction was kindly performed either by the West Midlands Regional 
Genetics Laboratory or by referring genetic centres. DNA was extracted from 
blood using the Puregene Genomic DNA Purification kit according to the 
manufacturer‘s instructions. Extracted genomic samples were then quantified by 
spectrophotometry (by measurement of A260:A280 ratios). 
2.3.2 SNP genotyping arrays 
In order to identify regions of common homozygosity and/or genomic copy 
number variants, a genome-wide scan using the Affymetrix 250K Sty SNP array 
was undertaken in affected children and their unaffected siblings. This 
microarray technology allows the simultaneous genotyping of a subject‘s DNA 
for 238,304 SNPs. SNP genotyping was kindly performed by a research 
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laboratory technician, according to the manufacturer‘s instructions (Affymetrix 
GeneChip Human Mapping 250K Assay Manual). In brief, genomic DNA 
(250ng) was digested with Sty I restriction enzymes (New England Biolabs) and 
ligated to Sty I adaptors using T4 DNA Ligase (New England Biolabs). Three 
PCR reactions were set up for each sample with primer 002 (Affymetrix) and 
Titanium DNA Amplification Kit (Clontech). The PCR products were run on a 
1.5% agarose gel, and ranged in size from 200-1100bp. The PCR products 
were cleaned up using a DNA Amplification clean-up kit (Clontech). The 
amplified DNA was then fragmented (to create products of <200bp), then 
labelled and hybridized to the Sty1 250K SNP chip (Affymetrix). Washing and 
staining of the arrays was then performed by a fluidics station. The chips were 
subsequently scanned using a gene-chip scanner (Affymetrix GeneChip 
Scanner 3000; Affymetrix) via GCOS 1.3 software. Data analysis was then 
undertaken (using GTYPE 4.1 software) to derive SNP genotypes, marker order 
and linear chromosomal location. Subsequent copy number analysis was 
performed using the Copy Number Analysis Tool (CNAT) 4.0.1. 
2.3.3 Microsatellite marker genotyping 
2.3.3.1 Primers for PCR  
The details of all microsatellite markers (and their UNISTS identification 
number) used for genotyping and fine mapping are tabulated in the relevant 
chapters. Forward and reverse primer sequences for known microsatellite 
markers were obtained from each marker‘s entry on the UNISTS database. Di- 
tri- and tetra-nucleotide markers with high heterozygosity scores were selected 
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using NCBI UNISTS and Ensembl genome browsers. Fluorescent dyes (FAM-
blue, HEX-yellow, TET-green) were added to the 5‘ end of the forward primer. 
Novel microsatellite markers were also designed and utilised for genotyping. 
The specific genomic region of interest was displayed on the UCSC genome 
browser and all microsatellites within this region were viewed. A tandem 
sequence of greater than 20 di- tri- or tetra-nucleotide repeats was chosen from 
this DNA contig and primer sequences were designed in the flanking genomic 
sequence using the Primer3 package. The region containing the tandem repeat, 
forward primer and reverse primer were all checked on NCBI BLAST (Basic 
Local Alignment Search Tool) to ensure primer specificity to the region around 
the novel microsatellite. 
2.3.3.2 PCR amplification for microsatellite marker genotyping 
PCR amplification was performed in 10μl reactions as follows:- 
 1.0μl genomic DNA (20ng/μl) 
 5.0μl BiomixTM Red 2X 
 3.6μl dH2O  
 0.2μl (2.0pmol) forward primer (tagged with fluorescent dye) 
 0.2μl (2.0pmol) reverse primer 
BiomixTM Red is a premixed, pre-optimised 2X solution designed for high 
throughput PCR applications. It contains an ultra-stable Taq DNA polymerase 
and an inert red dye, permitting easy visualisation and direct gel loading. 
After an initial denaturation at 95oC for 5 min, a standard PCR protocol was 
followed: 30 cycles of 95oC for 30s, annealing at 55oC for 30s and extension at 
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72oC for 30s, followed by a final extension step at 72oC for 5 min. Each set of 
PCR reactions included a negative control (in which dH2O was added instead of 
DNA) to check for contamination. 
2.3.3.3 Analysis of microsatellite marker PCR products 
Markers run on the ABI 3730 DNA Analyzer were initially diluted 1:15 with 
dH2O. 1μl of the diluted PCR product was added to 10μl Hi-Di Formamide and 
0.04μl Genescan-500 LIZ size standard. PCR product sizes were determined 
using Genemapper v4.0 software (Applied Biosystems). 
2.3.4 Gene sequencing 
2.3.4.1 Primers for sequencing candidate genes 
The DNA template for each gene sequenced in this thesis was downloaded 
from the Ensembl database. All transcripts for each gene were examined to 
ensure that primers were designed to cover all coding exons. Intronic primers 
flanking the coding sequence were designed for PCR amplification using 
ExonPrimer and Primer3. 
2.3.4.2 PCR amplification for gene sequencing 
Standard conditions for PCR amplification were used. PCR amplification was 
performed in 25μl reactions as follows:- 
 5.0μl genomic DNA (20ng/μl)   
 12.5μl BiomixTM Red 2X 
 6.5μl dH2O  
 0.5μl (5.0pmol) forward primer 
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 0.5μl (5.0pmol) reverse primer 
For GC-rich fragments, PCR amplification was performed in 25μl reactions:-  
 5.0μl genomic DNA (20ng/μl)   
 12.5μl BiomixTM Red 2X 
 5μl GC rich solution 
 1.5μl dH2O  
 0.5μl (5.0pmol) forward primer  
 0.5μl (5.0pmol) reverse primer   
PCR conditions were an initial denaturation of 95oC for 5 min followed by 30 
cycles of 45s denaturation at 95oC, 45s annealing at 50-65oC (temperature 
optimised specifically for each amplification reaction) and 1 min extension at 
72oC. This was followed by a final extension step at 72oC for 5 min. Each set of 
PCR reactions included a negative control (in which dH2O was added instead of 
DNA) to check for contamination.  
2.3.4.3 Agarose gel electrophoresis 
PCR products were checked on 1.5% horizontal agarose gels to separate the 
PCR products and to ensure that the PCR reaction had worked without 
contamination. The agarose gels were made by melting agarose with 1X TBE in 
a domestic 600W microwave oven, then cooling the mixture before adding 
ethidium bromide (0.5μg/ml final concentration) and casting the gel in a gel 
casting tray. The PCR products were loaded directly. Loading buffer was not 
required with the use of BiomixTM Red as the mix is of sufficient density to sink 
to the bottom of each well in the gel. A DNA sizing ladder (Hyperladder I) was 
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added to lane 1 to check for correct PCR product size. Separation of DNA was 
achieved by electrophoresis at 60-140V for 30-120 min (depending on the gel 
size and PCR product size). The bands were visualised using Ethidium Bromide 
and a UV transilluminator (254nm wavelength). 
2.3.4.4 PCR product clean-up 
The PCR product was cleaned up (to remove unwanted dNTPs and primer) by 
one of three methods. The Exo-SAP-IT® PCR product clean up kit was used to 
purify PCR products. ExoSAP contains Exonuclease I and Shrimp Alkaline 
Phosphatase. 2.5μl of PCR product was mixed with 2μl of ExoSAP-IT and 
incubated at 37oC for 15 min. Subsequent inactivation of enzymes was 
achieved by incubation at 80oC for 15 min. PCR products were also cleaned up 
using MicroCLEAN. 2.5μl MicroCLEAN was added to 2.5μl of PCR product, 
incubated at room temperature for 5 min and then centrifuged at 4000rpm at 
20oC for 40 min. The supernatant was removed by briefly spinning the plate 
upside down at 500rpm at 20o for 30s. The pellet was left to air-dry and then 
reconstituted with 4.5μl dH2O. In cases where PCR products were not clean 
and multiple bands were visible on gel electrophoresis, gel extraction of specific 
bands was performed. The PCR product was run on a 2% agarose gel. The 
fragment of interest was excised from the gel using a sterile scalpel, using a UV 
transilluminator for visualisation. Purification of gel-extracted products was then 
undertaken using the QIAquickTM Gel Extraction kit (Qiagen). Approximately 3 
volumes of Buffer QG was added to 1 volume of gel (approximately 450μl) and 
incubated at 55oC until the agarose gel dissolved. Then one gel volume of 
isopropanol was added. The tube contents were then added to a Qiaquick spin 
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column and centrifuged for 1 minute. The flow-through was discarded and a 
further 500μl of Buffer QG was added and centrifuged for 1 min. The flow-
through was again discarded and 750μl of PE buffer was added to the column 
and centrifuged again for 1 min. The flow-through was discarded and the 
column centrifuged again to remove residual PE buffer. The Qiaquick column 
was then placed into a clean 1.5ml microfuge tube and the DNA bound to the 
column was eluted by the addition of 20μl dH2O and centrifuging for a further 
min. 
2.3.4.5 Cycle sequencing 
The purified PCR product was then sequenced in both forward and reverse 
directions using relevant primers. Each 10μl reaction was set up as follows:- 
 4.5μl purified PCR product 
 0.5μl BigDye Reaction Mix 
 2.0μl 5X Sequencing buffer 
 1.0μl dH2O 
 2.0μl forward or reverse primer (4pmol) 
The cycling conditions were 96oC for 3 min followed by 30 cycles of 96oC (30s), 
50oC (15s) and 60oC (4 min). 
2.3.4.6 Sequencing reaction clean-up preparation  
Sequencing reactions were cleaned up to remove any incorporated dye 
terminators. The EDTA method of precipitation was used. To the 10μl 
sequencing reaction, 1μl EDTA (250nM) was added and mixed before adding 
30μl of absolute ethanol. This was incubated for 5-10 min at room temperature 
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and then centrifuged for 20 min at 2000rpm (20oC). The supernatant was 
removed by briefly spinning the plate upside down to a maximum of 400rpm. 
90μl of 70% ethanol was then added, mixed and the plate centrifuged again for 
a further 10 min at 2000rpm (20oC). The supernatant was discarded by inverting 
the plate and spinning to 400rpm. The pellet was left to air dry. 
2.3.4.7 Preparation and analysis of sequencing reactions 
Pellets were resuspended in 10μl Hi-Di Formamide and then denatured for 5 
minutes before snap-chilling on ice. Sequencing reactions were run on the ABI 
3730 DNA Analyzer. Analysed sequences were then downloaded using 
‗Chromas‘ software, printed and assessed manually for mutations. 
2.3.5 Long range PCR 
For determination of the genomic breakpoint of putative intragenic deletions, 
long range PCR techniques were utilised, using the PCR extender system. A 
forward primer (FP) and reverse primer (RP) were designed outside the 
margins of the putative deletion. Primers were designed manually by 
identification of a 25-30 nucleotide base sequence comprising of approximately 
50% G and/or C nucleotide bases. Primer specificity was checked on NCBI 
BLAST. Each 50μl long range PCR amplification reaction was set up using 2 
mastermixes as follows:- 
Mastermix 1 (10μl): 
 8.0μl genomic DNA (20ng/μl) 
 1.0μl (10pmol) of forward primer (FP) 
 1.0μl (10pmol) of reverse primer (RP) 
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MasterMix 2 (40μl): 
 32.1μl dH2O 
 5.0μl 10X tuning buffer 
 2.5μl dNTP 
 0.4μl PCR extender 
40 μl of mastermix 2 was added to mastermix 1 and the solution was mixed 
very gently by pipetting up and down.  
The plate was placed directly onto the Tetrad preheated to 93oC. PCR 
conditions were an initial denaturation at 93oC for 5 min followed by 35 cycles of 
denaturation at 93oC (45s), annealing at 60oC (45s) and extension at 68oC for X 
min. The extension time for each cycle (X) was determined by, and equivalent 
to the approximate predicted size of the PCR product in kb. For example, if a 
PCR amplicon of 8kb was expected, the extension time for each cycle of 8 
minutes was used. The long range PCR was completed with a final extension at 
68oC for 5min. Subsequent PCR gel electrophoresis and PCR product clean-up 
was undertaken exactly as described in 2.3.4.3 and 2.3.4.4. For the sequencing 
reaction, a series of forward/reverse primers were again manually designed at 
300-400bp intervals from the original FP/RP. Each sequential primer was 
utilised for cycle sequencing of the original PCR amplicon in order to determine 
the exact genomic location of the deletion breakpoint. Subsequent sequencing 
reaction clean-up and preparation/analysis of sequencing reactions was as 
described in 2.3.4.5-2.3.4.7. 
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2.4 RNA analysis 
2.4.1 Isolation of total RNA 
Total RNA was extracted from fresh blood samples by the West Midlands 
Regional Genetics Laboratory. Leucocytes were lysed and total RNA recovered 
in 60ul RNase free water using QIAamp spin columns (QIAamp RNA Blood Mini 
Kit) without a DNase treatment step. RNA integrity was checked on 2% agarose 
gels.  
2.4.2 Reverse transcription and amplification of RNA (RT-PCR) 
2.4.2.1 Reverse transcription 
All samples were reverse transcribed in duplicate and a negative control (which 
contained no RNA) was included. The Promega reverse transcription system 
A3500 was used. For each sample a mastermix of 18μl was made with the 
following reagents:- 
 1.0μl (500ng) random primers 
 0.75μl (15 units) of Avian Myeloblastosis Virus (AMV) reverse transcriptase  
 2.0μl (1/10 volume) of 10X reverse transcriptase buffer 
 0.5μl (20 units) of RNase inhibitor 
 4.0μl (5mM MgCl2)  
 2.0μl (1mM) dNTPs  
 7.75μl dH20 
2μl (approximately 200-300ng) of total RNA was added to this mastermix to give 
a final volume of 20μl. An equivalent volume of dH2O was added to an 
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additional tube (instead of RNA) which acted as a control for DNA 
contamination of the RNA. 
The mixture was then reverse transcribed at 42oC for 30 min, followed by 94oC 
for 2 min to inactivate the reverse transcriptase. The cDNA was then stored at -
20oC or used immediately for PCR.  
2.4.2.2 Design of primers for PCR amplification of cDNA 
All mRNA transcript variants for a particular gene were verified using both NCBI 
Nucleotide and a thorough literature search on PubMed. For each mRNA 
transcript variant, the cDNA sequence was downloaded from Ensembl and 
primers were designed (using ExonPrimer and Primer3) for amplification and 
subsequent sequencing of the relevant cDNA sequence. 
2.4.2.3 PCR amplification of cDNA 
The PCR was carried out in 25μl reactions. A mastermix was made for each 
sample as follows:- 
 12.5μl BiomixTM Red 2X 
 10.5μl dH20 
 0.5μl (5pmol) forward primer  
 0.5μl (5pmol) reverse primer  
This 24μl pre-mix was added to fresh 0.2ml Eppendorf tubes. 1μl of the cDNA 
were then added, gently mixed and 40 cycles of PCR performed.  
 
PCR conditions were an initial denaturation at 94oC for 2 min, followed by 40 
cycles of 94oC for 10s, annealing at 60oC for 30s and extension at 72oC for 1 
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min, followed by a final extension step at 72oC for 5 min. The PCR products 
were then prepared for sequencing as described in Chapter 2.3.4.3–2.3.4.7. 
2.5 Website addresses for internet resources 
A number of websites were utilised for various aspects of experimental design 
and data analysis (Table 2-1). 
Table 2-1  
Web-based resources 
 
Affymetrix http://www.affymetrix.com/estore/  
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi  
ClustalW2 http://www.ebi.ac.uk/Tools/clustalw2/index.html  
dbSNP http://www.ncbi.nlm.nih.gov./projects/SNP/  
Ensembl www.ensembl.org 
ExonPrimer http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html  
Berkeley Dropsophila Genome Project http://www.fruitfly.org/seq_tools/splice.html  
Gene cards http://www.genecards.org/  
NCBI http://www.ncbi.nlm.nih.gov./  
NCBI Nucleotide http://www.ncbi.nlm.nih.gov/sites/nuccore  
OMIM http://www.ncbi.nlm.nih.gov./sites/entrez?db=OMIM&itool=toolbar  
Primer3 http://frodo.wi.mit.edu/primer3/  
PubMed http://www.ncbi.nlm.nih.gov./pubmed/  
Superlink Online http://bioinfo.cs.technion.ac.il/superlink-online/  
The GDB Human Genome database www.gdb.org/  
UCSC http://genome.ucsc.edu/  
UNISTS http://www.ncbi.nlm.nih.gov./unists/  
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3.1 Introduction 
The early onset epileptic encephalopathies are characterised by drug resistant 
seizures, psychomotor retardation, and, in the majority of cases, a poor 
neurological outcome. It is postulated that the infantile brain may be particularly 
susceptible to epileptic encephalopathy because the active and dynamic 
processes of synaptogenesis, apoptosis and progressive myelination occur in 
an environment of relative neuronal excitation (Ben-Ari et al., 1997; Vallano, 
1998; Simeone et al., 2004).  If a sustained diffuse epileptic encephalopathy 
occurs in the midst of this reorganisation, developmental milestones of brain 
maturation may not be achieved. Aberrant synaptogenesis and apoptosis may 
cause the brain to become inappropriately ‗hardwired‘, thus increasing 
susceptibility to excitation (Rice and Barone, 2000; Velisek and Moshe, 2001; 
Kalinichenko and Matveeve, 2008; Zupanc, 2009).  The result is a severe, early 
onset epileptic encephalopathy with chronic seizures and concomitant cognitive 
and motor impairment.  
The epileptic encephalopathies of infancy and childhood are often associated 
with a wide spectrum of aetiologies (including structural abnormalities and 
inborn errors of metabolism) and identified genetic defects account for a 
number of cases. In many children the underlying cause is not elucidated, and it 
is likely that a significant proportion of these cases have a currently 
undetermined genetic basis. In order to further investigate these disorders, I 
performed molecular genetic investigations in a consanguineous family with an 
affected child who presented with seizures in early infancy (and subsequently 
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developed infantile spasms) and identified a pathogenic deletion of PLCB1 
(MIM *607120) (Kurian et al., 2010a) 
3.2 The spectrum of early onset epileptic encephalopathies 
The early onset epileptic encephalopathies are characterised by the onset of 
refractory seizures in infancy or early childhood (Zupanc, 2009). They are 
commonly associated with neurodevelopmental delay or regression and a poor 
prognosis. They may be clinically classified as epilepsy syndromes, according 
to specific electro-clinical criteria as follows:- 
 Preferential age of onset at a specific developmental period (age-dependency) 
 Clinical presentation, seizure semiology and disease evolution 
 EEG findings 
 
The epileptic encephalopathy syndromes of infancy and childhood include a 
wide variety of heterogeneous disorders including Ohtahara syndrome (early 
infantile epileptic encephalopathy), early myoclonic epileptic encephalopathy, 
migrating partial seizures of infancy, West syndrome (infantile spasms), 
Lennox-Gastaut Syndrome, Dravet syndrome, Doose syndrome (myoclonic 
astatic epilepsy) and other progressive myoclonic epilepsies. Approximately 
50% children with an early onset epileptic encephalopathy do not entirely match 
the electro-clinical criteria of a particular syndrome (Scheffer, personal 
communication, 2010). The salient features of the major epileptic 
encephalopathies subtypes that present in infancy (with typical disease onset 
<1 year of age) are summarised in Table 3-1, and described in detail in the 
following sections. 
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3.2.1 Ohtahara syndrome (OS) 
Ohtahara et al. first described the features of this early infantile epileptic 
encephalopathy in 1976. The majority of cases present either in the neonatal 
period or in early infancy (Yamatogi and Ohtahara, 2002).  
 
The main seizure pattern is tonic spasms (which may occur in clusters), but 
other seizure types are also observed (focal and generalised tonic-clonic 
seizures). Affected children experience a high number of seizures usually 
ranging from 100-300 single episodes or between 10-20 seizure clusters per 
day (Aicardi and Ohtahara, 2002).  
 
The most specific interictal EEG feature burst-suppression, characterised by 
high voltage bursts alternating with almost flat suppression phases at an 
approximately regular rate (Figure 3-1). This specific EEG pattern is important 
in the diagnosis of OS (Ohtahara et al., 1992; Aicardi and Ohtahara, 2002).  
 
The aetiology of OS is heterogeneous but the syndrome is most commonly 
associated with structural brain abnormalities such as brain malformations and 
cortical dysplasias (Yamatogi and Ohtahara, 2002). Recently, mutations in 
STXBP1 have been identified in patients with OS (Saitsu et al., 2008, Chapter 
3.3).  
 
The prognosis for infants with OS is poor (Yamatogi and Ohtahara, 1981; 
Ohtahara et al., 1987). Affected children develop drug resistant seizures. During 
infancy, the EEG pattern changes from burst-suppression to either a 
hypsarrhythmic or diffuse encephalopathic pattern (Ohtahara and Yamatogi, 
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1990). Children develop severe psychomotor retardation and are at increased 
risk of mortality in infancy (Yamatogi and Ohtahara, 2002).  
Figure 3-1 
Burst-suppression pattern on EEG  
 
 
 
 
 
3.2.2 Early myoclonic epileptic encephalopathy (EME) 
EME is another epileptic encephalopathy with onset in early infancy usually 
before 3 months of age (Aicardi and Goutieres, 1978; Dalla Bernardina et al., 
1983). Although this syndrome is distinct from OS, both these early infantile 
encephalopathies share some common features. It is clinically characterised by 
fragmentary myoclonic jerks or violent myoclonic spasms (Lombroso, 1990). 
Over time, children also develop focal seizures and tonic events (Aicardi, 1992). 
Typical interictal EEG demonstrates an invariant burst-suppression pattern 
similar to OS (Figure 3-1). This pattern is increasingly distinct during deep sleep 
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and can persist in early childhood. On ictal recordings, each generalized 
myoclonic jerk is typically associated with a generalized or fragmentary burst of 
polyspike, spike, and slow wave discharges. In the majority of EME cases, an 
underlying aetiology is not determined. EME is rarely associated with brain 
malformations (Guerinni et al., 2003). In a subset of patients, EME may be 
associated with an inborn error of metabolism such as non-ketotic 
hyperglycaemia, methylmalonic acidaemia, proprionic acidaemia, Menke‘s 
disease and pyridoxine dependency. (Ohtahara and Yamatogi, 2003) A 
therapeutic trial of pyridoxal-5-phosphate and/or folinic acid is thus very 
important in this group of patients. Like OS, EME may be refractory to 
antiepileptic medication. The majority of affected children either die within the 
first 2 years of life or survive with severe neurodevelopmental delay. 
 
3.2.3 Migrating partial seizures of infancy (MPSI) 
MPSI was first reported in 1995 (Coppola et al., 1995) and to date 
approximately 50 worldwide cases have been reported (Coppola, 2009). 
Seizure onset is usually within the first 6 months of life and semiology is 
characterised by continuous migrating polymorphous focal seizures (often with 
secondary generalisation and autonomic features (Coppola, 2009). Multifocal 
ictal EEG changes are usually characteristic of MPSI. The aetiology is 
unknown. Mutational screening of KCNQ2, KCNQ3, SCN1A, SCN2A, and 
CLCN2 genes failed to detect significant results (Coppola et al., 2006). Children 
with MPSI usually have a poor prognosis, with drug resistant seizures, severe 
psychomotor retardation and increased risk of mortality.  
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3.2.4 West syndrome (WS) 
The clinical features of WS were first reported by Dr West in a letter to the 
Lancet in 1841, describing the semiology of seizures in his own 4 months old 
son (West, 1841). His account, to this day, is a clinically relevant description of 
this epileptic encephalopathy: 
 
“…slight bobbing  of the head forward…” which, over time, “…increased in frequency, 
and at length became so frequent and powerful, as to cause a complete heaving of the 
head forward toward his knees, and then immediately relaxing into the upright position, 
something similar to the attacks of emprosthotonus: these bowings and relaxings would 
be repeated alternately at intervals of a few seconds, and repeated from 10 to 20 or 
more times at each attack, which attack would not continue more than 2 or 3 minutes; 
he sometimes has two, three, or more attacks in the day…” 
 
 
WS is the most common of all the early onset epileptic encephalopathies, with 
an average incidence of approximately 0.31 per 1,000 live births (range 0.05 to 
0.60 per 1,000 live births) (Frost and Hrachovy, 2003). WS has a typical age of 
onset between 4 and 8 months of age, and the majority of cases (94%) present 
before one year of age. Clinical spasms may be flexor, extensor or mixed in 
nature (Lux and Osborne, 2004a). Spasms are more sustained than myoclonic 
jerks but do not last as long as a tonic seizure. Brief head nods may be an early 
subtle presenting feature. Atypical events such as autonomic features and focal 
events may also occur. The onset of spasms is very often accompanied by 
neurodevelopmental regression.  
 
The most common EEG pattern is hypsarrhythmia (Figure 3-2) which is a 
chaotic high voltage pattern of slow waves interspersed at random with 
asynchronous spikes and sharp waves (Hrachovy and Frost, 2003). An ictal 
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event during an EEG may be associated with an attenuation of voltage known 
as generalised electrodecrement (Figure 3-3).  
 
A wide variety of aetiologies are associated with WS (Zupanc, 2009), including 
brain malformations, cortical dysplasias, hypoxic-ischaemic injury, trauma, 
inborn errors of metabolism, meningitis/encephalitis, chromosomal 
abnormalities, tuberose sclerosis and other single gene defects (see Chapter 
3.3). The multiple aetiologies strongly suggest that WS is the final, common 
clinical pathway for a diffuse central nervous system abnormality occurring at a 
specific age-dependent time during brain maturation.  
 
Frost and Hrachovy (2003) reviewed 67 studies regarding outcome in infantile 
spasms. The average mortality rate was 12% and only 16% had normal 
development. Approximately one half of patients continued to have seizures at 
follow-up. Over time,17% of patients developed Lennox-Gastaut syndrome, an 
epileptic encephalopathy of childhood characterised by drug-resistant epilepsy, 
multiple seizure types (especially tonic or atonic seizures), a characteristic EEG 
(with generalized slow spike and slow wave discharges at 1.5-2 Hz) and poor 
neurodevelopmental outcome (Zupanc, 2009). Neurologic deficits were present 
in 44% of patients, and 61% had abnormal EEG findings. Certain factors were 
predictive of good outcomes. The most favourable prognostic factor was 
classification into the ‗cryptogenic‘ category (normal prior development, 
absence of causative factors, normal brain imaging studies). Absence of other 
seizure types and sustained response to therapy (without relapse) are also 
considered to be favourable prognostic factors. 
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Figure 3-2  
EEG of a patient (age 8 months) with infantile spasms. The chaotic, high 
amplitude spike and slow wave pattern of hypsarrhythmia is evident 
  
 
 
Figure 3-3 
EEG of patient aged 8 months demonstrating electrodecrement on EEG 
following the onset of a clinical spasm (indicated by the black arrow) 
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3.2.5 Classical Dravet syndrome (DS) 
Charlotte Dravet (1978) first reported a group of children with seizures onset in 
infancy, early normal development and a devastating course with ongoing 
seizures and cognitive decline. Classical DS is characterised by the onset of 
recurrent (often prolonged) episodes of hemiclonic/generalised status 
epilepticus in previously normal children, from approximately 6 months of age 
(Dravet et al., 2005). This is followed by the evolution of other seizure types 
(myoclonic, complex partial, absence and atonic seizures) in early childhood. 
Seizures are refractory to most anti-epileptic medications and may even be 
exacerbated by certain agents (carbamazepine and lamotrigine) (Guerrini et al., 
1998). The developmental trajectory of DS is classically normal in infancy and 
then plateaus thereafter. Regression may also be evident, often in the context 
of multiple episodes of status epilepticus. Over time, ataxia and pyramidal signs 
may also evolve. The EEG is usually normal in the first two years of life, after 
which generalized spike wave activity (with photosensitivity) may develop. 
Multifocal discharges are also frequent. Brain MRI is usually normal although 
non-specific changes such as mild atrophy may be seen. In the majority of 
cases, intellectual disability and a seizure disorder persist into adulthood. 
(Jansen et al., 2006). Following the seminal finding that de novo mutations of 
SCN1A underlie Dravet syndrome (see Chapter 3.3), many studies have 
confirmed high mutation frequency rates, with 70–80% cases having SCN1A 
mutations (Claes et al., 2003), including many alleged cases of ‗vaccine 
encephalopathy‘ (Berkovic et al., 2006).  
 80 
 
Table 3-1 
Clinical features of the infantile epileptic encephalopathies  
Syndrome Ohtahara syndrome  
 
 
 
(OS) 
Early myoclonic 
epileptic 
encephalopathy  
 
(EME) 
Migratory partial 
seizures of infancy  
 
 
(MPSI) 
West syndrome 
 
 
 
(WS) 
Dravet syndrome  
 
 
 
(DS) 
Typical age of 
clinical 
presentation  
<1 month <3  months <6 months 
<12 months 
(average 4-8 months) 
<12 months 
(average 6 months) 
Predominant 
seizure type at 
presentation 
Tonic Myoclonic Focal Flexor/extensor spasms 
Hemiclonic 
Generalised tonic colic 
Typical EEG at 
presentation 
Suppression-burst Suppression-burst 
Multifocal 
abnormalities 
Hypsarrhythmia 
Ictal electrodecrement 
Suppression-burst in sleep 
Normal 
 
Commonly 
associated 
aetiologies 
 
Brain malformations 
 Including cortical 
dysplasias 
Inborn errors of 
metabolism 
Unknown 
Brain malformations  
Hypoxic-ischaemic injury  
Trauma 
Inborn errors of metabolism 
Meningitis/ encephalitis, 
Chromosomal abnormalities  
Tuberose sclerosis  
Episodes triggered by 
fever 
Single gene 
defects identified 
or implicated 
STXBP1 SLC25A22 None 
ARX 
CDKL5 
STXBP1 
MAGI2 
SCN1A 
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3.3 Monogenic defects in infantile epileptic encephalopathies 
As described in 3.2, the infantile epileptic encephalopathies are associated with 
a diverse spectrum of aetiologies.  Single gene defects have been identified in 
some patients with infantile epilepsy syndromes. In OMIM, the monogenic 
infantile epileptic encephalopathies are classified as follows:- 
 Early infantile epileptic encephalopathy type 1 (ARX, MIM #308350) 
 Early infantile epileptic encephalopathy type 2 (CDKL5, MIM #300672) 
 Early infantile epileptic encephalopathy type 3 (SLC25A22, MIM #609304) 
 Early infantile epileptic encephalopathy type 4 (STXBP1, MIM #612614)  
 Severe myoclonic epilepsy of infancy (SCN1A, MIM #607208) 
 
The salient features of these genes and their proposed role in the pathogenesis 
of these epilepsy syndromes are summarised in Table 3-2. Mutations of such 
disease-causing genes are proposed to cause infantile epileptic 
encephalopathy through a wide variety of underlying disease mechanisms, 
including defective interneuron function (‗interneuronopathies‘), synaptic vesicle 
dysfunction, disrupted transport of excitatory/inhibitory neurotransmitters and 
ion channel defects (Table 3-2). 
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Table 3-2 
Single gene defects associated with infantile and childhood epileptic encephalopathies 
Gene 
MIM 
Inheritance 
Proposed physiological of protein 
 
References 
 
Epilepsy 
Syndrome 
Postulated disease mechanism 
 
References 
 
ARX *300382 
X-linked 
ARX interacts via its homeodomain with 
IPO13, a mediator of nuclear import. 
Shoubridge et 
al., 2007 
WS Interneuron specific loss, especially calbindin 
expressing interneurons, resulting in an overall 
increase in excitation. Functional impairment of 
GABAergic interneurons in the basal ganglia is 
thought to play an important role. 
Stromme et al., 
2002 
Marsh et al., 
2009 
Friocourt and 
Parnavelas, 
2010 
CDKL5 *300203 
X-linked 
Kinase involved in autophoshorylation 
and phosphorylation of other proteins 
such as MECP2. MECP2 may recruit 
CDKL5 to a DNA binding complex that 
contains a functional substrate of the 
kinase. 
Mari et al., 2005 
Lin et al., 2005 
WS in ‗Rett‘ 
like patients 
Mutations may either disrupt CDKL5 
phosphorylation role (required for its entrance into 
the nucleus)  or cause protein mislocalisation in 
the cytoplasm (a portion of the COOH-terminal 
domain is responsible for a stable residency in this 
nuclear compartment probably through protein-
protein interactions). 
Kalscheuer et 
al., 2003 
Weaving et al., 
2004 
Bertani et al., 
2006 
SLC25A22 *609302 
Autosomal 
recessive 
SLC25A22 is prominently expressed in 
the brain cortex, hippocampus and 
pontine nuclei. It catalyses co-transport 
of L-glutamate with H
+
 or its exchange 
with OH
- 
Fiermont et al., 
2002 
Molinari et al., 
2005 
EME 
(Described in 
one family) 
Defective patient fibroblast glutamate oxidation 
Defective [
14
C]glutamate uniport and 
[
14
C]glutamate/glutamate exchange by mutant 
protein in reconstituted proteoliposomes 
 
Molinari et al., 
2005 
STXBP1 *602926 
Autosomal 
dominant 
Regulation of synaptic vesicle release, in 
part, by binding to syntaxin 1A and the 
SNARE complex  
Dulubova et al., 
2007 
Toonen and 
Verhage 2007 
OS 
WS 
Impaired STXBP1 mutant protein binding to 
syntaxin leading to defective vesicle release 
Mutant STXBP1 protein much more thermolabile 
than wild type protein 
 
Saitsu et al., 
2008 
SCN1A *182389 
Autosomal 
dominant 
SCN1A forms the glycosylated alpha 
subunit of the voltage-sensitive sodium 
channel, essential for the generation and 
propagation of action potentials in the 
brain   
Isom et al., 2002 DS Reduced sodium currents in GABAergic inhibitory 
interneurons resulting from heterozygous SCN1A 
mutations may cause the hyperexcitability that 
leads to epilepsy in patients with SMEI 
Claes et al., 
2001 
Yu et al., 2006 
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Although many of these genes were initially identified in the context of early 
onset epileptic encephalopathy syndromes, over time, extensive mutational 
analysis of other epileptic disorders has revealed that they are also associated 
with other epileptic syndromes and neurodevelopmental phenotypes. ARX 
mutations have been identified in at least ten well-defined clinical entities 
(Shoubridge et al., 2010), including Ohtahara, Partington and Proud syndromes, 
X-linked infantile spasms, X-linked lissencephaly with ambiguous genitalia, X-
linked myoclonic epilepsy and non-syndromic intellectual disability. Mutations in 
SCN1A have now been documented in a spectrum of epilepsy syndromes, 
ranging from the relatively benign generalized epilepsy with febrile seizures plus 
[GEFS(+)] to Dravet syndrome and also in rare cases of familial migraine 
(Gambardella et al., 2009). De novo STXBP1 mutations have been identified in 
patients with mental retardation and non-syndromic epilepsy (Hamdan et al., 
2009) and more recently in patients presenting initially with WS (Scheffer, 
personal communication, 2010). This phenotypic pleiotropy is evidence that 
defects in such genes may contribute not only to epileptogenesis, but also to 
aberrant brain development. 
Other genes have been implicated in specific conditions in which infantile 
epileptic encephalopathy may be a feature of the syndrome. On chromosome 
7q11.23-q21.1, interstitial deletions involving MAGI2 (MIM *606382) have been 
detected in patients with a severe form of Williams-Beuren syndrome (MIM 
#194050) associated with WS (Marshall et al., 2008). MAGI2 encodes a 
synaptic scaffolding protein that interacts with Stargazin, a protein also 
associated with epilepsy in the stargazer mouse (Deng et al., 2006). More 
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recently mutations in PNKP (MIM *605610), causing DNA repair defects, have 
been identified in patients with a novel syndrome ‗MCSZ‘, characterised by 
microcephaly, early onset intractable seizures and developmental delay (Shen 
et al., 2010). Defects in SPTAN1 (MIM *182180) encoding alpha-II spectrin 
have been identified in individuals with features of WS associated with severe 
cerebral hypomyelination, spastic quadriplegia, and developmental delay. It is 
postulated that the pathological aggregation of alpha/beta spectrin heterodimers 
and abnormal axon initial segment integrity resulting from SPTAN1 mutations 
are involved in the pathogenesis of infantile epilepsy (Saitsu et al., 2010). In 
2009, mutations in PCDH19 were originally detected in patients with X-linked 
epilepsy and mental retardation limited to females (Dibbens et al., 2009). More 
recently, PCDH19 mutations have also been identified in (mainly female) 
patients with early onset epileptic encephalopathy and an SCN1A-negative 
Dravet‘s phenotype (Depienne et al., 2009, Marini et al., 2010). The unusual 
disease expression pattern in females (and mosaic males) implies that cellular 
interference may be an important pathogenic mechanism (Dibbens et al., 2009, 
Depienne et al., 2009) 
Despite these genetic advances, there are a significant proportion of patients 
with infantile epileptic encephalopathy of undetermined aetiology (Scheffer, 
personal communication, 2010). In WS, an underlying cause cannot be 
identified ~43% patients (Lux et al., 2004b). It is likely that a number of these 
patients will have an underlying monogenic aetiology. In order to further 
investigate these disorders, molecular genetic investigation was undertaken in a 
consanguineous family using autozygosity mapping strategies.  
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3.4 Methods 
3.4.1 Clinical case acquisition and assessment 
3.4.1.1 Acquisition of consanguineous family and index case  
A national surveillance study was set up in collaboration with the BPNSU 
(British Paediatric Neurology Surveillance Unit) in order to identify all UK cases 
of infantile epileptic encephalopathy of undetermined aetiology. The index case 
and family studied in this chapter was one of the families acquired through this 
reporting service. 
3.4.1.2 Clinical assessment  
For accurate phenotyping, the index case was clinically assessed independently 
by two paediatric neurologists. The medical notes were examined for details of 
disease evolution and the results of neurological investigations. 
3.4.1.3 Acquisition of infantile epileptic encephalopathy cohort 
In order to screen identified genes for mutation frequency, DNA from patients 
was ascertained through the BPNSU (as outlined above), the UKISS (United 
Kingdom Infantile Spasms Study) group, and from a cohort of patients from the 
Epilepsy Research Centre, Melbourne, Australia. All patients had an 
undetermined infantile epileptic encephalopathy (and no structural brain 
abnormality) and the majority developed WS. For all patients, written informed 
consent was provided and study approval was obtained from local ethics 
committees. 
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3.4.2 Molecular genetic investigation 
3.4.2.1 Isolation of DNA and cDNA 
DNA was extracted from peripheral lymphocytes using standard techniques 
(Chapter 2.3.1). cDNA was obtained by reverse transcription of RNA as 
described in Chapter 2.4.1 and 2.4.2.1. 
3.4.2.2 Genome wide scan  
Array studies and copy number variant analysis was undertaken (by Fatimah 
Rahman) in the index case using the Affymetrix 250K SNP microarray 
(Affymetrix UK Ltd) as described in Chapter 2.3.2.   
3.4.2.3 Development of primers 
All annotations and physical positions are recorded as in NCBI Genome 37.1 
build. The DNA template of PLCB1 was taken from Ensembl genome browser 
chromosome 20p12.3, NC_000020.10 (8,112,824–8,949,003bp). Based on all 
Ensembl coding transcript variants of this gene, primer pairs for exon-specific 
PCR amplification of the genomic exons (and flanking exon-intron boundaries) 
were designed either manually or using Primer3 software (Table 3-3). Primer 
pairs for amplification of cDNA fragments of PLCB1 transcripts were manually 
designed (Table 3-4). In order to define the deletion breakpoint, a forward 
primer upstream of exon 1 (FP) and a reverse primer in intron 3 (RP) were 
manually designed (Table 3-5) for long range PCR amplification. Sequential 
forward primers (A-G) were then designed for sequencing this amplicon to 
determine the exact deletion breakpoint DNA sequence (Table 3-5). 
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Table 3-3 Primers used for genomic PLCB1sequencing 
TRANSCRIPT NUMBER         
001 003 004 005 007 008 201 202 Primer Sequence Annealing 
Temp (
o
C) 
PCR Product 
Size (bp) 
1F 1F 1F 1F     CTCAACCCGGAGTGCACGCCTTG 60 200 
1R 1R 1R 1R     CTTTGGCAGATGCCAACCTG   
2F 2F 2F 2F     AAAATGCCATGTCTAATTTCTTTTG 58 328 
2R 2R 2R 2R     AAGATCTGTGAAATGGATGTTCTTC   
3F 3F 3F 3F     GAGGAAAGAAATATCCCAACTGC 58 346 
3R 3R 3R 3R     AAAGTGTTTAGGGCATACTGGC   
4F 4F 4F 4F    1F TTGAAGTTATGCTATCACGTTGG 58 291 
4R 4R 4R 4R    1R AAAATTCAGTCTTTTGCAGGC   
5F 5F 5F 5F    2F GCCAAGCTAAAAGCATGTGTC 55 220 
5R 5R 5R 5R    2R TCACAAAGGAGAAAGGAAACTG   
6F 6F 6F 6F    3F AAATGTACAAAGGCATGGGC 60 245 
6R 6R 6R 6R    3R GGCTGCTGGAGAAACAAAAC   
7F 7F 7F 7F    4F TGGCATCATCTGTTAGTGCTG 58 272 
7R 7R 7R 7R    4R TCATGGAAGCTCTTAATTTCCTC   
8F       5F GGTGGGTCACAAGAAAGAA 58 289 
8R       5R CCACCATATTCTCAATGCC   
 8F 8F 8F     AAACAGGGAGGGAGGAAGC 62 240 
 8R 8R 8R     CCAAGTCCTGCTCTAGCCAC   
 9F 9F 9F     CACAGTGTTTTCAGGGCAAG 58 391 
 9R 9R 9R     TGGTGTTCCTAACTCCCAGC   
 10F 10F 10F     AAAAGAGGCGACTTGACACC 58 265 
 10R 10R 10R     AGGTTGGTGAAATTTGGTGAG   
 11F 11F 11F     ACCACGGTCATCCTTGCTTC 58 293 
 11R 11R 11R     TTTCTACCTTAGGAGGCTTTAACC   
 12F 12F 12F     TCAGGCCATTCGATACAATTC 58 274 
 12R 12R 12R     TGATAAACAATTACTCAGTATGCCC   
 13F 13F 13F     TTCAGGTTCTTTGGATAAGCC 58 209 
 13R 13R 13R     TTTCCCTCAACCTCATTCATC   
 14F 14F 14F     AGGGGATCTGAAAGAGGGAG 58 297 
 14R 14R 14R     CCCAGAGCAGCAATTCTTAAAC   
 15F 15F 15F     CAAATGCTGTAAAGCTAAATGTTG 58 190 
 15R 15R 15R     AGACCCAGGAGAGTACAGGG   
 16F 16F 16F     TGAATCATGTTGTCATTTTCCTG 58 261 
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 16R 16R 16R     TCTTTGGTCCCATTACTCCG   
 17F 17F 17F     TGAGGATTATTTGCCCTCAAC 58 322 
 17R 17R 17R     GGCTATATACTTAAGCCATTTTATGC   
 18F 18F 18F     CCAAATGGAGAAAGATGGAAG 58 310 
 18R 18R 18R     CTGGCAATTTTCTCTCCCC   
 19F 19F 19F   1F  CAAAAGTGGACTGGGATCAAC 58 324 
 19R 19R 19R   1R  AAGCCACTTCTTTATGCAATG   
 20F 20F 20F 1F  2F  TTGCTGAAGAGCATTTGTGG 58 406 
 20R 20R 20R 1R  2R  GAATGGCTTTCAAAAGGTAATTG   
 21F 21F 21F 2F  3F  GAAAAGAAAAGCTAGTCCTGATTG 58 337 
 21R 21R 21R 2R  3R  AACTAAATCTCATCGCCCTTG   
 22F 22F 22F 3F  4F  CATGCTTTCATCACATAGATGC 58 292 
 22R 22R 22R 3R  4R  GCTTTGTTTGGTTCAGTTTTCC   
 23F 23F 23F 4F  5F  ATGAATGCATGGACTGATGG 58 316 
 23R 23R 23R 4R  5R  TGCTATTCCTTCTCCCAAGG   
    5F  6F  CCTTAAGGGAAAGGCTGGCTC 58 305 
    5R  6R  CCAGGAGAATGGCGTGAACC   
 24F 24F 24F     GCCTTGTTGGTTTAGGAAGG 58 265 
 24R 24R 24R     TGGCACTAATGAACTGGAGG   
 25F 25F 25F     AAAGAGATTTAGATTCAAGGCCC 58 227 
 25R 25R 25R     CCTCTCCTCTAAATACTTCCACTG   
 26F 26F 26F     TTTCCATCTGGATGTTCAGC 58 381 
 26R 26R 26R     TCTTGCCATGGTACAGGTCC   
 27F 27F 27F     TTCCCTCCACCTTGTTATGG 58 302 
 27R 27R 27R     ATCCAAAGTTTCCTATAAGGGAG   
 28-29F 28-29F 28-29F     TGGGAAGGAAGCTCTGTTTG 58 435 
 28-29R 28-29R 28-29R     CACGAAGGAGTCTTTGACTGG   
 30F 30F 30F     GCAACAGAGCGAAACCTTG 58 359 
 30R 30R 30R     ACCCTGTGAAACAGCTCTGC   
 31F 31F 31F  1F   TGAAAAGCTTTCGGTATTTTCTG 58 247 
 31R 31R 31R  1R   ATGTAAACCAGGAAGGTTTTACTC   
     2F   GGGTAGACAGGTTACATACAG 58 300 
     2R   GGCACAACGTTTTTAAGCCATGAAG   
 32F       GAGTTTCTATGGGAGTGGG 60 393 
 32R       CTCGGGAAGATGGTCCTGGG   
  32F 32F     CAAATAATTGGAAACACCAGATG 58 235 
  32R 32R     CCTTCTCTCAAAAGCGACCC   
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Table 3-4 
Primers used for cDNA PLCB1 sequencing 
ENSEMBL PLCB1 
TRANSCRIPT 
PRIMER SEQUENCE Annealing 
Temperature (
0
C) 
PCR product 
size (bp) 
003 004 005    
1F 1F 1F ACGGTCCCCAGTCCCTG 62 565 
1R 1R 1R GAATACGCCCTTCTGGAGTG   
2F 2F 2F CAGTTTGGCAACAAACCTGC 64 569 
2R 2R 2R AGTGAGAAAGGGGCTGAGAC   
3F 3F 3F GACAAATATCAGTGGATGGGTTC 62 576 
3R 3R 3R TTTTGCCGCTTCCTTCTG   
4F 4F 4F GATGCCCTTCTCATGGAGC 60 572 
4R 4R 4R AGTGCCACCATCTGACAACC   
5F 5F 5F CAAAATGCAGCTTAGCAGG 60 571 
5R 5R 5R TGGTTCCTTTCATTCCTTAGAC   
6F 6F 6F TGGCCTGTTTGAGAATAGCAG 60 576 
6R 6R 6R CCAGGTCTTTCATTTCTTTGTAGTG   
7F 7F 7F GCTCCAGGTTCTGTAAAGGC 60 633 
7R 7R 7R CTCCTCTTCCATCTGACTTTTG   
8F 8F 8F AAGTTGACGGATGTCGCAG   
8R   AGAGTCCGATGACGCTGG 60 586 
 8R 8R CTTTTCCAGGGTCTGAGGAC 60 575 
 
Table 3-5 
Primers used for long range PCR and delineation of the genomic 
breakpoint 
 
  
 
PRIMER PHYSICAL 
LOCATION (bp) 
PRIMER SEQUENCE 
 
UPSTREAM FORWARD PRIMER (FP) 8 029271 GAGCTTATCTTCGGGGATAGCTACTC 
INTRON 3 REVERSE PRIMER (RP) 8 522598 GATGGTGAAGGTGTTGGTGCTGCAAGGG 
UPSTREAM FORWARD PRIMER A 8 030637 GCCCAGGTTTTCTTTCCAGGG 
UPSTREAM FORWARD PRIMER B 8 031845 GCATATATTGAACCAGCCTTG 
UPSTREAM FORWARD PRIMER C 8 032258 GCTTTCGGAGAGTGTATGTGTCGAGG 
UPSTREAM FORWARD PRIMER D 8 032438 GTCTTGCTAGCGGTTTATC 
UPSTREAM FORWARD PRIMER E 8 033042 CTATTAGGTCTGCTTGGTGC 
UPSTREAM FORWARD PRIMER F 8 033663 CAGCTGGTACCAGTTG 
UPSTREAM FORWARD PRIMER G 8 034292 CCATTGCTGATACCCTTTC 
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3.4.2.4   PCR amplification and sequencing 
Investigation of PLCB1 was undertaken. PCR amplification and sequencing of 
genomic DNA (as described in Chapter 2.3.4.2–2.3.4.7) was performed in the 
index case, his family and also in 60 patients from the infantile epileptic 
encephalopathy cohort. Sequencing of PLCB1 cDNA (using methodology 
described in 2.4.2.3) from the parents of the index case was also performed.  
Long range PCR techniques (as described in Chapter 2.3.5) were utilised to 
characterise the genomic breakpoints of the putative deletion in the index case 
and his family. Once the PCR reaction was set up, the plate was placed directly 
onto the Tetrad preheated to 93oC. PCR conditions were an initial denaturation 
at 93oC for 5 min followed by 35 cycles of denaturation at 93oC (45s), annealing 
at 60oC (45s) and extension at 68oC for 8 min (the estimated predicted size of 
the PCR product was 7-8kb). The long range PCR was completed with a final 
extension at 68oC for 5min. Subsequent PCR gel electrophoresis and PCR 
product clean-up was undertaken exactly as described in 2.3.4.3 and 2.3.4.4. 
Each sequential forward primer (FP and Primer A-G) was utilised for cycle 
sequencing of the original PCR amplicon in order to determine the exact 
genomic location of the deletion breakpoint. Subsequent sequencing reaction 
clean-up and preparation/analysis of sequencing reactions was as described in 
2.3.4.5 -2.3.4.7. 
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3.5 Results 
3.5.1 Clinical assessment of index case and family 
A male infant presented in early infancy with seizures. He was the first child of 
consanguineous (first cousin) healthy parents from Bangladesh (Figure 3-4). 
His younger brother (currently 16 months old) was fit and well. There was no 
family history of epilepsy or other progressive neurological disorders. Initially the 
pregnancy followed a normal course with no history of abnormal fetal 
movements. However, during the third trimester there were concerns regarding 
moderate intrauterine growth retardation. Labour was induced at 38 weeks 
gestation and he was born by normal vaginal delivery. Birth weight was 2.44 kg 
(2nd centile) and head circumference was 32 cm (0.4th centile). His early 
neonatal course was uneventful. 
The infant‘s clinical course is summarised in Figure 3-5. Seizures heralded 
disease onset at 10 weeks of age. Focal seizures were characterised by eye 
rolling, lip smacking, drooling and peri-oral cyanosis followed by tonic stiffening 
and flexion of arms and legs. Each seizure was short, lasting between 5 and 20 
seconds. Sometimes clusters of 10-20 seizures would occur several times in a 
24 hour period. On clinical examination, he had mild axial hypotonia and his 
head circumference was on the 0.4th centile, but otherwise detailed neurological 
examination revealed no abnormalities. At 10 weeks, neurodevelopmental 
assessment was age-appropriate. At this stage, awake and sleep EEG was 
normal for age. Clinical seizures were not observed during the EEG recording. 
Phenobarbitone therapy was subsequently instigated. He had no further 
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seizures till 6 months of age. At this stage, the recurrence of seizures (which 
were identical in semiology to the previous seizures) was managed by a further 
increment of the phenobarbitone dosage. He was seizure-free again for a 
further 2 months.  
At 8 months, he developed the clinical and EEG features of WS.  Clinical 
spasms were characterised by sudden symmetrical whole body flexion. 
Episodes lasted 1-2 seconds, followed by a pause for 5-10 seconds, then 
followed by a further spasm. Over a 24 hour period, he had 2-5 such clusters of 
spasms (each lasting 10-60 minutes). The onset of spasms was associated with 
regression in all areas of development. Hypsarrhythmia was evident on EEG 
(Figure 3-6A) which persisted despite two weeks of vigabatrin therapy. 
Cessation of spasms was subsequently achieved by a course of prednisolone 
therapy.  
At 10 months, he developed seizures of different semiology. Seizure onset was 
heralded by an arrest of activity followed by staring, irregular breathing and 
bilateral peri-oral twitching. Over the next 2 years, he developed recurrent tonic 
and generalised tonic-clonic seizures. By 13 months, the EEG showed features 
of a diffuse encephalopathic process characterised by generalised slowing 
(Figure 3-6B). Sustained seizure control was not achieved despite the use of 
multiple anti-epileptic agents (Figure 3-5). The parents declined a trial of ACTH 
therapy. 
His head circumference continued to track along the 0.4th centile (body weight, 
2nd centile). Following the onset of clinical spasms at 8 months, there was 
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progressive developmental regression. By 2.5 years, he was functioning at the 
0-3 month level, such that he could not lift his head when prone or roll over. 
Visual fixing and following was inconsistent. Over time, he developed severe 
head lag, axial hypotonia and a spastic quadriparesis.  
MRI brain scans (at age 5 and 13 months) were normal but no further imaging 
studies were undertaken during the course of his life. Visual evoked responses 
(VEP) and electroretinogram (ERG) at age 6 months were normal. Wood‘s light 
examination and extensive neurometabolic investigations were also normal.  
At 2.9 years of age, he developed adenovirus pneumonitis (confirmed by blood 
PCR analysis) followed by a secondary bacterial respiratory infection. He 
required ventilator support (with high frequency oscillation and nitric oxide 
therapy) for progressive respiratory difficulties. He failed to clinically respond to 
antiviral drugs, multiple antibiotic agents, inotropic support and a trial of 
steroids. He died secondary to cardiorespiratory failure. Post mortem 
examination of the brain was not performed. 
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Figure 3-4 
Family tree of consanguineous kindred 
Affected child with epileptic encephalopathy is indicated by black shading (IV:1). Circles indicated females; squares 
indicate males; diamonds indicate undisclosed gender 
 
 
  
 
 
           I:1                                            I:2 
           II:1                          II:2        II:3         II:4         II:5         II:6           II:7                           II:8 
   III:1         III:2        III:3        III:4         III:5         III:6      III:7                               III:8       III:9      III:10        III:11      III:12        III:13 
    IV:1                                                              IV:2 
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Figure 3-5 
Schematic representation of the evolution of the index case‟s clinical course over the first 28 months of his life (prior to his 
death at 2.9 years) 
N  Normal EEG 
H Hypsarrhythmic pattern on EEG 
E Encephalopathic pattern on EEG – diffuse generalised slowing  
Age (months) 
 
              
               
Seizure Type  Tonic   Spasms          
               
EEG    N   H     E        
               
Medication               
Phenobarbitone               
Vigabatrin               
Prednisolone               
Sodium Valproate               
Pyridoxine                
Nitrazepam               
Phenytoin               
Topiramate               
Clobazam                
               
Developmental 
assessment 
 Normal   Subacute 
Regression 
6 month 
level 
4 month 
level 
 0-3 
month 
level 
 0-3 
month 
level 
  0-3 
month 
level 
Head circumference 
(HC) 
32cm  38.1cm  43cm      46.5cm   47.5cm 
HC Centile 0.4  0.4  0.4      0.4   0.4 
Neurological 
examination 
 
 
 Normal   Mild axial 
hypotonia 
    
 
 
     
Multiple seizure types – tonic, generalised tonic clonic seizures 
0      2        4           6               8       10          12              14              16            18             20              22             24             26    28 
Moderate axial hypotonia 
Decreased limb movement 
Mild limb hypertonicity/ 
hyperreflexia 
Severe axial hypotonia 
Limited limb movement 
Severe limb hypertonicity/ 
and brisk reflexes 
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Figure 3-6 
EEG recordings of index case (VI:1)  
3-6A 
Hypsarrhythmia on interictal EEG, age 8.5 months 
 
3-6B 
Non specific excessive generalised slow wave activity on sleep EEG recording, 
age 13 months 
 
1 second 
100μV 
1 second 
100μV 
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3.5.2 Molecular genetic investigation 
3.5.2.1 Genome-wide scan 
Using the Affymetrix 250K SNP, whole genome array studies were undertaken 
in the index case IV:1. On detailed analysis, a 0.5Mb region containing 23 
sequential absent SNP calls was identified between SNP rs6118078 
(8,048,714bp) and rs6086520 (8,507,651bp). This 0.5Mb region (from ~8.04Mb 
to 8.50Mb) was located within an extended region of homozygosity on 
chromosome 20 (with SNP homozygosity evident from 5.26Mb to 10.26Mb). 
Subsequent copy number analysis for this region indicated a homozygous 
deletion on chromosome 20 involving the PLCB1 gene and no other coding 
genes (Figure 3-7). 
Figure 3-7 
Copy number variant analysis, indicating a homozygous deletion of 
approximately 0.5Mb at chromosome 20p12.3, in the region of PLCB1 
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3.5.2.2 Genomic DNA sequencing of PLCB1 
For the index case, specific PCR primers flanking PLCB1 exons 1, 2 and 3 
(predicted to be contained within the deletion) failed to amplify on repeated 
attempts (Figure 3-8) but all other PLCB1 coding exons were amplified and 
sequencing demonstrated no abnormality. 
 
Figure 3-8 
Agarose gel photograph illustrating PCR amplification of exons 1-4 of PLCB1 
in the index case and his parents. A hyperladder has been added to lane 1 to 
aid estimation of PCR product size 
M III:7 (Mother of index case) 
F III:8 (Father of index case) 
A IV:1 (index case) 
In III:7 and III:8 all 4 exons were amplifiable. However, in the index case, on 
repeated attempts, PCR amplification of exons 1, 2 and 3 was not possible. 
Exon 4 was amplifiable in the index case 
 
  
 
3.5.2.3 Characterisation of the putative deletion 
Repeated failed attempts at PCR amplification of PLCB1 exons 1, 2, and 3 was 
further evidence of a possible homozygous deletion in the index case. Long 
range PCR techniques were employed to characterise the putative deletion. 
 M    F    A   M     F   A   M    F   A    M    F    A 
       EXON 1          EXON 2            EXON 3      EXON 4 
1000 kb 
  600 kb 
  400 kb 
   200kb  
 
df 
 
d 
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Using the primers FP and RP, an amplicon of approximately 7kb (Figure 3-9) 
was obtained in the index case (IV:1). Both parents were also positive for the 
deletion-specific PCR amplicon. To exclude the possibility that the deletion was 
a polymorphic variant, 660 ethnically matched control chromosomes were 
analysed for the presence of the deletion-specific PCR product and did not 
identify any chromosomes carrying the deletion (Figure 3-9). 
Figure 3-9 
Long Range PCR Amplification  
A - IV:1 (Index Case) 
P - III:8 (Father) 
C1-C16 - Control DNA samples 
Agarose gel photograph illustrating PCR amplification (using primers FP and 
RP for long range PCR) of a ~7kb product in both the index case (IV:1) and his 
father (III:8). PCR amplification was not achieved in control samples (C1-16 
shown here) 
A hyperladder has been added to lane 1 to aid estimation of PCR product size 
 
 
 
 
 
Sequencing of this PCR fragment (in IV:1, III:7 and III:8) using serial forward 
primers A-G (Table 3-5) allowed the genomic deletion to be characterised 
(Figure 3-10). The telomeric and centromeric genomic breakpoints were 
mapped to 8,034,442-8,034,510bp and 8,520,654-8,520,722bp respectively. 
                   A   P   C1  C2  C3  C4 C5 C6  C7 C8  C9    C10  C11 C12 C13 C14 C15 C16 
 10 000 kb 
   8 000 kb 
   7 000 kb 
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The precise location of the breakpoint could not be further defined as there was 
a 68bp sequence which showed 100% sequence homology for both the 
upstream and intron 3 sequence (Figure 3-10) defining a 486kb deletion. Using 
NCBI BLAST, I determined that the deletion occurred within a region of 96% 
sequence homology between the upstream sequence (8,029,511 and 
8,035,562bp) and intron 3 sequence (8,575,746 and 8,581,771bp). Using 
genome browsers, I identified a heterozygous deletion with similar breakpoints 
(8,002,182-8,595,665bp) which was detected in 1/540 HapMap chromosomes. 
The homozygous deletion has not been reported as a copy number variant. 
(http://www.sanger.ac.uk/humgen/cnv/data/cnv_data/display/,http://genome.ucs
c.edu/cgibin/hgc?hgsid=162444873&o=8002181&t=8595665&g=ct_WGTPCNV
s_617&i=..%2Ftrash%2Fct%2Fct_genome_773f_8dfd30.bed+819). 
3.5.2.4 cDNA sequencing of PLCB1 
To confirm that the homozygous 0.5Mb deletion produced loss of PLCB1 
expression, PLCB1 was sequenced in parental cDNA and genomic DNA 
samples. This revealed two heterozygous SNPs in parental genomic DNA 
(rs2076413 and rs2294597) but only monoallelic PLCB1 expression in parental 
cDNA (Figure 3-11). The expressed allele was the non-deleted allele that had 
not been inherited by the affected child. These results were consistent with loss 
of PLCB1 expression from the deleted allele.  
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Figure 3-10 
Definition of the genomic breakpoint of the deletion. The upstream genomic breakpoint was determined to be between 8,034,442 and 
8,034,510bp and the downstream genomic breakpoint was determined to be between 8,520,654 and 8,520,722bp. A 68bp sequence 
which showed 100% sequence homology for both the upstream and intron 3 sequence was identified (highlighted in the yellow box).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
    8 034441bp                                          8 520723bp 
100% sequence homology between upstream and intron 3 sequence 
EXON 1 EXON 2 EXON 3 EXON 4 
     8 113272bp      8 130941bp              8 352029bp                                    8 608941bp 
8 034442bp                  8 520722bp 
8 520654bp                   8 034510bp 
UPSTREAM GENOMIC 
DELETION BREAKPOINT 
INTRON 3 GENOMIC 
DELETION BREAKPOINT 
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Figure 3-11 
Sequencing analysis of genomic and cDNA in the index case‟s mother (III:7) and father (III:8) for PLCB1 exons 24 and 31. 
Although there is biallelic expression of SNPs rs2076413 (G/A) and rs2294597 (C/T) in genomic DNA, there is monoallelic 
expression of these SNPs rs2076413 (A) and rs2294597 (T) in cDNA. 
 
PARENT MOTHER MOTHER FATHER 
EXON 24 31 31 
SNP rs2076413 (G/A) rs2294597 (C/T) rs2294597 (C/T) 
GENOMIC 
DNA 
   
cDNA 
   
G/A     C/T               C/T 
A     T               T 
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3.5.2.5 PLCB1 mutational analysis of other cases 
In order to establish the frequency of PLCB1 mutations, PLCB1 sequencing and 
mutational analysis was undertaken in 60 cases (8 familial and 52 sporadic 
cases) from the acquired cohort. No pathogenic mutations were identified in any 
cases and none of the samples were positive for the deletion-specific PCR 
products. 
3.6 Discussion 
In this chapter, I have reported the novel association of infantile epileptic 
encephalopathy with the first homozygous loss-of-function PLCB1 mutation 
described in humans. This infant developed an intractable seizure disorder in 
early infancy, which subsequently progressed to WS. Over time he continued to 
have features of a severe epileptic encephalopathy with marked developmental 
regression and eventual death in early childhood. This identified PLCB1 
deletion shows appropriate familial segregation with disease status, and is 
absent in an extensive analysis of ethnically-matched control chromosomes.  
The homozygous deletion in this patient results in loss of the predicted PLCB1 
promoter sequence (Peruzzi et al., 2002) and the first three coding exons of the 
gene. No other coding genes are affected by the 0.5Mb deletion. Analysis of 
parental genomic and cDNA for expressed SNPs in exons 24 and 31 
demonstrated that the deleted allele is associated with complete loss of 
expression of PLCB1 (although PLCB1 transcripts are alternatively spliced, the 
promoter deletion was associated with silencing of PLCB1 expression in all 
transcripts). The genomic deletion is likely to have originated from an abnormal 
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recombination event between two highly homologous repetitive sequences 
located upstream of exon 1 and in intron 3. It may be that this region on 
chromosome 20 is particularly susceptible to recombination events. Indeed, 
similar somatic (heterozygous) rearrangements of this chromosome band 
20p12 occur in a number of solid tumours (Peng et al., 2002; Hu et al., 2003;  
Gordon et al., 2003) and monoallelic interstitial deletions of PLCB1 have been 
detected in a cohort of patients who show rapid progression of myelodysplastic 
syndrome to acute myeloid leukaemia (Lo Vasco et al., 2004). 
As outlined in Chapter 3.2, accurate diagnosis and subsequent clinical 
management of the epileptic encephalopathies is established by careful clinical 
assessment of seizure semiology, disease evolution and findings on EEG. 
Identification of causative gene mutations can be helpful in refining the 
diagnosis but is only possible in some cases. However, defining genetic defects 
such as PLCB1 can provide valuable insights into the pathophysiological 
mechanisms underlying this group of disorders. 
PLCB1 is a member of group of phosphoinositide-specific phospholipase C-ß 
enzymes which couple with guanine-nucleotide-binding G proteins to mediate a 
wide variety of extracellular signals transduced across the cell membrane. 
There are four known isoenzymes (ß1-ß4). PLCB1 maps to chromosome 
20p12.3 (Peruzzi et al., 2000) at 8,112,824-8,949,003bp and encodes several 
transcripts ranging in size from 288bp (30 amino acids) to 6729bp (1216 amino 
acids) (Table 3-6). 
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Table 3-6 
PLCB1 Transcripts (adapted from Ensembl genome browser) 
 
PLCB1 is a post-synaptic receptor activated, G-protein coupled 
phosphodiesterase, which catalyses the generation of inositol 1,4,5-
trisphosphonate (IP3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-
bisphosphonate (PIP2). In turn DAG activates the phosphorylating enzyme 
protein kinase C (PKC). IP3 regulates the release of calcium (Ca) from the 
endoplasmic reticulum (ER) (Figure 3-12) (De Camilli et al., 1996; Hannan et 
al., 2001). IP3, PIP2 and DAG all have direct effects on vesicular trafficking within 
the cell (Fisher et al., 1992; Fabbri et al., 1994; De Camilli et al., 1996). PLCB1 
thus plays a key role in the intracellular transduction of a large number of 
extracellular signals (involving neurotransmitters and hormones) thus 
modulating diverse developmental and functional aspects of the mammalian 
central nervous system. 
 
 
Name Transcript ID Length (bp) Protein ID Length 
(amino acids) 
PLCB1-001 ENST00000404098 697 ENSP00000384001 232 
PLCB1-003 ENST00000338037 6729 ENSP00000338185 1216 
PLCB1-004 ENST00000378637 3854 ENSP00000367904 1173 
PLCB1-005 ENST00000378641 7295 ENSP00000367908 1173 
PLCB1-007 ENST00000439627 707 ENSP00000391162 196 
PLCB1-008 ENST00000437439 288 ENSP00000389911 30 
PLCB1-201 ENST00000338061 1856 ENSP00000338402 223 
PLCB1-202 ENST00000441163 460 ENSP00000396398 152 
PLCB1-001 ENST00000404098 697 ENSP00000384001 232 
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Figure 3-12 
Proposed cellular function of PLCB1. The G-protein coupled mACh receptor 
activates PLCB1 which hydrolyses PIP2 to DAG and IP3. DAG directly activates 
PKC, whereas IP3 activates the IP3-activated ER-Ca
2+ a channel. Ca2+ released 
from the ER also activates PKC. PKC phosphorylates the potassium (K+) 
channel increasing K+ efflux causing depolarisation (Kurian et al., 2010a) 
 
 
The consequences of bi-allelic loss of PLCB1 are evident from a specific Plcb1 
homozygous knockout mouse model (Kim et al., 1997) which presents with an 
epileptic phenotype. Kim et al., demonstrated that while mice heterozygous for 
the generated Plcb1 null mutation were normal and fertile, the homozygote 
Plcb1-/- mice displayed retarded growth and low viability after birth. Most mice 
died suddenly, starting from week three after birth. The death of these mice was 
preceded by status epilepticus or intractable intermittent seizures. The seizures 
Ca2+ 
Ca2+ 
Ca2+ 
Ca2+ 
 
 
 
 
Chapter 3                                                                          Early Onset Epileptic Encephalopathy and PLCB1 
 
107 
 
were generalised in nature, either tonic events, or generalised tonic-clonic 
episodes. Histochemical analysis of the Plcb1-/- hippocampus after spontaneous 
seizure revealed selective loss of somatostatin-containing interneurons in the 
hilus (Kim et al., 1997). There is evidence that hilar interneurons containing 
somatostatin are selectively lost by electrical stimulation of adjacent granule 
cells of the hippocampus, thus indicating that seizures in Plcb1-/- are evoked 
through hippocampal hyperexcitability. PLCB1 deficiency selectively impairs 
muscarinic acetylcholine receptor (mACh) signalling (Figure 3-12; Kim et al., 
1997) in the hippocampus as well as the temporal cortex and cerebellum. It may 
thus disrupt normal inhibitory neuronal circuitry, thus lowering the brain‘s 
threshold for seizures.  
As described in Chapter 3.2, developmental arrest and poor neurological 
outcome are seen almost universally in infantile epileptic encephalopathies. The 
exact pathogenic mechanisms for this cognitive decline remain controversial 
and are yet to be fully elucidated. Although the seizure disorder may itself 
significantly contribute to the psychomotor difficulties (Dulac et al., 1996), the 
underlying aetiology may also contribute to the neurodevelopmental outcome. 
For example (as discussed in Chapter 3.3), defects in genes such as ARX 
cause epilepsy, but may also result in brain malformations and mental 
retardation.  
Studies in mice raise the possibility that loss of PLCB1 function may also have 
neurodevelopmental implications independent of (and which may precede the 
onset of) the seizure disorder (Hannan et al., 2001; Böhm et al., 2002; Spires et 
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al., 2005, McOmish et al., 2008; Koh et al., 2008). Plcb1-/- mice display a 
dramatic reduction in group 1 mGluR-stimulated phosphoinositide hydrolysis 
during cortical barrel formation, resulting in significant disruption of the 
cytoarchitechtural differentiation of barrels in the mouse somatosensory cortex 
(Hannan et al., 2001). It has also been reported that the ability of muscarinic 
receptors to induce the inward aftercurrent underlying the slow 
afterdepolarization is also markedly reduced in a Plcb1-/- knockout mouse. 
Accordingly, this phenomenon has been hypothesized to allow for the transient 
storage of memory traces in neuronal networks (Yan et al., 2009). Plcb1-/- mice 
also show absence of long-term depression in the visual cortex (Choi et al., 
2005). This data suggests that PLCB1 activation via mGluR5 receptors is 
critical for the co-ordinated development, differentiation and plasticity of the 
cortex. In addition to increasing susceptibility to epileptogenesis, loss of PLCB1 
function may thus also have independent neurodevelopmental consequences. 
Sequencing of PLCB1 in a further 60 infants with epileptic encephalopathy/WS 
did not reveal any pathogenic mutations. PLCB1 mutations are thus rare and 
likely to account for <5% of such cases (95% CI for 1/61 = 0-4.8%), consistent 
with genetic heterogeneity in this disorder. It is however important to note that 
the index case had final MR brain imaging at 13 months of age. The evolution of 
focal seizures in this patient could potentially herald the development of a 
radiologically discernible focal brain abnormality that may have only been 
evident on later scans, following completion of brain myelination after 2 years of 
age. In the future, mutational screening of PLCB1 should thus be considered in 
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all children with early onset epileptic encephalopathy, including those with focal 
brain abnormalities. 
3.7 Conclusion 
In this chapter I have described PLCB1-associated epileptic encephalopathy in 
a male infant originating from a consanguineous family. Identification of this 
homozygous PLCB1 deletion (inherited in an autosomal recessive manner) has 
facilitated appropriate genetic counselling and the possibility of future prenatal 
diagnosis for this family. Although only a single case has been identified, future 
mutational analysis of further cases of infantile epileptic encephalopathy may 
identify more PLCB1 cases, allowing enhanced phenotypic delineation of this 
disorder. The identification of a human model of PLCB1 inactivation has also 
implicated a novel disease pathway (and further potential candidate genes) 
which can be explored in the future to elucidate the molecular basis of other 
unresolved epileptic encephalopathies.  
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4.1 Introduction 
The inherited neurotransmitter disorders represent an expanding group of 
neurometabolic syndromes caused by abnormalities of neurotransmitter 
synthesis, breakdown and transport (Pearl et al., 2005). This group of diseases 
include disorders of monoamine, glycine, pyridoxine and GABA metabolism. 
Patients present with a wide variety of symptoms determined by the type and 
severity of the disorder. The monoamine neurotransmitter disorders may 
manifest with neurological features of global developmental delay, pyramidal 
and extrapyramidal motor deficits, epilepsy and autonomic dysfunction. Infantile 
parkinsonism-dystonia (IPD) is a monoamine neurotransmitter disorder 
characterised predominantly by a complex movement phenotype (Assmann et 
al., 2004). In this chapter, the preliminary clinical investigation and molecular 
characterisation of IPD will be described (Kurian et al., 2009). Two 
consanguineous families with IPD were investigated. The disease locus was 
mapped to chromosome 5p15.3 and different germline SLC6A3 mutations were 
identified in both kindreds. Functional studies (undertaken by collaborators) 
revealed that both mutations led to a reduction in the level of mature dopamine 
transporter. 
4.1.1 The monoamine neurotransmitter biosynthetic pathway 
Enzyme defects of the monoamine biosynthetic pathway can result in human 
neurotransmitter diseases. The monoamine neurotransmitters include the 
catecholamines (dopamine, norepinephrine and epinephrine) and serotonin. 
The key synthesis, degradation and salvage pathways are illustrated in Figure 
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4-1 (Assmann et al., 2003). Tetrahydrobiopterin (BH4) is a necessary cofactor 
for both tryptophan hydroxylase and tyrosine hydroxylase (Longo, 2009). BH4 is 
synthesized in three steps from guanine triphosphate. When tetrahydrobiopterin 
acts as a cofactor for these hydroxylases, it is converted to pterin-4a-
carbinolamine and subsequently ‗salvaged‘ back into tetrahydrobiopterin by a 2-
step process involving pterin-4a-carbinolamine dehydratase and 
dihydropteridine reductase. Tryptophan is converted to 5-hydroxytryptophan by 
tryptophan hydroxylase. Tyrosine is converted to L-dopa by tyrosine 
hydroxylase. Aromatic L-amino acid decarboxylase then catalyses the 
conversion of 5-hydroxytryptophan to serotonin and L-dopa to dopamine. 
Serotonin and dopamine are broken down through similar pathways, which 
involve monoamine oxidase-A and -B. In addition, dopamine is converted into 
norepinephrine by dopamine beta-hydroxylase.  
Figure 4-1 The monoamine metabolism pathway 
Metabolic pathway of serotonin and dopamine biosynthesis (solid arrows), 
catabolism (dotted arrows) and salvage (dashed arrows). The biogenic amines 
are boxed in orange. Tetrahydrobiopterin (BH4) is the essential cofactor for the 
rate-limiting enzymes tyrosine hydroxylase (TH) and tryptophan hydroxylase. 
BH4 is synthesised de novo via steps 8-11and recycled via the salvage pathway 
(steps 12-13).  
GTP is guanosine triphosphate, H2NP3 is dihydroneopterin triphosphate, NEO is 
neopterin, 6-PTP is 6-pyruvoyltetrahydropterin, SPT is sepiapterin, BH4 is 
tetrahydrobiopterin and qBH2 is (quinonoid) dihydrobiopterin, 5-HTP is 5 
hydroxytryptophan, L-DOPA is levodihydroxyphenylalanine (levodopa), OMD is 
3-ortho-methyldopa, VLA is vanillyllactic acid, 5-HIAA is 5-hydroxyindoleacetic 
acid, HVA is homovanillic acid.  
1 is tryptophan hydroxylase; 2 is tyrosine hydroxylase (TH); 3 is aromatic L-
amino acid decarboxylase (AADC); 4 is monoamine oxidase (MAO); 4a is 
monoamine oxidase plus aldehyde dehydrogenase; 5 is catechol-O-
methyltransferease (COMT); 6 is dopamine -hydroxylase;7 
phenylethanolamine N-methyltransferase 8 is GTP-cyclohydrolase I (GTPCH I); 
9 is 6-pyruvoyltetrahydropterin synthase (PTPS); 10 is aldose reductase; 11 is 
sepiapterin reductase (SR); 12 is pterin-4-carbinolamine dehydratase; 13 is 
dihydropteridine reductase (DHPR) 
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Figure 4-1 The monoamine metabolism pathway 
Metabolic pathway of serotonin and dopamine biosynthesis 
(Adapted from Kurian et al., 2010b) 
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4.1.2. Clinical features of neurotransmitter disorders  
Inherited defects of the monoamine biosynthetic pathway can result in a number 
of neurotransmitter disorders in humans (Pearl et al., 2006; Pearl et al., 2007; 
Longo, 2009). The key clinical features of monoamine neurotransmitter 
disorders are summarised in Table 4-1.  
Hoffmann and colleagues (1998) have attempted to separate the clinical 
consequences of dopamine and serotonin deficiency. Defects in the metabolism 
of dopamine show relatively distinct phenotypes. Extrapyramidal movement 
features are prominent, especially parkinsonism-dystonia, dystonia and chorea 
(Assmann et al., 2003). The spectrum of extrapyramidal symptoms is wide, 
ranging from intermittent focal dystonia (such as in autosomal dominant GTP 
cyclohydrolase deficiency, Segawa, 2009) to severe, often lethal infantile 
encephalopathies (such as Type B tyrosine hydroxylase deficiency, Willemsen 
et al., 2010).  
Dopamine deficiency is also associated with other clinical symptoms (Grattan-
Smith et al., 2002) including oculogyric crises, meiosis, ptosis, hypersalivation 
and myoclonic epilepsy. Nonspecific symptoms are also attributable to 
dopamine deficiency, and include epileptic encephalopathy, progressive mental 
retardation, microcephaly, swallowing difficulties, limb hypertonia, truncal 
hypotonia and pyramidal tract dysfunction. The manifestations of serotonin 
deficiency are less well described but include temperature instability and 
sweating. Behavioural difficulties and hypotension are seen in neurotransmitter 
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disorders of monoamine degradation (Brunner et al., 1993; Robertson et al., 
1991). 
The early onset neurotransmitter disorders display phenotypic similarity to other 
movement disorders of infantile/childhood onset such as cerebral palsy. The 
complex motor features seen in these neurotransmitter disorders can mimic 
spastic diplegia as well as dyskinetic, spastic or mixed cerebral palsy 
phenotypes. Clinical recognition and appropriate investigation is thus imperative 
to prevent misdiagnosis and/or diagnostic delay of these disorders (Assmann et 
al., 2003; Willemsen et al., 2010). 
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Table 4-1 
Clinical features of the monoamine neurotransmitter disorders 
 
 MIM Gene Inheritance Summary of common clinical features 
Disorders of BH4 synthesis     
Autosomal dominant guanine 
triphosphate cyclohydrolase (GTPCH) 
deficiency  
#128230 GCH1 
 
AD Focal limb dystonia (action and postural), torticolllis, scoliosis, pes cavus 
Gait abnormalities including ataxia 
Tremor 
Autosomal recessive GTPCH 
deficiency 
 
Pyruvoyl-tetrahydropterin synthase 
(PTPS) deficiency 
 
Sepiapterin reductase (SPR) 
deficiency 
 
Dihydropteridine reductase (DHPR) 
deficiency 
#233910 
 
 
#261640 
 
 
#612716 
 
 
#261630 
GCH1 
 
 
PTS 
 
 
SPR 
 
 
QDPR 
AR 
 
 
AR 
 
 
AR/AD 
 
 
AR 
 
 
Clinical features evident in these 4 disorders include:- 
Microcephaly 
Global developmental delay 
Irritability, poor feeding, swallowing difficulties and failure to thrive  
Seizures 
Extrapyramidal features  - dystonia, choreoathetosis, parkinsonism, tremor, oculogyric crises 
Truncal hypotonia, pyramidal tract features, spasticity 
Autonomic features  
Hyperthermia, sweating, hypersalivation, sleep disturbance 
 
Intracerebral calcification specifically seen in DHPR deficiency 
 
Pterin-4a-carbinolamine dehydratase 
(PCBD) deficiency 
 
#264070 
 
PCBD 
 
AR 
 
Mild phenotype with transient hyperphenylalaninaemia– may have no neurological symptoms 
If symptomatic, usually transient neonatal gross motor delay, abnormal tone or  tremor  
Disorders of Monoamine Synthesis     
Tyrosine hydroxylase (TH) deficiency 
 
#605407 TH 
 
AR Global developmental delay  
Type A:infantile hypokinetic-rigid syndrome with dystonia  
Type B: complex encephalopathy with neonatal onset 
Aromatic L-amino acid decarboxylase 
(AADC) deficiency 
#608643 DDC 
 
AR Developmental delay, 
Irritability, poor feeding, gastro-oesophageal reflux, constipation, diarrhoea 
Dystonia, choreoathetosis, decreased voluntary movement 
Hypertonia, hyperreflexia 
Ocular features – ptosis, meiosis and oculogyric crises 
Autonomic features , hypotension, sweating , temperature instability and hyperthermia 
Disorders of Monoamine 
Degradation 
    
Monoamine oxidase (MAO) deficiency +309850 MAOA 
MAOB 
X-linked Monoamine oxidase A deficiency – mental retardation and aggressive behaviour 
Monoamine oxidase B deficiency  -  associated with Norrie disease 
Dopamine beta-hydroxylase (DBH) 
deficiency 
#223360 DBH AR Hypoglycaemia and hyperthermia, ptosis, delayed eye opening in neonates 
Hypotension (and hypotensive seizures) Impaired/retrograde ejaculation and nocturia 
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4.1.3. Diagnosis of inherited neurotransmitter disorders 
When a neurotransmitter disorder is suspected, diagnosis is established on the 
basis of clinical history and examination together with biochemical 
investigations, enzyme analysis and mutation analysis of the causative gene 
(Marin Valencia et al., 2008). A stepwise approach to diagnostic investigations 
is generally undertaken as follows:- 
4.1.3.1 Diagnostic lumbar puncture (LP) 
Measurement of lumbar cerebrospinal fluid (CSF) neurotransmitters can aid 
diagnosis of a neurotransmitter disorder. The amine neurotransmitter 
metabolites HVA and 5-HIAA can be measured. These are the stable 
degradation products of dopamine and serotonin respectively and thus provide 
insight into the turnover of these biogenic amines in the mesolimbic and 
mesostriatal areas of the brain (Garelis et al., 1974; McConell et al., 1994; 
Marin-Valencia et al., 2008). Individual pterin species can also be measured. 
The specific pattern of these neurotransmitter metabolites can thus be indicative 
of a particular neurotransmitter disorder (Table 4-2) thereby aiding diagnosis. 
CSF neurotransmitter analysis is undertaken in collaboration with a specialist 
neurometabolic laboratory. High pressure liquid chromatography (HPLC) with 
electrochemical detection and reversed phase column is the most common 
method chosen to analyse HVA and other monoamine metabolites. These 
procedures are sensitive and specific in diagnosing such inborn errors of 
metabolism with rapid reproducible results (Mena et al., 1994). Such 
laboratories have strict protocols regarding specimen collection and 
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interpretation, as this standardised approach is essential for reliable results 
(Bräutigam et al., 2002, Pearl et al., 2005). The rostro-caudal gradient of 
neurotransmitter metabolites and BH4 necessitates that the same fraction of 
CSF must be used for each metabolite analysis (with reference ranges 
established by the same technique). Samples need to be snap frozen in liquid 
nitrogen or dry ice, as BH4 in CSF is labile. Red blood cells in the CSF lead to 
rapid oxidation of neurotransmitter metabolites and blood-contaminated 
samples must be centrifuged immediately, with clear CSF transferred to new 
tubes prior to freezing. CSF samples must be stored at -80oC until analysis. It is 
important to specify the time of day when the CSF is taken, because diurnal 
variation can affect metabolite levels. Metabolites are interpreted with reference 
to age-matched control data. The concentrations of metabolites decrease 
rapidly within the first few months of life and then continue to decrease, at a 
slower rate into adulthood (Hyland et al., 1993). It has been proposed that high 
HVA and 5-HIAA levels in infancy are required to regulate the metabolic 
pathway during mitosis, neurogenesis, migration and network formation of 
dopamine neurons.  
4.1.3.2 Blood and urine investigations 
As well as CSF investigations, analysis of pterin and biogenic amine 
metabolites in blood and urine can also aid diagnosis (Table 4-2). As dopamine 
suppresses the release of prolactin, the level of serum prolactin can sometimes 
be a useful as a marker of dopamine depletion. In some children with 
dopamine-deficient states, hyperprolactinaemia may be observed which may 
even manifest as galactorrhoea prior to the onset of neurological symptoms 
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(Yeung et al., 2006). Although prolactin measurements can be helpful, it is 
neither highly specific nor sensitive for dopamine deficiency. Indeed patients 
with profound dopamine deficiency have had normal serum prolactin while 
patients with normal dopamine turnover have been reported to have increased 
prolactin levels (as additional confounding factors, such as the stress/anxiety 
during blood sampling can alter prolactin levels). Serum prolactin levels should 
thus be interpreted in clinical context. Serum creatine kinase (CK) levels may 
also be measured and are particularly useful in aiding the diagnosis of 
rhabdomyolysis during status dystonicus. 
4.1.3.3 Enzyme analysis 
For many neurotransmitter disorders, a biochemical diagnosis can be confirmed 
by direct measurement of the residual enzyme activity in tissue samples, blood 
cells or cultured fibroblasts (Table 4-2). 
4.1.3.4 Phenylalanine (phe) loading test 
In disorders of biopterin metabolism without hyperphenylalaninaemia 
(autosomal dominant GTPCH deficiency and sepiapterin reductase deficiency), 
the diagnostic workup may be aided by a bedside investigation known as the 
oral phe loading test (Table 4-2, Bandmann et al., 2003). Elevated serum 
phenylalanine: tyrosine ratios following an oral phe load are diagnostic of a 
defect in BH4 metabolism. Measurements are usually taken at 1, 2, 4, and 6 
hours, but a single measurement 4 hours post ingestion may be sufficient for 
diagnosis. Normalisation of serum tyrosine levels after a phe load following 
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antecedent BH4 supplementation indicates a defect in BH4 supplementation 
rather than phenylalanine hydroxylase activity.  
4.1.3.5 Genetic analysis 
Mutational analysis of the specific causative gene (Table 4-1) is also 
undertaken. In some neurotransmitter disorders, such as tyrosine hydroxylase 
deficiency, there is a high rate of mutation detection (Willemsen et al., 2010). 
However in other disorders, such as autosomal dominant GTPCH deficiency, 
genetic analysis may only yield positive results in approximately 50-60% of 
patients with true GTPCH deficiency (Tassin et al., 2000). Although 
comprehensive screening of GCH1 by conventional and quantitative PCR 
analysis can further increase the diagnostic yield (Hagenah et al., 2005), it is 
possible that such patients may harbour mutations which are within the 
promoter region, deeply intronic or have heterozygous deletions/duplications 
which have not been detected by direct sequencing. It is important to interpret 
the results of genetic investigation in the context of the presenting clinical 
phenotype and biochemical investigations. 
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Table 4-2 
Characteristic biochemical profile of the monoamine neurotransmitter disorders 
 
 CSF 
HVA 
CSF 
5-HIAA 
CSF 
BH4 
CSF 
BH2 
Urine (CSF) 
Biopterin 
Urine (CSF) 
Neopterin 
Serum Phe 
levels 
Other investigations helpful for diagnosis 
BH4 synthesis 
AD GTPCH 
deficiency 
N/↓ N/↓ ↓ N N (↓) N (↓) N 
Transient hyperphenylalaninaemia on phe loading test 
Reduced GTPCH enzyme activity  
AR GTPCH 
deficiency 
↓ ↓ ↓ N ↓ ↓ ↑ Reduced GTPCH enzyme activity 
PTPS deficiency ↓ ↓ ↓ ↓ ↓(↓) ↑(↑) ↑ Decreased or absent PTPS enzyme activity 
SPR deficiency ↓ ↓ ↓/N ↑ N (↑) N N 
Increased CSF sepiapterin 
Transient hyperphenylalaninaemia on phe loading test 
SPR deficiency on enzyme analysis 
DHPR 
deficiency 
↓ ↓ ↓/N ↑ ↓ N ↑ Decreased or absent DHPR enzyme activity  
PCBD 
deficiency 
N N N N ↓ N ↑  
Monoamine Synthesis 
TH deficiency ↓ N N N N N N Decreased activity of tyrosine hydroxylase enzyme 
AADC 
deficiency 
↓ ↓ N N N N N 
Increased CSF urine and plasma L-dopa, 5-hydroxytryptophan 
and 3-O-methyldopa 
Decreased plasma catecholamines  
Decreased AADC enzyme activity 
Monoamine Degradation 
MAO deficiency N N N N N N N Measurement of urine neurotransmitters and metabolites 
 
DBH deficiency  
N/↑ 
 
N 
 
N 
 
N 
 
N 
 
N 
 
N 
Undetectable norepinephrine/epinephrine and high dopamine 
in plasma/urine/CSF 
High plasma dihydroxyphenylacetic acid (DOPAC) 
Undetectable DBH protein in plasma, CSF, or sympathetic 
fibres. Undetectable plasma DBH enzyme activity 
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4.1.4 Treatment of neurotransmitter disorders 
Accurate recognition and diagnosis of neurotransmitter disorders has important 
therapeutic implications as a number of these diseases can be effectively 
treated (Pearl et al., 2006). In general terms, treatment is aimed at, where 
appropriate, normalising blood phenylalanine, restoring brain neurotransmitter 
levels and correcting the deficiency of other chemicals. In conditions associated 
with hyperphenylalaninaemia, a dietary phenylalanine restriction will normalise 
levels as in patients with classic phenylketonuria. However in most cases, BH4 
supplementation alone can improve phenylalanine hydroxylase activity in the 
liver and normalise phenylalanine levels (Longo, 2009). In certain patients with 
DHPR deficiency, who are resistant to BH4 therapy, dietary restriction and 
supplementation with neurotransmitter precursors is needed. As DHPR is 
important in maintaining folate in its active (tetrahydro) form (Smith et al., 1985), 
patients with DHPR deficiency may develop cerebral folate deficiency. Therapy 
with folinic acid has been effective in improving neurological outcome in some 
of these patients. In conditions of dopamine/serotonin deficiency, a clinical 
response and improvement or even normalisation of brain neurotransmitters 
can be obtained with the administration of neurotransmitter precursors 
(levodopa/carbidopa, 5-hydroxytryptophan) or inhibitors of their degradation 
(such as the monoamine oxidase inhibitor, selegeline). Therapy with such 
agents is initiated at low doses and the dose is gradually increased as needed 
to minimise dyskinesias and other side effects. In some disorders, treatment 
can lead to complete resolution of symptoms, as illustrated by many patients 
with autosomal dominant GTPCH deficiency who display a dramatic and 
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sustained response to relatively low doses of levodopa (L-dopa) (Gordon, 
2008). 
 4.1.5  Other monoamine neurotransmitter disorders 
Advances in biochemical and molecular techniques have greatly increased our 
current knowledge, understanding and diagnosis of neurotransmitter disorders. 
Recently, neurotransmitter abnormalities have been described as a secondary 
phenomenon in a number of neurometabolic diseases (García-Cazorla et al., 
2007; García-Cazorla et al., 2008) such as mitochondrial disorders, Reye 
syndrome, succinic semialdehyde dehydrogenase deficiency, phenylketonuria, 
Lesch-Nyhan disease and disturbances of folate metabolism (5-methyl 
tetrahydrofolate deficiency). Abnormalities in HVA levels have also been 
reported in non-metabolic disease such as hydrocephalus (Gopal et al., 2008), 
opsiclonus-myoclonus syndrome (Pranzatelli et al., 1995), epilepsy (Shaywitz et 
al., 1975; Devinsky et al., 1992), infantile spasms (Ito et al., 1980), attention 
deficit hyperactivity disorder (Gillberg and Svennerholm, 1987), younger cases 
of Rett syndrome (Nielsen et al., 1992) and children with perinatal asphyxia 
(Blennow et al., 1995, Serrano et al., 2007). 
There also remains a number of neurotransmitter diseases (of likely genetic 
aetiology) in which the underlying molecular basis is not resolved. Examples of 
such inherited neurotransmitter disorders include some types of dopa non-
responsive dystonia associated with selective reduction of serotonin turnover 
(Assmann et al., 2002) and infantile parkinsonism-dystonia (IPD) with elevated 
dopamine metabolites on CSF investigation (Assmann et al., 2004). 
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In order to define the molecular basis of IPD, I undertook molecular genetic 
investigations in two consanguineous families using an autozygosity mapping 
strategy (Kurian et al., 2009). 
4.2 Materials and methods 
4.2.1 Clinical assessment 
4.2.1.1 Case acquisition 
Three affected children with IPD from two unrelated consanguineous families 
were ascertained through collaborators from the British Paediatric Neurology 
Association. Family A was of Pakistani origin and family B was of mixed 
European descent. Informed consent was obtained from all participants and the 
study was approved by local research ethics committees.  
4.2.1.2 Clinical phenotyping 
All three children with IPD were clinically assessed by myself and also 
independently by another paediatric neurologist. Extensive video footage of the 
children was examined in order to accurately categorise the observed 
movement disorder. Patient medical case notes were analysed to establish the 
clinical history, pattern of disease evolution and response to medication.  
4.2.1.3 CSF neurotransmitter analysis/biochemical investigations 
LP for CSF neurotransmitter analysis was performed in all three patients. The 
results of other biochemical investigations including urine catecholamine 
metabolite analysis and serum prolactin were also ascertained from the medical 
notes.  
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4.2.2  Molecular Genetic Investigation 
General molecular genetic techniques were carried out as described in Chapter 
2. In this chapter, all annotations and physical positions are recorded as in 
NCBI Genome 36.3 build.  
4.2.2.1 DNA Extraction  
DNA was extracted from peripheral lymphocytes using standard techniques. 
4.2.2.2 Genome wide scan  
In order to identify common regions of shared homozygosity in affected 
individuals of family A, a genome wide scan using the Affymetrix 250K SNP 
microarray was initially undertaken. DNA was amplified and hybridized to the 
Affymetrix 250K SNP chips, as per the manufacturer‘s instructions. SNP array 
studies were kindly undertaken by Louise Tee. 
4.2.2.3 Microsatellite marker analysis of the IPD locus 
All significant regions of common homozygosity identified on genome-wide scan 
were further investigated for linkage using polymorphic microsatellite markers 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=unists) (Table 4-3). After PCR 
amplification of genomic DNA samples, amplified fragments were genotyped 
using an ABI 3730 Genetic Analyser and analyzed with GeneMapper© 
software. Scored genotypes were assembled as haplotypes and analysed for 
evidence of linkage. 
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Table 4-3 
Microsatellite markers used for linkage analysis of the common regions of 
homozygosity identified in the affected children of family A 
 
Marker Start Position (bp) End Position (bp) 
Approximate 
Size (bp) 
UNISTS 
reference 
D5S2488 180431 180657 227-245 28850 
D5S1981 1 207429 1 207692 224-268 33655 
D5S2005 1 395107 1 395278 169-187 32955 
D5S678 1 418810 1 418928 123 64831 
D5S1.92 1 925437 1 925876 105-121 Novel marker 
D5S1970 2 497996 2 498117 112-128 39892 
D5S417 3 174219 3 174442 214 78601 
D7S817 32 102921 32 403079 155-177 80302 
D7S2211 33 602237 33 602 615 383-384 45359 
D7S2758 33 611477 33 611617 138-141 12956 
D7S678 43 247692 43 247865 166-180 71858 
D7S2436 44 686503 44 686764 222-270 73367 
D7S519 46 082558 46 082813 255-268 7883 
D7S2561 47 359975 47 360192 212-228 48440 
D9S1817 33 849625 33 849887 209-237 14086 
D9S1791 36 383383 36 383557 168-190 56137 
D9S1874 37 212295 37 212493 167-203 56570 
D9S2148 38 285718 38 285887 148-172 64272 
D9S273 71 729255 71 729401 199-217 14074 
D9S301 72 992540 72 992774 209-237 17012 
D14S1280 25 725631 25 725926 289-301 4601 
D14S275 25 766620 25 766814 194-205 62366 
D14S608 27 919195 27 919400 188-224 60255 
D14S70 33 528945 33 529156 212 23745 
D14S599 33 723548 33 723631 84-99 3467 
 
 
4.2.2.4 Multipoint linkage analysis 
Multipoint linkage analysis was undertaken combining data from both families 
and LOD scores were calculated using the SUPERLINK website. To perform 
multipoint linkage analysis, a pedigree file was prepared containing the 
genotyping data from both pedigrees studied, for all markers studied (Appendix 
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1). All 4 markers within the common region of linkage were used for analysis, 
except the novel marker D5S1.92 for which there was no Marshfield genetic 
map position available for data analysis. Data sets for both families were 
created in one pedigree file and the two pedigrees were separated by the 
headings Pedigree: A (family A) and Pedigree: B (family B).The format for every 
horizontal line (where each line represents one individual) of the pedigree file 
consisted of 13 columns as follows:- 
(1) The individual‘s ID, where each individual is given a unique numerical ID 
(2) The individual‘s father‘s ID (0 if unknown) 
(3) The individual‘s mother‘s ID (0 if unknown) 
(4) Gender (1 for male, 2 for female) 
(5) Affection status (0 if affected status unknown, 1 for unaffected, 2 for 
affected) 
(6) – (13) 8 allele markers for the 4 microsatellite markers analysed. For each 
marker, each allele was labelled as an integer starting with 1 (for the lowest 
numerical allele call) upwards 
Using the SUPERLINK program, analysis was undertaken as follows:- 
 The option ‗Simplified input format‘ was chosen 
 The number of markers in the simplified input file was inserted (4) 
 The disease mutant gene frequency was inserted (0.001) 
 The mode of inheritance was chosen (Autosomal recessive) 
 The disease penetrance was added (0.99) 
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Using UNISTS, the Marshfield genetic map position (in cM) for each 
microsatellite marker was established as below 
D5S2488 0.00cM 
D5S1981 1.72cM 
D5S2005 1.72cM 
D5S678 1.72cM 
The distances (cM) between the 4 markers were inputted: 1.72, 0.0, 0.0 
 A list of sequential marker names was given (D5S2488, D5S1981, D5S2005, 
D5S678) 
 The allele frequencies were assumed to be distributed in a uniform fashion 
 The data was then submitted for analysis 
4.2.2.5 Gene Sequencing 
Following linkage analysis, mutation analysis of the candidate gene SLC6A3 
was undertaken as described in Chapter 2.3.4 Primer pairs for exon-specific 
PCR amplification of the 14 translated exons of the SLC6A3 
(ENST00000270349) gene were designed (Table 4-4).  
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Table 4-4 
Primers used for sequencing of coding regions of SLC6A3 gene 
Exon Primer Pairs (5’ – 3’) PCR Product Size 
(bp) 
Annealing 
Temperature (
o
C) 
2 TGGCTGAAGACCAAGAGGG 427 58 
 CTCGTTTCCGTACGTGCC   
3 CTCCCACGAGGAGAGATGG 263 58 
 TTGAAAGCTCCAGCGTCAC   
4 GTTGCTGATGGTGGCTCTG 374 58 
 GTGTCCAACCAAGGGGCTAC   
5 CAGTTCCAGGTGGGTTGAC 279 58 
 GTGCACCTCCTGTCCAGC   
6 CAGTGTCTGCTCCCACCAAG 266 58 
 AATGCATATGGAAACCTGGG   
7 AGGGTGCTCAGGTCCTTTG 243 58 
 TTCTGGAAGTCAGCGACC   
8 CCCCTTCCCCAGACACAG 315 58 
 TCTCCTTCCTCTTTCACAAGG   
9 CAGGATGGGCGGGAGAG 227 62 
 GGGTGGAAGGAACCCAAC   
10 TGACAAGTAGGTCTTGGCCC 264 62 
 CGTGCCACGTGCTAAGG   
11 GTGTGCACAGTGAATCCC 272 58 
 GAAAGGTGTTTCCTCACGG   
12 GAGTCAGCGAGGACCCC 284 62 
 CACAGTGACAACCCACATGC   
13 CCTGCTTTGTCCTGGCAC 289 58 
 CACGGAGCCTTTCTGGTG   
14 GCAGTGTGAGTCAGTGGTGG 181 58 
 CTGAGCTTGGGATCATTCTG   
15 TCAGCTGCTCTTAAATGGGG 146 58 
 GGTTTGTTCGTGTCTCTCCC   
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4.2.3 Functional analysis of mutant DAT proteins 
All functional investigations were kindly undertaken by collaborators in 
Professor Reith‘s group, Department of Psychiatry and Pharmacology, 
Millhauser Laboratories, New York University School of Medicine, New York, 
USA. Methodology is described in Appendix 2. 
4.3 Results 
4.3.1 Clinical assessment 
Family A, an extended consanguineous kindred of Pakistani origin (Figure 4-2A) 
had 2 affected children with IPD (Patient #1 and #2) who were first cousins. 
Family 2 (Figure 4-2B) was of mixed European descent with one affected child 
(Patient #3). The diagnosis of IPD was based on characteristic clinical features 
and CSF neurotransmitter studies (Table 4-5). In brief, following a normal 
pregnancy and birth, all children had neonatal irritability and feeding difficulties. 
Parkinsonian symptoms heralded disease onset in early infancy and were 
rapidly followed by the development of pyramidal tract features and dystonia. All 
patients were initially misdiagnosed with cerebral palsy. On examination at ages 
6-12 months, all patients had features of parkinsonism, dystonia and pyramidal 
tract signs with evidence of global developmental delay. CSF biogenic amine 
metabolite studies in affected patients revealed markedly elevated 
concentrations of HVA (with normal 5-HIAA levels). MRI brain did not reveal 
structural abnormalities in any of the patients. In light of their severe motor 
disability, neuropsychiatric assessment to determine whether the children had 
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any evidence of cognitive impairment could not be undertaken. All patients 
showed a poor clinical response to multiple therapeutic agents. CSF HVA levels 
did not normalise after L-dopa or tetrabenazine therapy. Insertion of a deep 
brain stimulator device in Patient #3 resulted in some transient improvement of 
dystonia and rigidity. All children showed a progressive disease course with 
worsening symptoms of parkinsonism, dystonia and hypertonicity. None of the 
affected children had evidence of psychiatric or behavioural/conduct disorders. 
Detailed neurological examination of all the children‘s parents (aged 21 to 37 
years) and siblings (age 1 to 9 years) revealed no neurological abnormalities. 
Additionally, none of the unaffected family members (including siblings, obligate 
carrier parents, parental siblings and grandparents) were known to have a 
neurological, neuropsychiatric or age-related movement disorder. 
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Figure 4-2 Family trees of consanguineous kindreds. Children affected with IPD are indicated by black shading. Circles indicate females; squares 
indicate males; diamonds indicate undisclosed gender 
Figure 4-2A Family A kinship 
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  Figure 4-2B 
  Family B kinship   
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Table 4-5 
Phenotypic data for children with IPD  
 Patient #1 
Family A 
Patient #2 
Family A 
Patient #3 
Family B 
Age of child (years) at assessment 3.9 2.5 10.7 
Ethnic Origin Pakistani Pakistani Caucasian European 
Parental consanguinity Parents - 1
st
 
cousins 
Father and 
maternal 
grandmother - 1
st
 
cousins 
Parents 2
nd
 cousins 
Family History Nil Nil Nil 
Pregnancy and Birth Normal Normal Well controlled 
gestational diabetes 
Early course in infancy Irritable                                   
Feeding 
Difficulties 
Irritable                                   
Feeding 
Difficulties 
Irritable                                   
Feeding Difficulties 
Onset of Symptoms (months) 
Parkinsonism  
Dystonia  
Pyramidal tract signs 
Eye movement disorder 
 
4 
4 
4 
- 
 
4 
6 
6 
- 
 
5 
5 
5 
48 
Features on clinical examination 
Generalised bradykinesia 
Reduced facial expression 
Rigidity 
Dystonia 
Pyramidal tract signs in limbs 
Axial hypotonia/head lag 
Global developmental delay 
 
++ 
++ 
++ 
++ 
++ 
+ 
++ 
 
++ 
++ 
++ 
++ 
++ 
+ 
++ 
 
++ 
+ 
++ 
++ 
+ 
++ 
++ 
Eye examination 
Saccade initiation failure 
Ocular flutter 
 
- 
- 
 
- 
- 
 
+ 
++ 
Investigations 
CSF  
HVA concentration
A 
5-HIAA concentration
B 
HVA:5-HIAA ratio
C
  
Urine (Reference Range) 
HVA:Creatine ratio
D 
Serum 
Prolactin
E
  
 
 
1873 
141 
13.2 
 
22 
 
150 
 
 
1704 
250 
6.8 
 
27 
 
915 
 
 
1135 
91 
12.5 
 
ND 
 
688 
Clinical Course 
Response to medication* 
Response to deep brain stimulator 
Progression of symptoms 
 
Nil 
NA 
+ 
 
Nil 
NA 
+ 
 
Nil 
Some improvement 
+ 
 
-  Absent    A Reference range 154 – 867 nmol/L 
+ Present    B Reference range 89 – 367 nmol/L 
++ Present and severe  C Reference range 1.0 – 3.7 
NA Not applicable   D Reference range 2-15μmol/mmol creatinine 
ND Not determined   E Reference range 93 – 630 mIU/L 
 
*Therapeutic agents including levodopa, carbidopa, tetrabenazine, diazepam, carbamazepine, 
baclofen, 5-hydroxytryptophan and trihexyphenidyl  
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4.3.2   Results of molecular genetic investigation 
4.3.2.1 Genome wide scan  
Genome-wide SNP genotyping (with the Affymetrix 250K SNP microarray) was 
performed in  individuals VII:1 (Patient #1), VII:2 (unaffected sibling of Patient 
#1) and VII:3 (Patient #2) from Family A. In the 2 affected cousins, five possible 
regions of extended homozygosity (>2Mb) were detected on chromosomes 5 
(2.3Mb), 7 (one region of 2Mb and one of 6Mb), 9 (41Mb) and 14 (9Mb).  
4.3.2.2 Microsatellite marker analysis  
These four regions were then further analysed using polymorphic microsatellite 
markers mapping to these regions of interest (Table 4-3). Linkage to the 
candidate regions on chromosome 7, 9 and 14 was excluded by segregation of 
the microsatellite marker alleles (Appendix 3). Genotyping of the family with 
microsatellite markers within the interval on chromosome 5 revealed an 
identical homozygous haplotype in the 2 affected children (which was different 
to that of the unaffected sibling and parents), consistent with possible linkage to 
this region (Figure 4-3). Subsequent microsatellite marker analysis of family 2 
was also consistent with linkage to this region (Figure 4-4). The SNP data for 
chromosome 5 was further analysed, and showed that Patient #1 and #2 
shared a common homozygous haplotype of 201 SNPs from 1 to 2,373,003bp 
(thereby defining the margins of the homozygous region) whilst the unaffected 
sibling of patient #1 demonstrated SNP heterozygosity in this region (Figure 4-
5).  
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Figure 4-3 
Microsatellite marker linkage analysis on chromosome 5 in Family A 
Affected individuals are shaded in black. SLC6A3 gene is located at 5p15.3. 
Microsatellite markers are positioned according to physical distance (MB). 
Haplotypes for these markers are shown and the disease associated 
haplotypes are boxed in blue. The two affected children share a common 
homozygous haplotype in this region 
(N) –Novel microsatellite marker 
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Figure 4-4 
Microsatellite Marker Analysis on chromosome 5 in family B 
The affected child is shaded in black. Microsatellite markers are positioned 
according to physical distance (MB). Haplotypes for these markers are shown 
and the disease associated haplotypes are boxed in red. Microsatellite markers 
show evidence of segregation with disease status in this family. 
(N) –Novel microsatellite marker 
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Figure 4-5 
Localisation of the disease locus on chromosome 5 on 250K SNP array  
SNP array data is illustrated on family A: Patient #1 (VII:1),Patient #2 (VII:3) and 
the unaffected sibling of Patient #1 (VII:2) 
 
Dark blue: AA homozygous SNP call 
Mid blue: BB homozygous SNP call 
Light blue: No call 
White: AB Heterozygous call 
 
Patient #1 and #2 display a region of SNP homozygosity from 0–2.3MB 
The unaffected sibling (VII:2) does not display this common SNP homozygosity 
and has a heterozygous SNP haplotype in this region 
 
 
 VII:1  VII:3      VII:2 
 
 
0 MB 
2.3MB 
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4.3.2.3 Multipoint linkage analysis 
 
Results from the multipoint linkage analysis were obtained from the 
SUPERLINK website (Appendix 1, Table 4-6). A maximum combined LOD-
score of 5.28 was obtained. 
Table 4-6  
Multipoint linkage analysis for Family A and Family B 
 
Marker position from marker D5S2488 (cM) 0.0 1.72 
Pedigree A (Family A)   
Ln (Likelihood) -36.4603 3.4589 
LOD-Score -36.4041 3.4833 
Pedigree B (Family B)   
Ln (Likelihood) -27.7487 1.7902 
LOD-Score -27.7270 1.7996 
Both pedigrees A and B combined   
Ln (Likelihood) -64.2090 5.2491 
LOD-Score -64.1311 5.2829 
 
4.3.2.4 Candidate gene selection and mutational analysis 
Having established the region on chromosome 5 as the likely IPD locus, the 39 
genes within the region were examined for a candidate IPD gene. SLC6A3 
(located at chromosome 5, 1,445,909–1,498,538bp) encoding a dopamine 
transporter (DAT1) was selected as a potential candidate and subsequent 
mutation analysis of SLC6A3 was initiated. A homozygous putative missense 
mutation c.1103T>A, p.Leu368Gln (Figure 4-6) was detected in exon 8 in 
Patients #1 and #2. SLC6A3 mutation testing subsequently performed in Family 
B and a homozygous variant in exon 9, c.1184C>T (p.Pro395Leu), was 
detected in Patient #3 (Figure 4-6). Both mutations segregated with IPD disease 
status in the families and neither mutation was detected in an extensive 
analysis of ethnically-matched control chromosomes (544 Asian and 438 
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Caucasian control alleles respectively). Sequence alignment showed Leu368 
and Pro395 to be highly conserved throughout species (Figure 4-7).  
 
 
Figure 4-6 
SLC6A3 mutations in Family A and Family B 
The alignments of SLC6A3 nucleotides c.1091-c.1116 (Panel A, B and C) and 
c.1168 -c.1197 (Panel D, E and F) are shown. Panel B illustrates c.1103T>A in 
Family A. Panel E illustrates c.1184C>T in family B 
 
 
 A: Parent (VI:3) (Family A)            D: Parent (IV:2) (Family B) 
 
         
  B: Patient #1    E: Patient #3  
 
        
C: Wild type     F: Wild type 
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 Figure 4-7  
Conservation of the mutated DAT1 residues Leu368 and Pro395 
Five representative vertebrate sequences are aligned. Leucine 368 (Leu368) and Proline (Pro395) are coloured in red. Residues matching 
the consensus sequence are in grey. 
     
        Leu368    Pro395 
 
 Human           DAIVTTSINSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLS 404 
 Dog             DAVITTSVNSLTSFSSGFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEALATLPLS 401 
 Mouse           DAIITTSINSLTSFSSGFVVFSFLGYMAQKHNVPIRDVATDGPGLIFIIYPEAIATLPLS 403 
 Rat             DAIITTSINSLTSFSSGFVVFSFLGYMAQKHNVPIRDVATDGPGLIFIIYPEAIATLPLS 403 
 Zebrafish       DAIITSSINSLTSFFSGFVIFSFLGYMSQKHNVALDKVATDGPGLVFIIYPEAIATLPGS 413 
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4.4 Discussion 
As discussed in the introduction of this chapter, inherited neurotransmitter 
disorders of infantile onset are usually associated with reduced CSF dopamine 
metabolites due to enzyme defects of the biogenic amine synthetic pathway 
(Table 4-2). Unlike these neurotransmitter disorders, IPD is characterised by 
paradoxically raised dopamine metabolites in CSF, and is thus a distinct 
neurotransmitter disorder associated with unique clinical, biochemical and 
genetic features. 
In this chapter, I have described the clinical phenotype of three patients with 
IPD, delineated the IPD disease locus and identified loss-of-function mutations 
of SLC6A3 in all three patients. 
4.4.1 The dopamine transporter (DAT) 
SLC6A3 (MIM *126455) encodes the dopamine transporter and is exclusively 
expressed in dopaminergic neurons with significantly higher levels of DAT 
expression in cells of the substantia nigra pars compacta, pars lateralis and 
ventral tegmental area (Storch et al., 2004). DAT mediates the active reuptake 
of extraneuronal dopamine and is a principal regulator of the amplitude and 
duration of dopaminergic action. Dopamine is transported inwardly against its 
concentration gradient using the driving force of the sodium gradient across the 
plasma membrane. The transport process of dopamine uptake involves 
translocation of dopamine, as well as two sodium and one chloride ion across 
the cell membrane (McElvain et al., 1992). The Na+/K+ pump thus has a crucial 
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role in generating the electrochemical gradient across the cell membrane. The 
role of dopamine and its transporter is discussed in more detail in Chapter 5. 
4.4.2 Functional investigation of mutant hDAT proteins 
All functional investigations were undertaken and analysed by collaborators 
from Professor Reith‘s group, Department of Psychiatry and Pharmacology, 
Millhauser Laboratories, New York University School of Medicine, New York, 
USA. To determine the effects of the p.Leu368Gln and p.Pro395Leu mutations, 
mutant hDAT proteins were transiently expressed in HEK-293 cells and their 
transport activity was compared with that of wild-type hDAT (Table 4-7) (Chen 
et al., 2004a; Chen and Reith, 2007; Zhou et al., 2007). In experiments carried 
out in parallel, wild type showed normal transport activity, whereas Leu368Gln 
and Pro395Leu were devoid of uptake activity. The binding affinity of the 
cocaine analogue [3H]CFT was near-normal in the mutants (30–36nM 
compared with 16nM in wild type, Table 4-7). In contrast, the potency of 
dopamine in inhibiting cocaine analogue binding was greatly reduced in 
Leu368Gln (Ki increased by an order of magnitude), whereas the potency of 
dopamine in Pro395Leu was close to that of wild type (Zhou et al., 2007). Thus, 
both mutations are loss-of-function mutations with respect to the capability of 
DAT to translocate dopamine, in conjunction with a loss of apparent binding 
affinity of dopamine in the case of one of the mutations. Maximal binding of 
[3H]CFT to cells, primarily representing surface binding (Chen et al., 2004a), 
indicated appreciable expression of DAT in both mutants, although Leu368Gln 
showed a reduction that was statistically significant (Table 4-7). 
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Table 4-7 
Dopamine transport and cocaine analogue binding by Wild-type, 
Leu368Gln and Pro395Leu hDAT 
 
 Wild type Leu368Gln Pro395Leu 
[
3
H]Dopamine uptake 
Km (µM) 
Vmax (pmol/min/mg prot.) 
 
0.249 + 0.029  
1.19 + 0.20  
 
N/A
A 
 
0
A 
 
 
N/A
A 
 
0
A 
 
 
   
[
3
H]CFT binding    
 Kd (nM) 
Bmax (pmol/mg prot.)                                  
 
15.9 + 1.9  
2.14 + 0.65  
 
35.6 + 8.2  
0.384 + 0.110
 B
  
 
30.2 + 6.5  
0.962 + 0.144  
    
Inhibition of [
3
H]CFT  
binding by dopamine Ki (μM)  
 
6.58 + 0.53 52.9 + 1.7
B
 3.35 + 0.65 
 
A  No transport activity detectable above non-specific uptake 
B  P < 0.05 (compared with wild type, one-way ANOVA followed by Dunnett multiple comparisons 
 
To investigate whether the observed reductions in dopamine transport were 
related to disordered production, localisation or function of the mutant proteins, 
immunoblotting was performed. Analysis of whole cell lysates demonstrated 
equivalent levels of immature (55 kDa) DAT for wild-type and Pro395Leu but 
there was some reduction for Leu368Gln (total protein loading - as judged by ß-
actin - was equivalent for wild-type, Leu368Gln and Pro395Leu hDAT). 
However both mutant proteins demonstrated a profound reduction in mature (85 
kDa) DAT compared to wild type DAT. Analysis of surface (biotinylated DAT) 
showed a similar pattern (Figure 4-8).  
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Figure 4-8 
Expression of the Leu368Gln hDAT and Pro395Leu hDAT in transiently 
transfected HEK293 cells via immunoblotting analysis 
Cells were transiently transfected with WT hDAT, Leu368Gln hDAT, Pro395Leu 
hDAT, and reagent only. In each respective panel, the same amount of protein 
was loaded in all lanes. Biotinylated (surface) protein (left panel) and total lysate 
(right panel) were probed with anti-DAT antibody for detection of the relative 
expression level of WT and mutant DAT protein. Anti--actin antibody showed 
the relative equivalent loading of total protein. There was no -actin in the 
surface preparation 
 
    
 
Based on the crystal structure of the bacterial transporter analogue LeuT 
(Yamashite et al., 2005) the primary substrate site and the sodium binding sites 
in DAT can be modelled deep in the protein interior where unwinding of the 
transmembrane helices 1 and 6 allows extensive interactions between protein 
residues in transmembrane domains 1, 3, 6, 7, and 8 and substrate or sodium 
(Beuming et al., 2006). A secondary substrate site has been proposed to be 
located towards the outside of the transporter (Shi et al., 2008) in an 
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extracellular vestibule where tricyclic antidepressants also bind in LeuT (Zhou et 
al., 2007; Singh et al., 2007) above the extracellular gate, which, in turn, lies 
between the two substrate sites.  
Among the positions of these two IPD-associated missense mutations reported, 
Leu368 in hDAT is in transmembrane domain 7 towards the exterior, many helix 
turns above the residue (Asn353) that presumably interacts with sodium (Figure 
4-9). Leu368 is one helix turn under Met371, and is conformationally sensitive 
to dopamine transport (Norregaard et al., 2003). The position of the second 
missense mutation, Pro395, is in one of the two helical portions of extracellular 
loop 4, EL4b, the one closer to transmembrane 8. Pro395 lies just one helix turn 
above Ala399, a residue that, like Met371, points outward the entire transporter 
structure and thus is easily accessible to solvent bathing the outside of the 
protein (Norregaard et al., 2003). Interaction between a sulfhydryl reagent in 
such solvent and the 399 position is not blocked in the presence of dopamine, 
whereas that at 371 is highly sensitive to dopamine, i.e., by dopamine causing 
conformational changes burying the residue away from solvent exposure. In 
consonance, the missense mutation of Pro395 (above 399) has no impact on 
dopamine binding affinity, whereas the missense mutation of Leu368 (under 
371) appears to interfere with conformational changes occurring with dopamine 
binding such that dopamine‘s apparent affinity is strongly reduced. Hence, 
despite the different impact of the two missense mutations on dopamine binding 
affinity, the location of the mutations and the mutations and their effect to 
completely impair transport of dopamine suggested that both mutations might 
interfere with conformational changes required during transport. 
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Figure 4-9  
Two-dimensional representation of dopamine transporter topology based on 
LeuT structure 
 
Twelve transmembrane domains are shown with helically unwound regions in 
first and sixth domain; extracellular and intracellular loops include helical 
portions (e2, e3, e4a, e4b, and i1, 15, respectively). Leu368, subject to 
missense mutation, is shown in red at the top of transmembrane domain 7, one 
helix turn under Met371 in blue. Pro395, also subject to missense mutation, is 
shown in red in the e4b portion of extracellular loop 4, one helix turn above 
Ala399 in blue. In the three-dimensional structure, sodium ions interact with 
residues of transmembrane domains 1, 6, and 8, and also 7  
 
 
 
 
 
 
 
In this chapter it has also been shown that the marked reduction in mature 
(glycosylated) 85 kDa DAT expression appears to be a major contributor to 
reduced dopamine transport. It has previously been demonstrated that 
immature non-glycosylated (55 kDa) DAT does not transport dopamine as 
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efficiently as mature 85 kDa DAT (Li et al., 2004). Hence the reduction in 
mature DAT will undoubtedly impair dopamine transport.  
4.5 Conclusion 
In this chapter, I have delineated the clinical features of a distinct 
neurotransmitter disorder and in all 3 patients, identified homozygous loss-of-
function mutations in the dopamine transporter gene, SLC6A3. Molecular 
characterisation has provided novel insights into this complex movement 
disorder. Although the condition appears to be rare, the children described in 
this chapter were initially diagnosed with cerebral palsy. Following gene 
identification, I instigated an extensive international search for further similar 
cases, in order to establish the frequency of SLC6A3 mutations. A cohort of 
children with biochemical markers suggestive of this novel syndrome was thus 
acquired and investigated, in order to further characterise the clinical, 
biochemical and genetic features of this disorder (see Chapter 5). 
Elucidation of the genetic basis of this disorder is of clinical benefit to patients 
and families. Identification of pathogenic mutations can confirm the clinical and 
biochemical diagnosis and can also contribute to accurate genetic counselling 
and prenatal diagnosis. Molecular characterisation of this syndrome may also 
provide a basis for the future development of effective therapeutic strategies. In 
these three patients, therapeutic approaches have not biochemically normalised 
HVA levels or clinically improved patient symptomatology. None of these 
patients demonstrated a clinical response to L-dopa. L-dopa therapy may be 
beneficial in some infantile neurotransmitter syndromes (see Chapter 4.1.4), 
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where exogenous administration can compensate for the reduction in 
endogenous dopamine production. The lack of clinical response to L-dopa in 
these three patients is not wholly surprising given that their mutations are 
predicted to result in complete absence of dopamine transporter activity. 
Complete loss of transporter function is likely to disrupt the fundamental role of 
DAT in controlling the amplitude and duration of dopaminergic transmission and 
it may be that L-dopa supplementation cannot compensate for complete loss of 
this physiological process. The moderate therapeutic success of deep brain 
stimulation (DBS) in Patient #3 may be attributable to the hypothesised role of 
such targeted neuronal high frequency stimulation in the modulation of 
dopamine, glutamate and GABA neurotransmitter systems within the basal 
ganglia (McIntyre et al., 2004). It is possible that such selective neuronal 
activation and suppression as well as changes in network synchrony could 
potentially alleviate parkinsonian/dystonic symptoms in DAT-associated 
movement disorders. Elucidation of the molecular basis of this disorder has 
facilitated a trial of novel therapeutic strategies in some of the affected children. 
This is discussed in more detail in Chapter 5.  
  
 
 
 
 
 
 
Chapter 5 
Dopamine Transporter Deficiency Syndrome 
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5.1 Introduction 
Accurate recognition of inherited disorders is important in preventing morbidity 
from misdiagnosis/diagnostic delay and in facilitating ‗personalised medicine‘. 
Advances in molecular diagnosis can lead to the recognition of novel genetic 
phenotypes that can provide critical insights into pathophysiological disease 
mechanisms.  
In Chapter 4, I described the identification of pathogenic mutations of SLC6A3 
in three patients with IPD (Kurian et al., 2009). Following gene identification, I 
acquired a cohort of children with a biochemical profile compatible with this 
novel syndrome. In Chapter 5, I will describe the phenotypic features of these 
patients, results of SLC6A3 sequencing and data from functional analysis of 
mutant human DAT. The physiological role of dopamine and its transporter 
(DAT) and postulated disease mechanisms in this disorder will also be 
discussed (Kurian et al., 2010b). 
As it is often common practice to name inherited diseases after the underlying 
pathogenic defect, I have renamed this novel disorder as dopamine transporter 
deficiency syndrome (DTDS) to reflect the underlying disease mechanism and 
encompass the wide spectrum of clinical phenotypes seen in this disorder 
(which extends beyond the clinical features of infantile parkinsonism-dystonia). 
DTDS is thus a newly recognised, autosomal recessive disorder related to 
impairment of dopamine transporter function. Delineation of the clinical, 
biochemical and genetic features will facilitate early diagnosis and trials of 
therapeutic agents based on an understanding of the pathophysiology. In 
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addition careful characterisation of such patients with DTDS should provide 
novel insights into the multiple and complex role of dopamine homeostasis in 
the human brain. 
5.2 Methods  
5.2.1 Clinical assessment of DTDS patients 
5.2.1.1 Acquisition of DTDS cases 
Eleven children with DTDS were identified. A brief overview of the clinical 
phenotype of Patients 1-3 was reported previously in Chapter 4 in association 
with the initial identification of SLC6A3 mutations in 2009 (Kurian et al., 2009) 
and the clinical and biochemical features of patients 4-6 have also been briefly 
reported in 2004 (Assmann et al., 2004). The 11 subjects were ascertained from 
paediatric neurologists specialising in movement disorders and biochemical 
laboratories performing paediatric CSF neurotransmitter analysis (Institute of 
Child Health, London, UK; Medical Neurogenetics, Atlanta, USA; University 
Children‘s Hospital, Heidelberg, Germany).  
5.2.1.2 Clinical phenotyping 
All children were clinically assessed by a paediatric neurologist. I assessed all 
living UK cases (3 patients) and extensive video footage of all cases was 
examined independently by 3 paediatric neurologists (myself, Dr Birgit 
Assmann, Germany and Dr Terry Sanger, USA) to accurately categorise the 
observed movement disorder (with consensus agreement on disparities). 
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Medical case notes were reviewed to establish the clinical history, pattern of 
disease evolution, results of investigations and response to medication. 
5.2.1.3 Biochemical investigations 
An LP for CSF neurotransmitter analysis was performed in all patients as 
described in Chapter 4.1.3.1. HVA and 5-HIAA levels were measured. Other 
investigations included urine catecholamine metabolite analysis, serum 
prolactin and serum CK. 
5.2.1.4 Neuroradiology 
Neuroradiological studies, including magnetic resonance imaging (MRI), 
magnetic resonance spectroscopy (MRS) and nuclear brain imaging were also 
evaluated. 
5.2.2 Molecular genetic investigation  
All annotations and physical positions are recorded as in NCBI Genome 36.3 
build 
5.2.2.1 SLC6A3 mutational analysis 
DNA extraction was performed as described in Chapter 2.3.1. SLC6A3 mutation 
analysis was performed by direct sequencing as previously described (Chapter 
2.3.4) using primer pairs for exon-specific PCR amplification of the 14 translated 
exons of the SLC6A3 gene (Table 4-4).  
5.2.2.2 Long range PCR 
In patient 8, long range PCR techniques (Chapter 2.3.5) were utilised to 
characterize a putative deletion. Primers 11F and 14R (Table 4-4) were used to 
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produce the deletion-specific amplicon. Conditions consisted of an initial 
denaturation step at 93 ºC for 5 min followed by 35 cycles of 45s denaturation 
at 93 ºC, 45s annealing at 60ºC and 8 min extension at 68ºC with a final 
extension at 68 ºC for 5 min. The PCR products were then checked, cleaned up 
and prepared for sequencing as described in Chapter 2.3.4.3-2.3.4.7. In order 
to determine the exact genomic deletion breakpoint DNA sequence, specific 
primers (Table 5-1) were utilized for cycle sequencing of the deletion-specific 
amplicon. These reverse primers were designed sequentially 300-400 bases 
apart from 14R. 
Table 5-1 
Primers used for cycle sequencing of deletion-specific amplicon in order 
to determine the genomic breakpoint of the deletion 
 
Primer Location (Bp) Primer Sequence 
DAT_13.1R 1,454,057 – 1,454,176 CCACCACTGACTCACACTGC 
DAT_13.2R 1,454,401 – 1,454,419 CCTGGAGATGGCTCTTGAG 
DAT_13.3R 1,454,710 – 1,454,728 CACTTGTACCTGGCTCAGC 
DAT_13.4R 1,454,940 – 1,454,961 CATCAGCTTTCCTGGGGCCATG 
DAT_13.5R 1,455,276 – 1,455,295 GGAGTGTCCTTGTCTCTTCC 
DAT_13.6R 1,455,556 – 1,455,575 CAAACACTTGGACACGAATG 
DAT_13.7R 1,455,790 – 1,455,808 CACACACACAGTGTTGTGG 
 
5.2.3 Functional and molecular analysis of mutant DAT proteins 
All functional investigations were kindly undertaken again by collaborators in 
Professor Reith‘s group, Department of Psychiatry and Pharmacology, 
Millhauser Laboratories, New York University School of Medicine, New York, 
USA. Methodology used in functional investigation is described in Appendix 2. 
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5.3 Results 
5.3.1 Clinical phenotyping of DTDS 
The detailed clinical phenotype and pattern of disease evolution in 11 children 
with DTDS (2 boys and 9 girls) from 10 distinct families is described. The salient 
clinical features of DTDS are summarised in Table 5-2. 7 children are alive (age 
range 1.9-11.4 years) and 4 children have died (age of death 9-16 years). Prior 
to neurological investigation and DAT mutational analysis, most children (7/11) 
in the cohort were initially misdiagnosed with cerebral palsy. 
5.3.1.1 Family history 
Patient 1 and 2 are 1st cousins from a consanguineous Pakistani kindred 
(family A in Chapter 4) and Patient 6 is of Turkish origin. The remaining eight 
children are of mixed European descent. Parental consanguinity was evident in 
7 families. In 5 cases (patients 1, 3, 6, 10 and 11), parents were 1st or 2nd 
cousins and in 2 cases (patients 2 and 7), parents were more distally related. In 
all cases, there was no family history of Parkinson‘s disease, movement 
disorders or neuropsychiatric disease. The mother of patient 11 suffered from a 
severe migraine disorder associated with aura. 
5.3.1.2. Pregnancy and early neonatal course 
All children were born following a normal pregnancy, except patient 6, in whom 
a marked reduction in foetal movements was reported from 35 weeks gestation. 
All children were born following an uneventful delivery, except patient 8, who 
was delivered by emergency lower segment caesarean section after an 
abnormal cardiotocography (CTG) trace suggested foetal distress. At birth, she 
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initially had low APGAR scores (3-9-9 at 3-5-10 minutes) but responded to a 
period of bag and mask ventilation followed by nursing in an incubator with 
ambient oxygen for five days. Neonatal irritability and early feeding difficulties 
were evident in 6/11 children. 
5.3.1.3 Onset of clinical symptoms in infancy 
All children presented with neurological symptoms in early infancy (median 2.5 
months (range 0.5–7 months). The children were not dysmorphic and there was 
no evidence of congenital microcephaly (although patient 1 and 2 developed 
acquired microcephaly within the first year of life). Five children presented with 
a movement phenotype with prominent hyperkinesia. In another four children, 
the predominant presenting neurological features were hypokinetic and 
parkinsonian in nature. Patient 3 and 4 had features of both a hypokinetic and 
dystonic movement disorder on initial clinical presentation. Presenting 
parkinsonian features included bradykinesia (6/11), rigidity (4/11), and tremor 
(3/11). A wide spectrum of dyskinetic phenotypes were seen on presentation: 
Six children presented with generalised dystonia with frequent protracted 
exacerbations characterised by severe distress and continuous crying 
associated with opisthotonus (4/11), oculogyric crises (1/11) and a raised CK in 
some cases. High amplitude choreiform movements (2/11) and orolingual 
dyskinesia (5/11) were also observed. Axial hypotonia was evident in 7/11 
children presentation. Concerns regarding early developmental progress were 
raised in 6/11 children.  
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5.3.1.4 Clinical features of the DTDS movement disorder  
 
All children in the cohort developed a complex movement disorder 
characterised by a number of features:- 
 
(a) Infantile hyperkinesia 
An early hyperkinetic movement disorder (associated with restlessness and 
irritability) was seen in six patients (Table 5-2). Two patients presented with 
florid dyskinesia characterised by repetitive generalised involuntary choreiform 
movements of variable amplitude. A further four patients developed choreiform 
movements (predominantly repetitive involuntary cycling movements of the 
lower limbs) within a year of presentation (Table 5-2). In the older patients, the 
hyperkinetic phenotype diminished gradually during childhood. 
(b) Orolingual dyskinesia 
Orolingual dyskinesia (thrusting choreiform movements of tongue associated 
with repetitive involuntary opening and closing of the mouth) was evident in six 
children.  
(c) Dystonia 
Dystonia was a universal feature. In six children it was present at symptom 
onset and the five other children developed it within one year of clinical 
presentation (time range 1-10 months). Generalised action and postural 
dystonia, with no diurnal variation, was evident in all children. All children had 
oromandibular dystonia with jaw opening. Striatal toe (hyperextension of the 
great toe) was evident in eight children and five had prominent upper limb 
dystonia, characterised by dystonic posturing of the arms and hand fisting. 
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Seven children had recurrent episodic dystonic crises which were often 
misinterpreted as epileptic events. These episodes were a multiple daily (often 
nocturnal) occurrence in some children, but in others were infrequent, occurring 
only once every few months. In some cases, hospitalisation was required for the 
medical management of such episodes. They often occurred in association with 
oculogyric crises, irritability, hyperthermia and/or temperature instability and 
diaphoresis and some children were associated with a rise in CK. In patient 9, 
severe rhabdomyolysis and deranged liver function tests were also observed 
during such episodes. 
(d) Parkinsonian features 
Parkinsonian features eventually became evident in all children with DTDS. 
Generalised moderate to severe bradykinesia was a common early feature of 
DTDS (10/11 cases). Six children had slowing of voluntary movement from 
disease onset and a further four children developed this feature 1–30 months 
after initial presentation. Generalised rigidity was also seen in the majority 
(10/11) of children, as a presenting clinical feature in four children and 
developing in the remaining six cases within one year of symptom onset. 
Cogwheeling rigidity was also evident in some patients. Over time, all gradually 
developed hypomimia, 2-18 months after initial clinical presentation (mean age 
of onset, 7 months). A coarse predominantly distal tremor was present in eight 
children (three at disease onset and five developed tremor 2-36 months after 
presentation). 
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(e) Pyramidal tract features 
Although the co-existence of dystonia and rigidity complicated the assessment 
of resting tone, none of the children had pyramidal tract features at presentation 
but eight subsequently developed pyramidal signs, including sustained ankle 
clonus, increased adductor tone and increased 4 limb tone when asleep (Table 
5-2). To date 3 young children have no signs of pyramidal tract abnormality 
(patient 8, 10, and 11, all <5 years of age).  
(f) Axial hypotonia 
Axial hypotonia, characterised by head lag and truncal hypotonia, was present 
from the onset in seven cases and developed within one year of clinical 
presentation in the rest.  
(g) Eye movement disorder 
Eight children manifested a characteristic eye movement disorder (three at 
presentation and five, 4-44 months after initial presentation). All these children 
had ocular flutter (confirmed on electronystagmography in two patients), 7/8 had 
saccade initiation failure and slow saccadic eye movements. Eyelid myoclonus 
was described in two patients. Oculogyric crises commonly occurred in two 
children, and were particularly prevalent during a dystonic storm.  
5.3.1.5 Disease course 
(a) Motor development 
All children had severe gross motor delay, failing to achieve motor milestones. 
Although most children had a limited degree of head control in infancy, none 
were ever able to voluntarily lift their head when prone, roll over or sit without 
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support. In early infancy, some children were able to grasp objects but grasping 
was often bradykinetic and superimposed by dystonia. This skill was lost over 
time, and eventually children were able to only hold objects placed in palm of 
hand for brief periods. All children displayed marked progression of motor 
symptoms and the movement disorder became markedly hypokinetic. 
Progressive dystonia resulted in severe fixed postural dystonia, particularly 
affecting the upper limbs. Parkinsonian symptoms also became progressively 
worse, resulting in akinesia, severe rigidity, marked facial hypomimia and 
prominent tremor. 
(b) Cognitive development 
No children with DTDS were able to speak, but despite the absence of 
expressive language (attributed mainly to their motor deficit), parents and 
clinicians reported that children had good receptive language and situational 
understanding. Children could often follow simple commands, follow 
conversations and smile responsively to interaction or humour. With the 
assistance of speech and language therapists, many children developed 
methods of non-verbal communication, for example, the use of head and eye 
pointing techniques. All children had urine and faecal incontinence and required 
extensive support for feeding and dressing. Despite the severe motor 
impairment, cognitive skills appeared to be affected to a lesser degree. Formal 
neuropsychology assessment was not possible in the majority of children due to 
the degree of physical disability. In patient 3, a formal neurocognitive 
assessment was undertaken at 11.3 years. On assessment she effectively used 
a communication book comprising four pictures for judgements via eye gaze. 
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She also demonstrated good working memory in response to verbal questions 
and prompted when given alternatives or choices. She was able to effectively 
mobilise via the use of head switches on her electric wheelchair. Following the 
introduction of ropinirole therapy, she showed improved motor function and 
facial expression, further enhancing her communication. She exhibited good 
social awareness and empathy as demonstrated by her enjoyment of watching 
the news or age-appropriate films and her ability to identify distressing 
situations when these are embedded within a complex narrative. She 
demonstrated accurate recognition of familiar information. She attended 
sessions in mainstream school and successfully used a Tobii device (a 
communication aid using eye gaze). Similar devices have also been used to aid 
learning in other DTDS children. 
(c) Secondary medical complications and life expectancy 
All children with DTDS developed gastro-oesophageal reflux and constipation. 
Orolingual dyskinesia and generalised bulbar dysfunction resulted in excessive 
drooling, choking and feeding difficulties and failure to thrive was observed in all 
patients. Sleeping difficulties, orthopaedic complications and frequent 
pneumonias were also prevalent in this cohort. Four children have died (median 
age of death 14.6 years, range 9-16 years) due to respiratory complications 
(aspiration pneumonia, chest infection) and secondary cardiac failure. 
5.3.1.6 Response to therapeutic strategies 
Multiple therapeutic strategies (dopamine agonists, dopamine antagonists, 
anticholinergics and GABAergic agents and surgical strategies) have been 
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attempted in the cohort but most were either ineffective or provided only a 
limited temporary clinical response.  
Nine children had a trial of Sinemet (L-dopa with a peripheral dopa 
decarboxylase inhibitor). A definitive clinical response was observed in two 
patients. In Patient 9, treatment with L-dopa improved upper limb motor 
function, facial expression and abolished the episodic crises (of severe 
dystonia, rhabdomyolysis, excessive sweating and hyperthermia). Four weeks 
after commencing L-dopa therapy, Patient 11 was noted to be more cheerful, 
with improved fine motor skills and more voluntary purposeful movement than 
on previous assessment. A significant reduction in her spontaneous sweating 
episodes was also reported. 
Following genetic diagnosis and proposition of a likely disease mechanism, 
direct dopamine agonists were tried with some success. Two children continue 
on ropinirole therapy. Since the instigation of ropinirole at age 10.5 years in 
patient 3, there has been a reduction in parkinsonian features with increased 
facial expression, an improved feeding pattern and a mild reduction in 
bradykinesia of her hands. In patient 9, the introduction of ropinirole (at age 5 
years) has led to a sustained improvement in hand function, reduced tremor 
and reduction of the frequency and severity of dystonic crises.  
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Table 5-2: Overview of clinical features in DTDS  
P Parkinsonian hypokinetic features (bradykinesia, rigidity, tremor, hypomimia) - Patient age <3 Years   
H Hypomimia only        Y Yes        `  
DK Dyskinesia (chorea, restlessness)      N No 
DY Dystonia      
MD Motor developmental delay in gross motor skills 
A Axial hypotonia 
PT Pyramidal tract features 
 
Patient 
Current 
Age 
(Years) 
Neonatal 
irritability/ 
feeding 
difficultie
s 
Age at 
clinical 
presentation 
(months)   
        
   
 
Eye 
movement 
disorder 
Bulbar 
dysfunction 
Misdiagnosis 
with cerebral 
palsy 
1 5.7 Y 0.75 P   A P  DY A PT MD P DY PT MD N Y Y 
2 4.2 Y 3 P   A P  DY A PT MD P DY PT MD N Y Y 
3 11.4 Y 5 P  DY A P DK DY A PT MD P DY PT MD Y Y Y 
4 DIED Y 4 P  DY A P DK DY A PT MD P DY PT MD Y Y N 
5 DIED N 4 P   A P DK DY A PT MD P DY PT MD Y Y Y 
6 DIED N 2.5 P    P DK DY A PT MD P DY PT MD Y Y N 
7 DIED N 1.5  DK DY  P DK DY A  MD P DY PT MD Y Y Y 
8 2 Y 0.5   DY  P  DY A  MD - - - MD Y Y Y 
9 6 N 3   DY A P  DY A PT MD P DY PT MD Y Y Y 
10 1.9 N 7  DK  A H DK DY A  MD - - - MD Y Y N 
11 4.3 Y 0.5   DY  P  DY A  MD P DY  MD N Y N 
Motor features > 3 years 
Early motor features 
present at disease 
onset  
Early motor features evolving before 3 
years of age 
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5.3.2 CSF neurotransmitter analysis and other investigations 
The results of CSF neurotransmitter analysis are given in Table 5-3. Biogenic 
amine metabolite analysis revealed the universal finding of increased levels of 
the dopamine metabolite HVA and a normal concentration of the serotonin 
metabolite 5-HIAA (using age related laboratory-specific reference ranges) 
(Hyland et al., 1993; Bräutigam et al., 1998). As a consequence, all children had 
a raised CSF HVA: 5-HIAA ratio (range in DTDS, 5.0-13.2, normal range 
approximately 1.3-4.0), thus reflecting an overflow of dopamine metabolites in 
the CSF in the presence of normal serotonin metabolites. Urine HVA excretion 
was moderately elevated in 6/7 children investigated (range in DTDS 22-47, 
normal range 2-15 μmol HVA/mmol creatine). Pterin levels (neopterin, 7, 8-
dihydrobiopterin, and tetrahydrobiopterin) were consistently normal in all 
children in the cohort, except in patient 8 who had a mild reduction in neopterin 
and tetrahydrobiopterin.  
Serum prolactin was elevated in patient 2 and 3 but found to be consistently 
normal on repeated testing in other children (Patient 1, 4, 7, 8 and 9). Elevated 
serum CK activity was evident in 6/11 children (242–1773 IU/L, normal range 
24-173 IU/L). Five of these children also had further elevation of CK during 
dystonic crises. 
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Table 5-3 
CSF neurotransmitter findings in the DTDS cohort 
Patient 
number 
Age at LP  CSF HVA  
 
CSF 5-HIAA 
 
 
 
CSF HVA:5-HIAA 
Ratio
B 
 (years) Concentration 
nmol/L 
Reference Range
A 
nmol/L 
Concentration 
nmol/L 
Reference Range
A 
nmol/L 
 
1 3.5 1873 154-867 141 89-367 13.2 
2 1.3 1704 154-867 250 89-367 6.8 
3 2.5 1135 154-867 91 89-367 12.5 
4 3.7 2046 384-769 169 110–265 12.1 
 4.0 1914 384-769 165 110-265 11.6 
 8.9 1099 285-560 131 101-237 8.4 
5 5.0 1633 154-867 143 89-367 11.4 
6 3.0 1810 154-867 149 89-367 12.1 
7 7.5 1043 346–716 158 100-245 6.6 
 8.3 814 339–668 143 109-214 5.7 
8 0.5 2048  310-1100 238 150-800 8.6 
 0.75 1114 403–919 225 170-412 5.0 
9 1.5 2280 294-1115 176 129-520 12.9 
 2.5 1345 233-928 176 74-345 7.7 
10 0.8 3000 295-932 285 114–336 10.5 
11 4.2 1600 233-928 145 74-345 11.0 
 
A   Age-related HVA and 5-HIAA reference ranges were established by each laboratory according to laboratory-specific sampling protocols 
B   The HVA /5-HIAA ratio is stable throughout the cranio-caudal gradient and does not change significantly with age. 
 Published data suggests that the normal range (above 4 months of age) is approximately 1.3–4.0 (Hyland et al., 1993; Brautigam et al., 
1998; Brautigam et al., 2002) 
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5.3.3 Neuroradiological findings 
5.3.3.1 Brain MRI and MRS  
All children had an MRI brain scan. No structural defects were present and no 
signal abnormalities were evident in the basal ganglia. 8/11 of the children in 
the DTDS cohort had evidence of subtle neuroradiological abnormalities 
(prominence of the external frontotemporal subarachnoid spaces and mild delay 
in myelination). Patient 9 had evidence of a white matter abnormality similar to 
periventricular leukomalacia (Figure 5-1). 
 
Figure 5-1 
MR Brain of patient 9, age 2.2 years 
Axial T-1 weighted images demonstrating symmetrical periventricular white 
matter changes (yellow arrows) 
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5.3.3.2 Nuclear brain imaging 
Nuclear brain imaging using single photon emission computed tomography 
(SPECT) was performed in two children. Following genetic diagnosis, SPECT 
brain imaging was undertaken in patient 3 after administration of the dopamine 
transporter ligand, DaTSCANTM (GE Healthcare), a solution of ioflupane [(123)I-
2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane, (123)I-
FP-CIT, 123I ]. The DaTSCAN imaging showed complete loss of dopamine 
transporter activity in the basal nuclei (Figure 5-2). Prior to genetic confirmation 
of DTDS, patient 4 had SPECT brain imaging with the ligand 
[123I]iodobenzamide (IBZM). The ratio of dopamine 2 receptor density in the 
striatum compared with the frontal cortex was reduced (1.21, adult reference 
range 1.5–1.55). 
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Figure 5-2 
Nuclear brain imaging (in age-matched individuals) using single photon emission computed tomography (SPECT) after 
administration of the dopamine transporter ligand DaTSCAN (Ioflupane, 123I) 
 
Figure 5-2A DaTSCAN imaging in a control subject demonstrating normal distribution of dopamine transporter sites. 
Figure 5-2B DaTSCAN imaging in a patient with juvenile parkinsonism (age 9.2 years), showing bilateral symmetrical loss of 
  dopamine transporter sites from the lentiform nuclei. 
Figure 5-2C DaTSCAN imaging in patient 3 (age 10 years) indicating complete loss of dopamine transporter sites in the basal 
  nuclei. This results in high background counts on the image without any activity from the basal nuclei. 
 
        5-2A          5-2B                     5-2C 
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5.3.4 Molecular genetic investigation 
5.3.4.1 SLC6A3 mutational analysis 
SLC6A3 gene mutations were identified in all eleven cases (Table 5-4). 
Mutations identified in cases 1-3 have previously been reported in Chapter 4. 
Nine novel SLC6A3 mutations were detected in patients 4-11 (Figure 5-3). 
Overall, nine patients (seven with consanguineous parents) had homozygous 
mutations and two children (Patient 5 and 9, born to unrelated parents) had 
compound heterozygous mutations. Three SLC6A3 variants were detected in 
patient 9 who inherited p.Gly327Arg and p.Gln439X from her mother and 
p.Pro529Leu from her father (Figure 5-3E). 
Overall, 14 missense mutations, 4 splice site variants, 4 deletions and 1 
nonsense mutation were identified. All mutations segregated appropriately with 
DTDS disease status in each family. None of the identified mutations were 
reported as polymorphisms in genomic databases and none were identified in 
an extensive analysis of 300-400 ethnically matched control chromosomes. 
Sequence alignment for the novel missense mutations showed Val158, Gly327, 
Arg521, Pro529 and Pro554 to be highly conserved throughout vertebrate 
species and Leu224 to be highly conserved throughout mammalian species 
(Figure 5-4).   
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Table 5-4 
SLC6A3 mutations identified in the DTDS cohort 
 
Patient Ethnicity 
Parents 
Related 
Mutation(s) State 
Effect on protein 
product 
Reference where 
mutation reported 
1 Pakistani Yes c.1103T>A Homozygous p.Leu368Gln Kurian et al., 2009 
2 Pakistani Yes c.1103T>A Homozygous p.Leu368Gln Kurian et al., 2009 
3 Mixed European Descent Yes c.1184C>T Homozygous p.Pro395Leu Kurian et al., 2009 
4 Mixed European Descent No c.1156+5delG Homozygous Unknown Novel mutation 
5 Mixed European Descent No 
c.472G>T 
c.1661C>T 
Compound 
Heterozygous 
p.Val158Phe 
p.Pro554Leu 
Novel mutations 
6 Turkish Yes c.1031+1G>A Homozygous Unknown Novel mutation 
7 Mixed European Descent Yes c.399delG Homozygous p.Ile134SerFsX5 Novel mutation 
8 Mixed European Descent No c.1499_1767del Homozygous p.Gly500GlufsX13 Novel mutation 
9 Mixed European Descent No 
c.979G>A 
c.1315C>T 
c.1586C>T 
Compound 
Heterozygous  
(3 variants) 
p.Gly327Arg 
p.Gln439X 
p.Pro529Leu 
Novel mutations 
10 Mixed European Descent Yes c.671T>C Homozygous p.Leu224Pro Novel mutation 
11 Mixed European Descent Yes c.1561C>T Homozygous p.Arg521Trp Novel mutation 
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Figure 5-3 
Novel mutations identified in patient 4, 5, 6, 7, 9, 10 and 11 
 
Figure 5-3A 
Patient 4 
The alignments of SLC6A3 nucleotides c.1153-c.1156 and first 9 nucleotide bases in 
intron 8 are illustrated 
The homozygous splice variant c.1156+5delG is boxed in yellow 
 
 
 
                  
 
 
 
Figure 5-3B 
Patient 5 
The alignments of SLC6A3 nucleotides c.469-c.475 and c.1658-c.1664 are illustrated 
The 2 heterozygous missense mutations identified are boxed in yellow 
 
 
     Exon 4     c.472G>T      Exon 13           c.1661C>T   
                                  
 
Patient 
 
Wild type 
Exon 8   Intron 8 c.1156+5delG 
 
Patient 
 
 
Wild type 
 
Patient 
 
 
Wild type 
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Figure 5-3C 
Patient 6 
The alignments of SLC6A3 nucleotides c.1028-c.1031and the first six nucleotide bases of 
intron 7are illustrated 
The homozygous splice variant c.1031+1G>A is boxed in yellow 
 
 
  Exon 7         Intron 7 
           c.1031+1G>A 
    
 
 
 
 
Figure 5-3D 
Patient 7 
The alignments of SLC6A3 nucleotides c.396-c.405 are illustrated 
No DNA was available from the child who had died prior to genetic investigation 
A heterozygous deletion c.399delG (boxed in yellow) was identified in both parents 
 
 
  Exon 3                     c.399delG  
                      
 
Patient 
 
 
Wild type 
   
 
Patient’s  
Father 
 
 
Wild type 
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Figure 5-3E 
Patient 9 
The alignments of SLC6A3 nucleotides c.978-c.985, c.1312-c.c1318 and  
c.1584-c.1589 are illustrated. The 3 heterozygous mutations  
(2 missense and one nonsense) identified are boxed in yellow 
 
 
     Exon 7   c.979G>A    Exon 10               c.1315C>T 
                                                                
 
 
 
 
`              Exon 12           c.1586C>T 
         
 
Patient 
 
 
Wild type 
 
Patient 
 
 
Wild type 
 
Patient 
 
 
Wild type 
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Figure 5-3F 
Patient 10 
The alignments of SLC6A3 nucleotide c.667–c.676 are illustrated  
The homozygous missense change 671T>C is boxed in yellow 
 
 
  Exon 5       c.671T>C  
           
 
 
 
Figure 5-3G 
Patient 11 
The alignments of SLC6A3 nucleotides c1557-c.1567 are illustrated  
The homozygous missense change c.1561C>T is boxed in yellow 
 
  
 Exon 12                     c.1561C>T 
          
 
Patient 
 
 
Wild type 
 
Patient 
 
 
Wild type 
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Figure 5-4 
Conservation of the mutated SLC6A3 residues Val158, Leu224, Gly327, Arg521,  
Pro529, Pro554. Six representative vertebrate sequences are aligned. 
 
 
H. SAPIENS        135   CPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHCNNSW   184 
C.L.FAMILIARIS*   130   CSPALGVGFTVILISLYVGFFYNVIIAWALHYFFSSFTVELPWVHCNNTW   179 
B. TAURUS*        135   CPILRGNGTRPILISLYIGFFYNVIIAWALHYLLSSFTTELPWTHCNHSW   184 
M. MUSCULUS       135   CPVLKGVGFTVILISFYVGFFYNVIIAWALHYFFSSFTMDLPWIHCNNTW   184 
R. NORVEGICUS     135   CPVLKGVGFTVILISFYVGFFYNVIIAWALHYFFSSFTMDLPWIHCNNTW   184 
D. RERIO          151   CPIFKGVGFTVILISLYVGSYYNVIIAWALFYLFSSFSGELPWIHCNNTW   200 
 
H. SAPIENS        185   NSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLG   234 
C.L.FAMILIARIS*   180   NSPNCSDAHSSNSS---SSPNDTFRTTPATEYFERGVLHLHESRGIDDLG   226 
B. TAURUS*        185   NSPRCSDARAPNAS---SGPNGTSRTTPAAEYFERGVLHLHESQGIDDLG   231 
M. MUSCULUS       185   NSPNCSDAHSSNSS-DGLGLNDTFGTTPAAEYFERGVLHLHQSRGIDDLG   233 
R. NORVEGICUS     185   NSPNCSDAHASNSS-DGLGLNDTFGTTPAAEYFERGVLHLHQSRGIDDLG   233 
D. RERIO          201   NSPNCSDPNA-------TLLNDTYKTTPALEYFERGVLHVHESSGIDDLG   243 
 
H. SAPIENS        305   LCEA--------SVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDA   346 
C.L.FAMILIARIS*   297   LCES--------SVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDA   338 
B. TAURUS*        330   PCARRTLPQEGWEVWIDAAIQICFSLGVGLGVLIAFSSYNKFTNNCYRDA   379 
M. MUSCULUS       304   LCEA--------SVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDA   345 
R. NORVEGICUS     304   LCEA--------SVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDA   345 
D. RERIO          314   LYDA--------QVWIEAATQICFSLGVGFGVLIAFSSYNKFSNNCYRDA   355 
 
H. SAPIENS        497   WFYGVGQFSDDIQQMTGQRPSLY--WRLCWKLVSPCFLLFVVVVSIVTFR   544 
C.L.FAMILIARIS*   489   WFYGVRQFSDDIKQMTGQRPSLY--WRVCWKFVSPCFLLFVVVVSIVTFR   536 
B. TAURUS*        523   WFYGVWQFSDDIKQMTGRRPSLY--WRLCWKFVSPCFLLFVVVVSIATFR   570 
M. MUSCULUS       496   WFYGVQQFSDDIKQMTGQRPNLY--WRLCWKLVSPCFLLYVVVVSIVTFR   543 
R. NORVEGICUS     496   WFYGVQQFSDDIKQMTGQRPNLY--WRLCWKLVSPCFLLYVVVVSIVTFR   543 
D. RERIO          506   WFYGVDRFSDDIEEMIGQRPGLY--WRLCWKFVSPCFLLFMVVVSFATFN   553 
 
H. SAPIENS        545   PPHYGAYIFPDWANALGWVIATSSMAMVPI--------------------   574 
C.L.FAMILIARIS*   537   PPHYGAYIFPEWANALGWAIATSSMSMVPI--------------------   566 
B. TAURUS*        571   PPHYGAYVFPEWATALGWAIAASSMSVVPI--------------------   600 
M. MUSCULUS       544   PPHYGAYIFPDWANALGWIIATSSMAMVPI--------------------   573 
R. NORVEGICUS     544   PPHYGAYIFPDWANALGWIIATSSMAMVPI--------------------   573 
D. RERIO          554   PPKYGSYYFPTWATMVGWCLSISSMIMVPL--------------------   583 
 
* Predicted protein sequence 
Val158 
Leu224 
Gly327 
Arg521 
Pro529 
Pro554 
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5.3.4.2 Characterisation of the deletion in patient 8 
In patient 8, specific PCR primers flanking SLC6A3 exons 12 and 13 failed to 
amplify on repeated occasions raising the possibility of a homozygous deletion 
involving exon 12 and 13.  
Long range PCR techniques were subsequently employed to characterise the 
putative deletion. A forward primer in intron 10 (11F) and a reverse primer in 
intron 14 (14R) were utilised for long range PCR (Chapter 4, Table 4-4). An 
amplicon was obtained both in the index case and both parents, but no PCR 
product was amplifiable in 400 ethnically matched control chromosomes (Figure 
5-5A).  
Sequencing of this PCR fragment (using serial reverse primers in intron 13, 
Table 5-1) allowed the genomic deletion to be characterised (Figure 5-5B). The 
telomeric and centromeric genomic breakpoints were mapped to 1,455,093–
1,455,095bp (intron 13) and 1,460,244-1,460,246bp (intron 11) respectively, 
defining a ~5kb deletion The precise location of the breakpoint could not be 
further defined as there was a 3bp sequence (CAG) common to both the intron 
11 and intron 13 sequence (Figure 5-5B).  
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Figure 5-5 
Definition of the SLC6A3 deletion in patient 8 
Figure 5-5A Agarose gel photograph of PCR amplification of introns 10 to 14 of 
SLC6A3 showing the presence of bands in patient 8 (Lane 5) and their parent 
(Lane 6) and the absence of bands in normal controls (Lanes 1-4). Lane 7 is a 
negative control. 
Figure 5-5B Determination of the DNA sequence of the genomic breakpoint of 
the deletion. The exons that are present are indicated in red (exon 11 and 14). 
The deleted exons/introns are represented in grey (exon 12 and 13). The 
telomeric and centromeric genomic breakpoints were mapped to 1,455,093–
1,455,095bp (intron 13, shaded in blue) and 1,460,244-1,460,246bp (intron 11, 
shaded in blue) There is a 3 base region of homologous sequence which show 
100% homology in both intron 11 and 13 (shaded yellow box). 
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5.4 Discussion 
In this chapter, I have characterised the clinical and molecular genetic features 
of a precisely diagnosed cohort of children with autosomal recessive DTDS 
associated with loss-of-function mutations in the SLC6A3 gene. DTDS is thus a 
disorder of dopamine homeostasis and the first identified disorder with 
parkinsonian features due to genetic alterations of the dopamine transporter. In 
the discussion section of this chapter, I will discuss the physiological and 
pathological roles of dopamine and its transporter (DAT), and will postulate 
hypotheses of the underlying disease mechanisms in DTDS. 
5.4.1 Dopamine: anatomical distribution and physiological role 
Until the mid 1950s, it was believed that dopamine was purely an intermediary 
substrate in the biosynthesis of norepinephrine and epinephrine. In 1958, 
Carlsson et al., discovered that dopamine was present in high concentrations in 
the rat corpus striatum and that administration of the drug reserpine (which 
blocks the vesicular monoamine transporter, VMAT) resulted in dopamine 
depletion and a ‗parkinsonian‘ phenotype. Following the reversal of reserpine-
induced hypokinesia by L-dopa, Carlsson proposed a biological role for 
dopamine in neurotransmission, independent of its catecholamine precursor 
function (Carlsson et al., 1959). This seminal work was, in part, the basis of the 
Nobel Prize in Medicine awarded to Carlsson in 2000. 
Advances in histochemical techniques to visualise cellular localisation of 
dopamine was the second major breakthrough in understanding the 
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physiological role of dopamine in the human brain (Anden et al., 1964). The first 
systematic mapping of dopaminergic pathways was performed by Dahlstrom 
and Fuxe in 1964, who demonstrated the concentration of dopaminergic cell 
bodies in the ventral midbrain as well as the widespread distribution of 
dopamine within the striatum. The finding that the highest concentrations of 
dopamine were present in the basal ganglia led to the hypothesis that dopamine 
may be involved in the control of motor function and that decreased striatal 
dopamine could be the cause of extrapyramidal disorders such as Parkinson‘s 
disease. Subsequent mapping studies by in rodents and humans (Hoffman et 
al., 1976; Sladek et al., 1982; Felten and Sladek, 1983) showed that dopamine 
has a much wider distribution outside the basal ganglia, which suggested that 
this neurotransmitter had a complex and more extended role in the brain. 
Dopaminergic neurons are thus located prominently in the substantia nigra pars 
compacta (with projections to the striatum via the nigrostriatal pathway) and in 
the ventral tegmental area of the midbrain (with mesocorticolimbic projections to 
the nucleus accumbens, hippocampus, and other corticolimbic structures) 
(Torres et al., 2003). Consistent with this widespread cerebral distribution, it is 
now deemed that dopamine has a variety of important physiological functions. It 
plays a fundamental role in the control of locomotion, cognitive processes, 
attention, memory and neuroendocrine secretion and is also involved in the 
control of motivated behaviours such as emotion, affect and reward 
mechanisms (Carlsson, 1987; Carlsson, 2001; Greengard, 2001). 
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5.4.2 The structure and physiological function of DAT 
As briefly discussed in Chapter 4, SLC6A3 encodes the dopamine transporter 
DAT, which is a member of the solute carrier family 6 (SLC6) group of Na+/Cl- 
dependent transmembrane transport proteins (Torres and Amara, 2007; He et 
al., 2009). A breakthrough in the structure-function understanding of DAT was 
made in 2005 by Gouaux and colleagues, who determined a high-resolution 
crystal structure of LeuTAa. This N
+ dependent 12 TM bacterial leucine 
transporter from Aquifex aoelicus is functionally homologous to the 
neurotransmitter sodium symporters (Yamashita et al., 2005). DAT consists of 
12 transmembrane spanning domains presumed to consist of primarily α-helical 
structure. These helices are linked through intracellular loops (IL) and 
extracellular loops (EL) with the N- and C-termini facing the cytoplasm (Figure 
4-9). The DAT possesses numerous post-translational modifications (which are 
not found in bacterial homologues) that regulate various aspects of its function 
including glycosylation and disulphide bonding on EL2 and phosphorylation and 
ubiquitylation on the long N-terminal tail (Parnas and Vaughan, 2008). 
DAT is exclusively expressed in dopamine neurons and recaptures released 
dopamine from the extracellular milieu around the synaptic cleft thereby 
transporting it back into the presynaptic neuron (Rice and Cragg, 2008). 
Dopamine is transported inward, against its concentration gradient using the 
driving force of the sodium gradient across the plasma membrane (see Chapter 
4.4). Of note, inherited mutations in the gene for the Na+/K+-ATPase alpha3 
subunit (ATP1A3) are associated with the extrapyramidal syndrome autosomal 
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dominant rapid-onset dystonia-parkinsonism (ROPD) (de Carvalho et al., 2004). 
It is conceivable that the underlying disease mechanism of ROPD (resulting 
from loss-of-function ATP1A3 mutations and disturbance of the electrochemical 
gradient across the cell membrane) may also thus be indirectly related to 
disturbance of DAT function. 
As briefly discussed in Chapter 4, the transporter thus plays a fundamental role 
in the deactivation of dopaminergic signalling and is the principle regulator of 
the amplitude and duration of dopaminergic action (Bannon, 2005). As seen 
from animal studies, DAT is thus fundamental in the maintenance of dopamine 
homeostasis since no other physiological mechanisms can sufficiently 
compensate for its loss of function in vivo.    
DAT is also a major target for several abused drugs (including amphetamine, 
cocaine and other psychostimulants) and also for therapeutic agents (such as 
methylphenidate and bupropion) (Kharkar et al., 2008). Cocaine and other 
related psychostimulants bind to DAT (thus inhibiting its activity) but are not 
transported. Amphetamine and other compounds (with structural similarity to 
dopamine) are carried by the DAT. These exogenous substances thus compete 
with dopamine for transport, thereby both reducing the rate of dopamine re-
uptake and inducing non-exocytotic efflux of dopamine form the neuron into the 
synapse via reversal of transport. The overall effect of these drugs is thus to 
increase the concentration and duration of dopamine in the synapse leading to 
supraphysiological activation of post-synaptic neurons, resulting in euphoria and 
psychomotor stimulation (Parnas and Vaughan, 2008). 
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5.4.3 The role of dopamine dysregulation in human diseases 
Dopamine dysregulation is implicated in a wide variety of human diseases. As 
discussed in Chapter 4, defects in the dopamine biosynthetic pathway (Chapter 
4, Figure 4-1) can cause a dopamine deficient state, resulting in complex 
neurological neurotransmitter disorders with predominant extrapyramidal 
features (see Chapter 4.1.2, Table 4-1). Aberrant dopaminergic transmission 
has also been implicated in other neurological and neuropsychiatric disorders 
including conditions associated with dopamine deficiency (such as Parkinson‘s 
disease) as well as disorders proposed to be associated with states of 
dopamine excess (such as ADHD, schizophrenia, bipolar disorder and Tourette 
syndrome) (Mehler-Wex et al., 2006; Mazei-Robinson et al., 2006). 
5.4.4 The role of variants in SLC6A3 in human disease 
As discussed in 5.4.3, dopamine dysregulation is implicated in a wide variety of 
neurological and neuropsychiatric conditions and as a consequence, the 
SLC6A3 gene (coding exons and gene variants such as the variable number 
tandem repeat, VNTR at the 3‘UTR) has been extensively investigated in a 
number of disorders including Parkinson‘s disease (Nutt et al., 2004), ADHD, 
Tourette syndrome, disorders of addiction (such as alcoholism and smoking) 
schizophrenia, bipolar disorder and migraine (Vandenbergh, 2008). The 
interaction of specific drugs (such as cocaine, amphetamines and 
methylphenidate) with SLC6A3 has further implicated the role of SLC6A3 in 
neuropsychiatric disorders. Despite initial hopes of uncovering new genetic 
information that would clarify the relationship between DAT and a 
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disease/disorder/personality, little in the way of consistent reproducible results 
have been reported. Association studies between SLC6A3 variants and 
Parkinson‘s disease were found by Le Couter et al., (1997) and Leighton et al., 
(1997) but subsequent work was unable to confirm these findings. 
Prior to this current work on DTDS, the strongest convincing genetic 
relationship between SLC6A3 and a human disease was with ADHD (Mazei-
Robinson and Blakely, 2006; Waldman and Gizer, 2006) with over 170 
publications as of 2010. The original work in 1995 demonstrated association 
and linkage between ADHD and the 10-copy allele of the SLC6A3 VNTR (Cook 
et al., 1995). Furthermore, the hyperactive features observed in the DAT 
knockout mouse model (Giros et al., 1996) also prompted extensive 
investigation of SLC6A3 in ADHD. Further evidence has been reported by 
Mazei-Robinson and colleagues (2008) who reported 2 siblings with an ADHD 
phenotype harbouring the rare coding missense SNP variant Ala559Val. 
Analysis of mutant DAT showed increased dopamine efflux (attenuated by 
amphetamine), via dopamine D2 autoreceptors (Bowton et al., 2010). 
Although from our study it is evident that loss-of-function DAT mutations cause 
DTDS, other SLC6A3 variants (such as the one described above in ADHD, 
Figure 5-6) may affect different facets of the complex functional role of the 
dopamine transporter (such as the control of behaviour or cognitive processes) 
thereby resulting in a different clinical phenotype. 
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5.4.5 Clinical features of DTDS 
In this chapter I have described novel variants in SLC6A3 associated with 
DTDS. This study has enabled detailed clinical delineation of this novel 
disorder. DTDS is thus an early onset, complex movement disorder (Assmann 
et al., 2004; Kurian et al., 2009). The onset in early infancy is characterised by 
an extrapyramidal syndrome, including hypokinetic parkinsonian features 
(bradykinesia, rigidity and tremor) and/or hyperkinetic symptoms (dystonia, 
chorea, dyskinesias and oculogyric crises). In DTDS, the variability and relative 
preponderance of parkinsonian and hyperkinetic features is not dissimilar to that 
reported in other neurotransmitter syndromes associated with an infantile 
parkinsonism-dystonia phenotype (Assmann et al., 2003). Over time, children 
with DTDS become profoundly hypokinetic, with increasingly severe 
parkinsonism-dystonia (akinesia, profound rigidity, marked tremor, amimia and 
a generalised fixed postural dystonia), pyramidal tract features and a complex 
eye movement disorder (saccade initiation failure, ocular flutter).  
To date, I have identified 11 cases of DTDS, but it is highly likely that there are 
more affected patients who remain undiagnosed. Only a limited number of 
paediatricians have become familiar with the broad clinical spectrum and 
diagnostic approach to neurotransmitter disorders (Assmann et al., 2003). 
Although CSF investigations are increasingly performed, in many centres, CSF 
neurotransmitter analysis is not a routine investigation for children with a 
complex motor disorder. Clinical features of DTDS can all mimic different forms 
of cerebral palsy (dyskinetic, spastic, and mixed cerebral palsy). Indeed, based 
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on the clinical features and early disease evolution, a significant number of 
children in this cohort were initially labelled as having cerebral palsy prior to 
neurological and genetic investigation. In patient 8, the evolution of motor 
features following a complicated labour and delivery was additionally suggestive 
of possible evolving cerebral palsy. In patient 9, although the white matter 
abnormalities on MRI brain scan may be an incidental feature, there is 
nevertheless radiological similarity to the peritrigonal MRI T2-hyperintensity of 
periventricular leukomalacia apparent in cerebral palsy (Deng et al., 2008). 
Misdiagnosis and diagnostic delay have also been reported in other 
neurotransmitter disorders, such as tyrosine hydroxylase deficiency (Willemsen 
et al., 2010). This work described in this chapter thus emphasises the 
importance of specific investigations (CSF neurotransmitter analysis and 
mutational analysis if appropriate) in all children with an undiagnosed complex 
movement disorder. 
5.4.6 Genetic features of DTDS 
All children in the cohort had homozygous or compound heterozygous SLC6A3 
mutations in the gene. A wide variety of variants were identified. 14 missense 
mutations resulted in amino acid substitutions which were absent in an 
extensive analysis of ethnically matched control subjects and occurred in highly 
conserved amino acids of DAT. Other identified mutations included 4 deletions 
and 1 nonsense mutation, which are likely to result in nonsense-mediated 
decay or a truncated protein product. In patient 8, a large intragenic out-of-
frame homozygous deletion was identified. The mechanism by which the 
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deletion was generated is unclear as both centromeric and telomeric 
breakpoints of this intragenic rearrangement did not occur within a repetitive 
sequence or within regions of sequence homology 
(http://www.repeatmasker.org). Two children (Patient 4 and 6) were 
homozygous for splice site variants, which are both predicted to cause aberrant 
splicing (http://www.fruitfly.org/seq_tools/splice.html). In the DTDS cohort, 
mutations were identified throughout the coding region of the gene and no 
mutation hotspots were evident (Figure 5-6). Patient 1 and 2 (originating from 
the same Pakistani kindred) had an identical homozygous missense mutation 
but otherwise, there was no evidence of any recurrent or common mutations in 
DTDS. No correlation between the genetic mutation and disease severity was 
evident in this cohort. 
 
It is possible that variants of the gene may also confer susceptibility to 
neurological/neuropsychiatric disorders. In our DTDS cohort, none of the 
parents (obligate carriers) or siblings (with SLC6A3 mutation carrier status) had 
a movement disorder or neuropsychiatric condition. However the mother of 
patient 11 (and heterozygous carrier of the missense mutation p.Arg521Trp) 
had a history of recurrent severe migraine with aura. Both dopamine and DAT 
have been implicated in the pathophysiology of migraine (Todt et al., 2009; 
Charbit et al., 2010) but the precise role of both remain unclear. Although 
migraine with aura is a common phenomenon, whether heterozygous SLC6A3 
mutation carrier status could increase susceptibility to migraine is yet to be 
determined.
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5.4.7 Functional analysis of mutant DAT proteins  
To determine the effects of the missense mutations, mutant human DAT (hDAT) 
proteins were transiently expressed in HEK293 cells and their transport activity 
compared with that of wild-type. No mutant hDAT was studied for identified 
splice site variants (patient 4 and 6), with protein product being unknown and 
deletions (patients 7 and 8), reflecting a frameshift which is likely to lead to 
nonsense mediated decay and non-DAT expression. 
The effect of mutations identified in cases 1-3 have been reported in Chapter 
4.4.2. While wild-type showed normal transport activity, other mutants studied 
(Val158Phe, Leu224Pro, Gly327Arg, Gly327Arg-Gln439X, Leu368Gln, 
Pro395Leu and Pro554Leu) did not show uptake activity above nonspecific 
uptake. Pro529Leu (identified in patient 9) displayed 6% of wild-type transport 
activity and Arg521Trp (identified in patient 11) displayed 27% of wild-type 
transport activity. Co-expression of Gly327Arg-439X with Pro529Leu (as in 
patient 9) further lowered activity to nonspecific levels (Table 5-5). 
The binding affinity (Kd) of the cocaine analogue [
3H]2β-carbomethoxy-3β-(4-
fluorophenyl)-tropane ([3H]CFT) was near normal in the mutants (13–44nM), 
compared with 19nM in wild-type (see Table 5-5) except in Gly327Arg-Gln439X 
where it was appreciably lower (higher Kd of 101nM) and in Val158Phe (absent 
binding). In many mutants, the nonspecific binding of [3H]CFT was appreciably 
higher than in wild-type, contributing to greater than normal variation in the data 
range.   
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The potency (Ki) of dopamine in inhibiting cocaine analogue binding was near 
normal in Gly327Arg, Pro395Leu, Arg521Trp, Pro529Leu and Pro554Leu but 
reduced (higher Ki) in Leu368Gln (with same tendency for Gly327Arg-Gln439X 
and Leu224Pro). Thus, whereas all mutations are loss-of-function mutations 
with respect to dopamine transport, some also appear to be accompanied by a 
loss of apparent binding affinity of dopamine.   
Maximal binding of [3H]CFT to cells, primarily representing surface binding 
(Chen et al., 2004a) indicated 3- to 5-fold decreases in mutants Leu368Gln, 
Arg521Trp, Pro529Leu and Pro554Leu and (with similar tendency for 
Pro395Leu), and 15-fold (or more) decreases in Val158Phe, Leu224Pro and 
Gly327Arg.  
Analysis of whole cell lysates by immunoblotting with anti-C-terminus DAT 
antibody showed deficiency in mature DAT (85 kDa) in Val158Phe, Leu224Pro, 
Arg521Trp, Pro529Leu, and Pro554Leu as the previously studied Leu368Gln 
and Pro395Leu (Figure 5-7). Val158Phe showed particularly low expression. In 
contrast, Gly327Arg resembled more wild-type with appreciable mature DAT. 
As expected, Gly327Arg-Gln439X with C-terminus deleted did not show a signal 
with anti-C-terminus DAT antibody. Some expression of this mutant was 
detected with anti-N-terminal DAT antibody in the form of lower molecular-
weight bands (Figure 5-7 middle panel). Similar patterns were observed for the 
mutants with both termini intact using both antibodies (compare top and middle 
panel, and note appreciable mature DAT in Gly327Arg with N-terminal targeting 
antibody).   
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Table 5-5: Dopamine transport and cocaine analogue binding by wild-type and mutant hDAT  
 
Patient hDAT Mutant [
3
H]dopamine uptake [
3
H]CFT binding
 
  % OF WT Kd 
(nM) 
Bmax 
 (pmol/mg)
 
Inhibition by 
dopamine, Ki 
 (µM) 
 Wild-type (WT) Normal 18.8 + 2.0 2.40 + 0.51 5.06 + 0.43 
1 Leu368Gln 
A
 0
C
 35.6 + 8.2 0.384 + 0.110 * 52.9 + 1.7 * 
2 Leu368Gln 
A
 0
C
 35.6 + 8.2 0.384 + 0.110 * 52.9 + 1.7 * 
3 Pro395Leu
 A
 0
C
 30.2 + 6.5 
0.962 + 0.144 3.35 + 0.65 
4 - 
B
     
5 Val158Phe 
Pro554Leu 
0
C 
0
C
 
N/A
D 
43.8 + 5.9 
N/A
D 
0.48 + 0.05 * 
N/A
D 
4.39 + 0.71 
6 - 
B
     
7 Ile134SerfsX5
 B
     
8 Gly500GlufsX13
 B
     
9 Gly327Arg 
Gly327Arg-Gln439X 
Pro529Leu 
Pro529Leu+Gly327Arg-Gln439X 
0
C
  
0
C
  
6.22 + 1.31
E
  
1.71 + 1.42
E 
24.3 + 12.4 
101 + 6 * 
16.5 + 5.4 
0.18 + 0.04 * 
0.85 + 0.14 * 
0.47 + 0.07 * 
2.93 + 1.59 
28.1 + 21.6 
3.54 + 1.75 
 
10 Leu224Pro 0
C
 13.0 + 1.3 0.15 + 0.04 * 28.8 + 6.0 
11 Arg521Trp 26.9 + 2.9
E 
20.5 + 3.1 0.48 + 0.09 * 3.82 + 1.37 
 
A
 Data from Kurian et al., 2009 
B
 Protein product unknown or mutation results in a frameshift 
C
 No transport activity above nonspecific uptake 
D
 No binding detectable above nonspecific binding 
E
 P<0.002 compared with wild-type (one-sample t-test with wild-type at 100%).  Average uptake in WT was 23 pmol/min/mg protein at 6 nM [
3
H]dopamine in the assay 
* P<0.05 compared with wild-type (1-way ANOVA followed by Dunnett multiple comparisons).  Statistics were applied to mutant groups compared with wild-type  
  examined within one and the same experimental set; wild-type values listed are the average of all experiments.  
  Data are mean + SEM for 3-5 independent determinations per group 
 * P<0.05 compared with wild-type (1-way ANOVA followed by Dunnett multiple comparisons).  Data are mean + SEM for 3-5 independent determinations per group.    
  Statistics were applied to mutant groups compared with wild-type examined within one and the same experiment; wild-type values listed are the average of all experiments
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Figure 5-7 
Expression of wild-type (WT) and mutant hDAT in HEK293 cells via 
immunoblotting analysis. Cells were transiently transfected with WT, mutant 
hDAT, or reagent only (mock). The same amount of total lysate protein was 
loaded in all lanes.  Protein was probed with antibody against the C-terminal 
(top panel) or N-terminal (middle panel) of DAT. Anti-β-actin antibody showed 
the relative equivalent loading of total protein (bottom panel) 
 
Notably, all mutations that are predicted to result in an expressed protein, when 
studied in hDAT expressing cultured cells, severely incapacitated dopamine 
transport. Transport was not detectable in any mutant except for an 
approximate 27% residual activity in Arg521Trp, which interestingly correlates 
with a degree of dopa-responsiveness in patient 11. In addition, there is 6% 
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residual activity in Pro529Leu, which is consonant with some dopa 
responsiveness in Patient 9.   
More work is needed to fully characterize the mechanisms underlying the loss 
of transport function of DAT in each case.  First, reduced expression of DAT 
(see Table 5-5), severe in some cases, is likely to play a role. Second, loss of 
dopamine recognition by the DAT by reduced affinity is involved for a number of 
mutants. Third, lack of glycosylation to form mature DAT is known to negatively 
impact trafficking to the cell surface and transport function of DAT (Li et al., 
2004). Glycosylation patterns can vary with the cellular environment, which is 
dependent upon cell type and physiological state of the cell in which the 
glycoprotein is made and so analysis of brain DAT glycosylation in IPD cases 
will be of considerable interest. Finally, homology modelling based on the 
structure of the bacterial analogue LeuT (Schmitt et al., 2010) of these point 
mutants compared with wild-type shows subtle structural changes far distal from 
the mutated residue that could impact conformational changes required during 
dopamine transport (Reith, personal communication, 2010). The location of 
mutated residues distal from the dopamine recognition site is consonant with 
the idea of a general defect in translocation mechanism, i.e. not selective for 
dopamine. Also in agreement with this is the fact that the point mutations 
observed in this study occur in amino acids that are present in many other 
members of the SLC6 transporter family that do not transport dopamine. Thus, 
for Val224 and Arg521 of DAT there is the same or a similar residue in other 
monoamine transporters (for norepinephrine and serotonin), whereas for all 
remaining mutants, the residue in question is even more widespread throughout 
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the family - also occurring in other transporters (such as in GABA and glycine 
transporters). Among the residues subject to mutation in the present study, 
Gly327 is the only one that is actually in the major substrate binding site, so the 
mutation of small-sized glycine to bulky arginine could be thought to cause a 
major disruption in the substrate site; however, the normal dopamine affinity 
measured in the [3H]CFT binding assay suggests  that this unwound region of 
TM6 can easily accept the extra bulk from the glycine to arginine substitution. 
5.4.8 Proposed disease mechanisms in DTDS 
In this chapter, imaging modalities for DAT using SPECT (Nikolaus et al., 
2007a; Nikolaus et al., 2007b) has provided a crucial link between the clinical 
phenotype, molecular genetic investigation and in vitro functional analysis of 
mutant DAT proteins. Such functional imaging of DAT has been a useful clinical 
tool in aiding the diagnosis and differentiation of movement disorders such as 
Parkinson‘s disease, other disorders of nigrostriatal dysfunction and ADHD 
(Spencer et al., 2005; Scherfler et al., 2007). The DaTSCAN imaging 
undertaken in patient 3 shows almost complete loss of dopamine transporter 
activity in the basal nuclei (Figure 5-2C). DaTSCAN imaging is not performed 
routinely in children and there is thus limited paediatric data for comparative 
analysis. The high background counts seen on this DaTSCAN image are also 
reported in adult patients with poor uptake in the basal nuclei. It is due to 
unbound DaTSCAN in the blood pool, occurring because there are little or no 
transporter sites with which to bind. DaTSCAN imaging in DTDS is markedly 
different to that of an age-matched control (Figure 5-2A). Loss of dopamine 
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transporter activity also appears to be much more extensive in DTDS than in a 
patient (of similar age) with juvenile parkinsonism, in whom DaTSCAN imaging 
showed symmetrical reduction (but not absence) of dopamine transporter 
activity from basal nuclei (Figure 5-2B). These in-vivo DaTSCAN SPECT 
imaging findings are consistent with the in-vitro assessment of mutant DAT 
function, and provide further evidence that loss of dopamine transporter function 
has a causative role in DTDS pathogenesis.    
The symptoms of DTDS thus appear to result from loss of DAT function. From 
this work it may be postulated that inhibition of dopamine re-uptake into the pre-
synaptic neuron causes accumulation of extraneuronal dopamine producing 
increased dopamine degradation by catechol O-methyltransferase (COMT) to 
HVA (Blackstone, 2009, Figure 5-8). Elevated HVA levels are thus detectable in 
lumbar CSF neurotransmitter analysis.  Dopamine transporter defects are not 
expected to affect the serotonin biosynthetic pathway so CSF 5-HIAA levels are 
normal in DTDS (and the ratio of CSF HVA: 5-HIAA ratio is thus increased). It is 
postulated that lack of dopamine re-uptake subsequently results in depleted 
pre-synaptic dopamine stores of intracellular dopamine to be packaged into 
synaptic vesicles for release into the synaptic cleft (Blackstone, 2009, Figure 5-
8) and subsequent diffusion perisynaptically (Rice and Cragg, 2008).  It is also 
postulated that excess synaptic dopamine may have effects on pre- and 
postsynaptic dopamine receptors. Overstimulation of presynaptic D2 
autoreceptors (D3 receptors) may result in inhibition of phosphorylation 
dependent activation of tyrosine hydroxylase (the rate-limiting step in dopamine 
production) thus decreasing dopamine production (Blackstone, 2009, Figure 5-
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8). Mutant mice lacking DAT and other monoamine transporters also show 
similar consequences of transporter dysfunction (reduced extracellular 
monoamine clearance rate, decreased amplitude of stimulated monoamine 
release, elevated basal extracellular monoamine levels, decreased monoamine 
storage, increased monoamine synthesis rate and disrupted autoreceptor 
function) (Gainetdinov and Caron, 2003). Excess extraneuronal dopamine may 
additionally have postsynaptic effects, such as downregulation or 
desensitisation of postsynaptic dopamine receptors, with alterations in 
downstream signalling (Figure 5-8). Knockout mouse models also show such 
evidence of postsynaptic receptor downregulation (Gainetdinov and Caron, 
2003). D2 receptor dysfunction may also be evident in children with DTDS. The 
reduced IBZM binding found on SPECT studies in patient 4 may be indicative of 
dopamine overflow (with enhanced dopamine levels competing for IBZM 
binding to D2 receptors) but could also be secondary to reduced dopamine 
receptor density. 
Figure 5-8 (overleaf) 
Diagram of a dopaminergic synapse postulating disease mechanisms in DTDS 
(adapted from Blackstone 2009).The presynaptic neuron, postsynaptic neuron 
and synaptic cleft are illustrated in the normal and DTDS disease state. 
Dopamine (indicated by orange circles) may bind presynaptically to D2 
autoreceptors, perisynaptically to DAT and postsynaptically to D1 and D2 
receptors. D1 and D2 receptors are coupled to adenyl cyclase (A) via G proteins 
(GP). Dopamine may also be metabolised to HVA by COMT and MAO-B. In 
DTDS, there is reduced DAT-mediated re-uptake of dopamine into the 
presynaptic cleft. This results in excess synaptic dopamine, which is converted 
by COMT to HVA. Excess synaptic dopamine may also overstimulate D2 
autoreceptors which will inhibit the activation of tyrosine hydroxylase, thereby 
reducing endogenous dopamine production. Prolonged dopamine in the 
synaptic cleft may also cause some downregulation/desensitisation of 
postsynaptic D1 and D2 receptors thereby altering downstream signalling. 
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Figure 5-8 
Proposed disease mechanisms in DTDS (Adapted from Blackstone, 2009) 
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5.4.9 DTDS is a dopamine ‘transportopathy’ 
The majority of the monoamine neurotransmitter disorders (see Chapter 4.1.2) 
are due to inherited recessive inborn errors of metabolism of the pterin or 
monoamine biosynthetic pathway and neurotransmitter analysis reveals a 
reduction in CSF dopamine metabolites. In this chapter, the CSF 
neurotransmitter profile and pathophysiology of dopamine deficiency in DTDS is 
different to the other monoamine neurotransmitter disorders and thus allows us 
to add ‗transportopathy‘ as a novel disease mechanism in this group of 
diseases (Blackstone, 2009). Indeed an increasing number of neurological 
diseases are attributed to inherited loss-of-function mutations in genes which 
encode other transporters, such as GLUT1 deficiency syndrome MIM #606777 
(due to mutations in the gene encoding the glucose transporter, SLC2A1) 
(Brockmann, 2009) and hyperekplexia MIM #149400 (due to mutations in the 
gene encoding the presynaptic glycine transporter-2, SLC6A5) (Rees et al., 
2006) 
5.4.10 Differences between DTDS and other related disorders 
Although DTDS and other monoamine neurotransmitter disorders share some 
common features of dopamine deficiency (Chapter 4.1.2), clinical differences 
are evident. In some dopamine deficiency syndromes, the replenishment of 
dopamine stores during motor inactivity can lead to improvement of motor 
symptoms after a night‘s sleep, and conversely, deterioration of symptoms over 
the afternoon and evening (Hoffmann et al., 1998; Pearl et al., 2007). Such 
diurnal variation of dystonic symptoms is not evident in this cohort of DTDS. 
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This is as predicted, as given the postulated pathogenic disease mechanism, 
dopamine transporter function is not expected to improve when neuronal 
dopamine stores are restored during a period of inactivity or rest. The extent of 
ocular features reported in this cohort appear specific to DTDS and have not 
been described in other disorders associated with dopamine deficiency 
(Assmann et al., 2004, Kurian et al., 2009). The exact pathogenic mechanism of 
the eye movement disorder remains unclear but may be caused by secondary 
brainstem involvement. The role of dopamine (and dopamine regulation) in 
aspects of early infantile brain development may also account for phenotypic 
differences between DTDS (and other infantile monoamine disorders) and 
adult-onset Parkinson‘s disease, in which pyramidal tract signs, prominent 
dystonia and such eye movement disorders are less commonly reported. 
5.4.11 DTDS and the SLC6A3 knockout mouse model 
Despite the fundamental phenotypic differences between DTDS and DAT 
homozygous null mice, several of the early clinical findings are recapitulated in 
the mouse phenotype, which is characterised by hyperlocomotion/ hyperkinesis 
(Giros et al., 1996) restlessness, irritability, feeding difficulties, growth 
retardation, sleep disturbance and cognitive delay (Gainetdinov et al., 2003). 
The relative cognitive sparing seen in human DTDS may indicate that although 
DAT dysfunction may impact on some aspects of learning, it may not 
completely prevent some intellectual progress. Although the mouse model does 
not accurately recapitulate all aspects of the human DTDS movement disorder, 
choreiform and dystonic components are often observed in such mice during 
the first few months of life. This is accompanied by a loss of medium spiny 
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neurons of in the striatum. However, the hypokinetic features evident in older 
children with DTDS (secondary to progression of parkinsonism-dystonia) is not 
evident in the established knockout mouse model. Interestingly, if these mice 
are treated acutely with an inhibitor of the synthesis of dopamine (which does 
not behaviourally affect wild type mice) they display one of the best 
pharmacologically inducible and reversible parkinsonian symptoms ever seen in 
an animal model. It is possible that the observed differences in mice and 
humans may reflect a more highly developed extrapyramidal system in humans 
as is evident in other mouse models of human infantile onset movement 
disorders (Koeller et al., 2002). However, this study may prompt further 
evaluation of disease semiology and evolution in DAT homozygous null mice as 
well as investigation of SLC6A3/DAT1 knock-in mice harbouring corresponding 
DTDS pathogenic mutations to understand their effects in a physiological 
context. 
5.4.12 Therapeutic strategies in DTDS     
Data from this DTDS cohort confirms that the vast majority of current medical 
and surgical therapeutic strategies do not correct the intraneuronal dopamine 
deficiency and have either little (and often temporary) or no impact on clinical 
symptomatology. In some neurotransmitter disorders, supplementation of L-
dopa can result in clinical improvement and in some cases, even symptom 
reversal (see Chapter 4.1.4). However in DTDS, for the majority of patients, 
there was no clinical improvement with L-dopa and in fact, some patients had 
deterioration of motor symptoms. Only patient 9 and 11 showed a clear clinical 
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response to L-dopa (with improvement in motor symptoms) and interestingly 
both these patients‘ mutations displayed a degree of residual DAT activity. 
Analysis of more cases of DTDS will allow further investigation into whether the 
level of residual DAT activity in DTDS may actually be predict a patient‘s 
response to medication. Identification and analysis of further cases of DTDS will 
allow these outstanding issues to be addressed. The recent use of the 
dopamine receptor agonist ropinirole (utilised in adult onset Parkinson‘s 
disease, Matheson and Spencer, 2000) has resulted in short term benefits for 
two patients, but the wider impact of these agents in other children with DTDS 
and their impact on long term outcome remain yet to be determined. It is 
possible that optimum clinical benefit from treatment with dopamine agonists 
may require the instigation of therapy early in the disease course, before the 
hypothesised postsynaptic downregulation of downstream signalling. If there 
were to be neurodegenerative loss of dopamine terminals in DTDS, which is 
currently not known, early treatment with neuroprotective agents such as 
pramipexole or ropinirole could thus be beneficial. Although deep brain 
stimulation (DBS) targeting the GPi was of minimal benefit in one patient, it is 
conceivable that early DBS (which is increasingly used to treat paediatric 
movement disorders, Marks et al., 2009) may have a future neuromodulatory 
role in DTDS. 
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5.5 Conclusion 
In Chapters 4 and 5, I have characterised the features of a novel and emerging 
neurotransmitter disorder. DTDS is a severe complex motor disorder and 
dopamine ‗transportopathy‘ which is predicted to cause cerebral dopamine 
deficiency. Future identification of DTDS cases will expand the phenotypic 
spectrum, allow accurate diagnosis and genetic counselling, prevent 
unnecessary neurological investigations, provide further insight into genotype-
phenotype correlations and facilitate molecular investigation of the 
consequences of DAT dysfunction. This multifaceted approach to 
understanding DAT-related disease mechanisms may then facilitate the 
development of novel therapeutic strategies to ameliorate the severe clinical 
symptoms in DTDS and other related/ parkinsonian phenotypes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
PLA2G6-associated Neurodegeneration (PLAN) 
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6.1 Introduction 
Neurodegeneration with brain iron accumulation (NBIA) comprises a 
heterogeneous group of progressive complex motor disorders characterised 
by the presence of high brain iron, particularly within the basal ganglia. A 
number of autosomal recessive NBIA syndromes can present in childhood, 
including phospholipase A2 group 6 associated neurodegeneration (PLA2G6-
associated neurodegeneration, PLAN). In this chapter, I have investigated a 
cohort of patients with PLA2G6 mutations in order to define the clinical, 
radiological and genetic features of infantile PLAN. 
6.1.1 Spectrum of NBIA disorders 
Neurodegenerative disorders with brain iron accumulation encompass a wide 
spectrum of adult and paediatric neurological diseases. Although, the 
accumulation of iron within the basal ganglia and dentate nuclei is part of the 
normal ageing process (Gelman et al., 2007), brain iron deposition is 
implicated in the pathogenesis of both common multifactorial 
neurodegenerative diseases and rarer inherited disorders. 
Iron deposits have been demonstrated in the substantia nigra in Parkinson 
disease and within structures affected by ß amyloid plaques in Alzheimer 
disease (Gerlach et al., 2006; House et al., 2007). Inherited monogenic NBIA 
disorders are also described and can be due to specific defects in iron 
metabolism. Autosomal dominant mutations in the ferritin light chain gene 
(FTL1) cause adult-onset neuroferritinopathy (Curtis et al., 2001), a 
progressive movement disorder with features of chorea, dystonia and 
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parkinsonism (Burn and Chinnery, 2006). Aceruloplasminaemia is another 
adult-onset NBIA disorder of autosomal recessive inheritance, caused by 
mutations in the gene encoding ceruloplasmin, CP (Yoshida et al., 1995). It is 
clinically characterised by a progressive extrapyramidal disorder, cerebellar 
ataxia, dementia, retinal degeneration and diabetes mellitus (McNeill et al., 
2008a). Recently NBIA has also been described in patients with a Kufor-
Rakeb phenotype associated with mutations in the ATP13A2 gene 
(Schneider et al., 2010). 
NBIA may also present in childhood. Childhood NBIA comprises a clinically 
and genetically heterogeneous group of disorders, characterised 
predominantly by a progressive extrapyramidal phenotype, associated with 
excess deposition of brain iron (Gregory et al., 2009). The two major NBIA 
phenotypes that present in childhood are classified as the autosomal 
recessive neuroaxonal dystrophies, and include pantothenate kinase 
associated degeneration (PKAN, caused by mutations in the PANK2 gene) 
and PLA2G6-associated neurodegeneration (PLAN, caused by mutations in 
the PLA2G6 gene). Mutations in these genes are thought to disrupt the 
normal cellular functions of phospholipid remodelling and fatty acid 
metabolism. Childhood NBIA is genetically heterogeneous and indeed a 
significant group of children with NBIA currently have no genetic diagnosis 
(‗idiopathic NBIA‘). It is likely that more, currently undetermined NBIA genes 
account for a number of these patients. 
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6.1.2 Radiological diagnosis of NBIA disorders 
Brain iron accumulation is radiologically discernible and thus brain MRI is an 
important diagnostic tool and a major key to the diagnosis of NBIA disorders. 
Iron deposition characteristically appears as a pattern of reduced signal 
intensity (hypointensity) on T2, FLAIR (Fluid-attenuated inversion recovery), 
T2* gradient, fast spin ECHO (FSE) and diffusion-weighted MRI (compared to 
age matched norms) in the globus pallidi and substantia nigra pars reticulata 
(Gregory et al., 2009). Examples of MR images showing these features are 
illustrated in figure 6-1. T1 isointensity distinguishes the lesions from other 
changes (such as calcium deposition). Brain iron also appears as reduced 
density on CT neuroimaging (Kurian et al., 2008). The specific pattern of iron 
accumulation helps to distinguish the various forms of NBIA (McNeill et al., 
2008b). In most cases of PKAN, abnormalities are restricted to the globus 
pallidus and substantia nigra and the majority of cases display the eye-of-the-
tiger sign. In PLAN, globus pallidus and substantia nigra are involved on T2* 
and FSE scans with dentate involvement seen only on T2*. By contrast, the 
dentate nuclei, globus pallidus and putamen appear to be consistently 
involved in neuroferritopathy, with confluent areas of hyperintensity (due to 
probable cavitation) involving the pallida and putamen in approximately half of 
cases. Some patients with neuroferritinopathy also have changes in the 
caudate nuclei and thalami. More uniform involvement of the basal ganglia 
and the thalami (without cavitation) is typical in aceruloplasminaemia. 
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Figure 6-1 
Examples of MR Images of NBIA disorders 
6-1A Patient age 5.9 years, classical PKAN. Axial T2-weighted FSE (fast spin 
echo) sequences showing bilateral eye-of-the-tiger sign with a medial central 
hyperintense region (yellow arrow) surrounding a region of hypointensity 
(white arrow) in the globus pallidi  
6-1B Patient, age 12 years, childhood PLAN. Axial susceptibility-weighted image 
showing abnormal low signal in the globus pallidi 
6-1C  Patient, age 9 years, idiopathic NBIA. Axial T2-weighted gradient echo image 
showing abnormal low signal in the globus pallidi 
6-1D  Patient age 12 years, idiopathic NBIA. Axial T2-weighted image (contrast 
 enhanced fast field echo, FFE) showing reduction in T2 signal in the 
 substantia nigra  
 
6-1A      6-1B 
    
6-1C      6-1D 
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6.2 PKAN 
PKAN is one of the two major NBIA disorders of childhood and shows 
phenotypic overlap with PLAN. The clinical features of this related disorder 
will thus be discussed in detail below. PKAN (MIM #606157) accounts for 
approximately 50% of childhood NBIA disorders. It has a proposed 
prevalence rate of between 1 and 3 per million population (Gregory et al., 
2009). 
6.2.1 Clinical syndromes 
6.2.1.1 Typical PKAN 
The clinical features of PKAN have been delineated by large cohort studies of 
patients from North America (Hayflick et al., 2003) and Western Europe 
(Hartig et al., 2006). Two thirds of PKAN cases have a classical phenotype, 
with a relatively homogenous presentation. The majority (88%) of cases 
clinically present before 6 years of age but there is great variability in age of 
presentation (range 0.5-12 years). Affected children are often thought to be 
dyspraxic or clumsy prior to neurological presentation and the majority of 
patients present initially with gait or postural problems secondary to dystonia 
(Gregory et al., 2009).  Extrapyramidal features predominate in the disease 
course (dystonia in 87%). The almost universal presence of oromandibular 
dystonia and dysarthria in PKAN patients was highlighted by Hartig et al., 
(2006). Corticospinal tract signs are also common, resulting in hypertonicity, 
hyperreflexia, spasticity and upgoing plantar responses. Though a movement 
disorder is the most prominent manifestation of PKAN, both visual impairment 
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and cognitive dysfunction contribute to the burden of disability. The majority 
also have retinitis pigmentosa which can lead to significant visual impairment 
(Hayflick et al., 2003) and cataracts can also develop. Patients with PKAN 
have a wide range of cognitive abilities, but tests of both IQ and adaptive 
behaviour indicate that cognition declines with disease progression (Freeman 
et al., 2007). The natural history of classical PKAN is for stepwise regression, 
with periods of clinical stability interspersed with periods of neurological 
deterioration. There is no correlation of neurological deterioration with periods 
of catabolic stress such as intercurrent infection. The majority of patients 
(85%) become non-ambulant within 15 years after diagnosis (Hartig et al., 
2006). Later complications include dysphagia (resulting in feeding difficulties), 
gastroesophageal reflux and constipation. Death is usually secondary to 
cardiorespiratory complications (chest infections, aspiration pneumonia), the 
secondary deleterious effects of malnutrition and rarely status dystonicus. 
6.2.1.2 Atypical PKAN 
Patients with atypical PKAN are on average significantly older at presentation 
with a mean age of 14 years (range 1–28, Hayflick et al., 2003; Hartig et al., 
2006). Atypical PKAN shows significant phenotypic overlap with atypical 
PLAN and idiopathic NBIA disorders. In such patients, speech difficulties 
(such as palilalia or dysarthria) are common presenting features although 
mild gait disturbance and neuropsychiatric presentation (with emotional 
lability, personality change, aggression, impulsivity, obsessive-compulsive 
disorder and depression) are also described. Motor and vocal tics and 
obsessions suggestive of Tourette syndrome have also been described 
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(Pellecchia et al., 2005). Almost a third of patients with atypical disease 
manifest psychiatric problems, behavioural difficulties or a frontotemporal like 
dementia early in their disease. Most atypical PKAN patients, over time, 
develop an extrapyramidal phenotype, although the dystonia is thought to be 
less severe than that seen in classical disease (Hayflick et al., 2003). Rarely 
movement phenotypes may be evident on initial presentation. An adult onset 
pure akinesia (Molinuevo et al., 2003), early onset-parkinsonism, focal hand 
dystonia and intermittent severe dystonia have been reported (Zhou et al., 
2005). Corticospinal tract signs and freezing of gait are also prevalent. 
Retinitis pigmentosa is also described in atypical disease although it is less 
prevalent than in classical disease. Atypical PKAN is less aggressive than 
classical disease, and most patients remain ambulant into adulthood.  
6.2.1.3 HARP syndrome 
The HARP (hypoprebetalipoproteinaemia, acanthocytosis, retinitis 
pigmentosa and pallidal degeneration) syndrome is caused by PANK2 
mutations and is part of the PKAN spectrum (Ching et al., 2002). 
6.2.2 Radiological features of PKAN  
The characteristic imaging feature is the ‗eye-of-the-tiger‘ sign (Figure 6-1A), 
defined as a medial area of hyperintensity within a hypointense globus 
pallidus (Hayflick et al., 2003). Cases of PKAN may also have hypointensity 
of the substantia nigra (Gregory et al., 2009). There are however reports of 
patients with PANK2 mutations without this classical radiological sign (Zolkipli 
et al., 2006). Although the majority of patients with PANK2 mutations have 
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this radiological sign, patients with an NBIA phenotype and an ‗eye-of-the-
tiger‘ sign who are PANK2 mutation negative are also described (Kumar et 
al., 2006). The ‗eye-of-the-tiger‘ is also observed in conditions other than 
PKAN, including multiple system atrophy (Strecker et al., 2007), 
neuroferritinopathy (McNeill et al., 2008b) and progressive supranuclear palsy 
(Kumar et al., 2006). The sign, whilst diagnostically useful, must be 
interpreted correctly in clinical context. 
6.2.3 Neurological Investigations in PKAN 
Full blood count will reveal acanthocytosis in 8% of patients (Hayflick et al., 
2003). ERG can demonstrate subclinical retinopathy in a significant proportion 
of patients (Egan et al., 2005). Ocular motility studies show hypometric 
slowed saccadic eye movements. Ophthalmological examination also reveals 
sluggish papillary reactions with sectoral iris paralysis and partial loss of the 
papillary ruff (Gregory et al., 2009).  
6.2.4 Molecular genetics of PKAN 
PKAN is caused by mutations in the Pantothenate Kinase 2 (PANK2) gene 
(Zhou et al., 2001). The PANK2 gene codes for the enzyme pantothenate 
kinase 2, which phosphorylates pantothenate, the initial rate limiting step in 
Co-enzyme A biosynthesis. Co-enzyme A has a vital role in ATP synthesis, 
fatty acid and neurotransmitter metabolism. The PANK2 enzyme has a 
mitochondrial targeting sequence and is localised to mitochondria in human 
brain. Mitochondrial dysfunction is proposed to result from PANK2 mutations, 
leading to neurodegeneration. The neurotoxic metabolites cysteine and 
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pantetheine are substrates for PANK2, and abnormal PANK2 function will 
lead to their accumulation. Cysteine is a potent iron chelator, and it is 
proposed that high local cysteine levels lead to secondary iron accumulation. 
Iron accumulation will exacerbate neuronal injury by inducing oxidative stress.  
There is no animal model of PKAN which satisfactorily recapitulates the 
human phenotype. A Drosophila melanogaster with deficient PANK2 has 
defects in cell division leading to sterility and is also described as 
uncoordinated with impaired ability to climb (Yang et al., 2005). A knockout 
mouse model of PKAN develops retinal degeneration and azoospermia (Kuo 
et al., 2005).  However, the mice do not develop a movement disorder despite 
being followed up to 12 months of age, and neither MRI nor brain histology 
demonstrated iron accumulation. It is possible that the other PANK isoforms 
(1, 3 and 4) compensate for PANK2 loss in knockout mice. Deprivation of 
dietary pantothenate causes a movement disorder proposed to be dystonia in 
wild type mice (Kuo et al., 2007). 
Mutations have been identified in all 7 exons of the PANK2 gene. The 
majority of PANK2 variants are missense mutations, evenly distributed across 
the conserved domains of PANK2. Deletions and splice site variants are also 
described (Hayflick et al., 2003). The amount of residual enzyme activity in 
the mutated PANK2 enzyme influences disease severity, with earlier disease 
onset in patients with homozygous null mutations and later disease onset in 
patients with mutations which allow residual enzyme activity (Pellecchia et al., 
2005). Globally the 1561G>A missense mutation is the most common cause 
of PKAN, and homozygotes have classical PKAN (Hartig et al., 2006). This 
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mutation has been described on a background of a shared haplotype, 
suggestive of a founder effect. The other most common identified mutations 
are 1583C>T and 1351C>T. In about 10 % of cases only 1 mutated allele can 
be detected, and it is believed that intragenic deletions, duplications and 
possibly mutations in the promoter or regulatory regions may account for a 
proportion of these cases. 
6.3 PLAN 
6.3.1 Discovery of a second NBIA locus  
In 2006, Morgan and colleagues undertook autozygosity mapping studies in a 
UK-based extended consanguineous Pakistani kindred with multiple affected 
members with NBIA. In this family, microsatellite marker analysis of the PKAN 
locus excluded linkage to the PANK2 gene. Subsequent genome-wide 
linkage analysis using microsatellite markers identified a minimal region of 
linkage of 4.9Mb on chromosome, 22q12-q13 between D22S426 and 
D22S276 containing the disease locus (LOD score 4.65). During the same 
time period, Hayflick and colleagues also undertook parallel genome-wide 
linkage studies (using microsatellite markers) in 12 families with INAD 
(infantile neuroaxonal dystrophy), and mapped a novel disease-locus to a 
6.0Mb region of chromosome 22q12.3-q13.2 (LOD score 4.78). In view of the 
common region of linkage, it was hypothesised that both the NBIA variant and 
INAD would be allelic, thus defining a new disease locus on chromosome 22.   
Chapter 6                                                                         PLA2G6-associated neurodegeneration (PLAN)  
213 
 
6.3.2 Identification of PLA2G6 mutations in NBIA and INAD 
Screening of candidate genes from this region on chromosome 22 was 
subsequently undertaken, initially in 3 families with INAD and in the extended 
kindred with NBIA. After sequencing 70 of the 100 genes in the region, 
germline mutations in PLA2G6 were identified in all 4 kindreds. PLA2G6 
mutations were identified in 28 additional probands with INAD, and in 
individuals with Karak syndrome (Morgan et al., 2006). A total of 44 unique 
mutations were identified, suggesting that PLA2G6 was the causative gene in 
the majority of cases of infantile neuroaxonal dystrophy and also in some 
cases of ‗idiopathic‘ NBIA (Morgan et al., 2006). 
6.3.3 PLAN is clinically heterogeneous 
It is now evident that PLAN comprises a phenotypically diverse group of 
autosomal recessive neurodegenerative disorders associated with genetic 
defects in the PLA2G6 gene. Following gene identification in 2006 the 
phenotypic spectrum of PLA2G6-related disorders has expanded and is 
becoming increasingly defined. There are currently 3 distinct phenotypes 
which may be classified according to the average age of disease presentation 
 Infantile PLAN 
Classical infantile neuroaxonal dystrophy, INAD, MIM #256600 
 Childhood PLAN  
Atypical neuroaxonal dystrophy and Karak syndrome, MIM #610217 
 Adult PLAN 
Early-onset dystonia-parkinsonism, MIM #612953  
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In order to better define the clinical phenotype of infantile PLAN, a cohort of 
children with PLA2G6 mutations was investigated. All clinical phenotypes of 
PLAN are subsequently discussed in detail in the Discussion section (Chapter 
6.6) 
6.4 Materials and methods 
6.4.1 Clinical assessment 
6.4.1.1 Case acquisition 
14 children with mutations in the PLA2G6 gene consistent with a phenotype 
of infantile onset PLAN were identified from the National PLA2G6 Diagnostic 
Screening Service (West Midlands Regional Genetic Laboratory). Informed 
consent was obtained from all participants and the study was approved by 
local ethics research committees.  
6.4.1.2 Clinical phenotyping 
All children with PLAN were clinically assessed by myself (8 children) or 
another paediatric neurologist. The patient‘s medical case notes were 
analysed in order to delineate the clinical features on history and 
examination. Where available, video footage of the children was also 
examined. CT and brain MRI of 17 patients were examined independently by 
me and two consultant paediatric radiologists to determine the radiological 
features seen in this disorder (with consensus agreement on disparities). 
Neurological investigations including electroencephalogram (EEG), nerve 
conduction studies (NCS), electromyogram (EMG), visual evoked potentials 
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(VEP) and skin/sural nerve biopsy were also undertaken in some patients 
and the results of these were also ascertained from the medical notes. 
6.4.2 Molecular genetic investigation 
PLA2G6 mutation analysis was kindly undertaken by the West Midlands 
Regional Genetic Laboratory as part of the routine diagnostic service. DNA 
was extracted from peripheral lymphocytes using standard techniques. 
PureGene (Gentra) chemistry was used to extract DNA from those samples 
received as blood. DNA samples were quantified using the NanoDrop-1000 
Spectrophotometer (LabTech, Sussex UK). The complete coding region of 
the PLA2G6 gene, including all splice junctions, was amplified and 
sequenced from genomic DNA using primers for exons 1-6, 8, 11 and 13-15 
designed by Dr Neil Morgan, Department of Medical & Molecular Genetics, 
University of Birmingham. Primers for exons 7, 9, 10, 12, 16 and 17 were 
designed using Primer3 software Primers were analysed using the National 
Genetics Reference laboratory Manchester Diagnostic SNP Check software 
(http://ngrl.man.ac.uk/SNPCheck/) in order to identify any single nucleotide 
polymorphisms (SNPs) lying under the primer binding site. Previously 
unreported putative mutations were evaluated by demonstrating appropriate 
segregation within families, absence in more than 200 ethnically matched 
control patients and conservation of normal amino acid throughout lower 
species. 
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6.5 Results 
6.5.1 Clinical phenotype of PLAN 
6.5.1.1 Family history 
14 children (5 boys and 9 girls) from nine families were studied. The majority 
of children in this cohort (11 children) were of Pakistani origin, 2 were British 
Caucasian, and 1 child was of Arabic origin. 8 children from 4 families were 
born to consanguineous parents. 8/14 children were found to have a similarly 
affected relative. There was a history of an unexplained death in childhood 
within the extended family in 6/14 cases. 
6.5.1.2 Presenting clinical symptoms and signs 
All children in this cohort presented with psychomotor regression following a 
normal infancy. They were born following an uneventful pregnancy, had a 
normal perinatal history and normal early developmental milestones. The 
median age at symptom presentation was 14 months (range 12–22 months). 
Initial symptom presentation followed a respiratory illness in 4 children. Of 
these, two had further profound neurologic regression and motor skill loss 
after subsequent intercurrent infections. All children presented with motor and 
cognitive skill regression and global developmental delay. All patients 
developed bulbar dysfunction within 7 years of presentation. Axial hypotonia 
was evident in all children by age 8 years. Spasticity was evident in all 
children within 15 months of presentation. Thirteen children developed 
contractures by 6 years of age. Spinal deformities such as kyphoscoliosis 
developed in 10/14 children. Dystonia developed in all patients. All children 
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had cerebellar features within 5 years of clinical presentation. Acquired 
strabismus was found in 13 children. Clinical ophthalmology examination 
revealed optic atrophy in 11 patients. None of the children were dysmorphic 
and epilepsy was not reported in this cohort. Microcephaly (occipitofrontal 
circumference below third percentile) was found in only two children. The age 
at onset of each clinical feature is summarized in Table 6-1. The development 
of neurological features in this cohort is illustrated in Figure 6-2. 
6.5.1.3 Disease progression 
After presentation, all children demonstrated rapid symptom progression, with 
further evidence of neurologic regression and increasing motor disability. The 
described clinical features became increasingly severe in all patients. To 
date, five children have died; mean age at death was 9.1 years (range 6.5–14 
years). 
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Figure 6-2  
Development of neurological features in the PLAN cohort 
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Table 6-1 
Age of onset of clinical features for patients in the PLAN cohort  
Patient 
Cognitive  
and motor 
regression 
Bulbar 
dysfunction 
Axial 
hypotonia 
Limb             
spasticity 
Contractures 
Spinal 
deformity 
Dystonia 
Cerebellar   
Ataxia 
Nystagmus Strabismus 
Optic              
Atrophy 
1 
15m 7y 18m 18m 4y 4y 18m 18m 18m 18m 18m 
2 
 
22m 3y2m 2y 3y2m 3y2m 3y2m 3y10m 3y2m 3y10m 2y 2y 
3 
 
12m 12m 15m 15m 15m 15m 15m 15m 15m 15m 15m 
4 
 
12m 3y10m 15m 15m 4y2m 4y2m 15m 15m 2y 15m 15m 
5 
 
15m 15m 18m 18m 6y 6y 18m 4y 4y 18m 18m 
6 
 
15m 4y 18m 18m 18m 4y 18m 18m 18m 18m 18m 
7 
 
12m 8y 8y 2y6m 4y A 7y 12m 2y6m 3y A 
8 
 
12m 8y 8y 2y A A 36m 15m 15m A A 
9 
 
18m 18m 21m 21m 21m A 2y 21m 21m 21m 21m 
10 
 
12m 12m 15m 15m 6y A 15m 15m 15m 15m 15m 
11 
 
18m 18m 20m 20m 20m 20m 20m 20m 20m 20m 20m 
12 
 
12m 12m 15m 15m 15m 15m 15m 5y6m 5y6m 15m 15m 
13 
 
18m 4y5m 22m 22m 4y 4y 22m 22m 22m 22m 22m 
14 
 
13m 13m 16m 16m 16m 16m 18m 16m 16m 16m A 
m   months     
y   years   
A   clinical feature absent 
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6.5.2 Radiological findings 
Patients 1–13 in the cohort had brain imaging. Patient 14 did not have brain 
imaging studies. All available brain scans were reviewed and the findings 
summarised in Table 6-2. Initial imaging (some including diffusion and T2* 
gradient MR sequences) was undertaken during active neuroregression, at a 
median time of 1.8 years after first clinical presentation. Cerebellar cortical 
atrophy was universally present (mean age 4.2 years) as illustrated by Figure 6-
3. Imaging of all patients showed either high signal on T2-weighted or FLAIR 
MR sequences or reduced density on CT imaging, indicative of cerebellar 
cortical gliosis (Figure 6-3). The extent of this gliosis was variable and most 
marked in Patient 6 (the oldest child in the cohort). Patient 13 showed 
borderline changes of cerebellar cortical gliosis, but the patient was only 3.8 
years when imaging was performed and no subsequent imaging was available 
for comparison. 
 
Figure 6-3 
MR Imaging of patient 4, age 5.8 years: axial FLAIR (6-3A) and coronal T2-
weighted (6-3B) sequences showing cerebellar cortical atrophy and gliosis, with 
increased CSF spaces around the cerebellum and increased signal on T2 and 
FLAIR sequences in the residual cortex of the cerebellum 
 
Figure 6-3A            Figure 6-3B 
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10/13 children had evidence of increased iron deposition in the globus pallidi 
seen as reduced signal on T2, FLAIR, and T2* gradient and diffusion 
weighted MR sequences (Figure 6-4) or as reduced density on CT imaging 
compared to age-matched norms. This hypointensity was most apparent in 
the medial aspect of the globus pallidus in 5/10 children, the others showing 
more diffuse globus pallidal changes. 6/10 children showed globus pallidal 
changes on the initial scan (performed at a mean age of 5.9 years). 4/10 
children did not have, or showed borderline changes in the globus pallidi on 
initial MR imaging (performed at a mean age of 2.4 years). However, definite 
changes were detected on subsequent scans performed 1-3 years later. 
From our cohort, it appears that the globus pallidal changes are more severe 
with increasing age (Figure 6-5). Increased iron deposition in the globus 
pallidus was not evident in 3 children; these children had brain imaging at a 
mean age of 2.8 years with no subsequent scans to date.  
10/13 patients had MR scans of sufficient quality to assess imaging changes 
of increased iron in the substantia nigra (Figure 6-4). 4 of these patients 
showed such changes on imaging performed at a mean age of 7.2 years. 
3/10 showed borderline changes on imaging performed at a mean age of 3 
years 5 months. 3/10 patients had early scans with normal signal in the 
substantia nigra, developing abnormal signal on later imaging performed over 
5 years of age. 
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Figure 6-4 
MR imaging of patient 6, age 13.9 years (6-4A and 6-4B) and patient 4, age 
5.9 years (6-4C and 6-4D). Axial T2* gradient sequences (6-4A, 6-4B, 6-4C) 
and coronal T2-weighted sequence (6-4D) showing marked reduction in T2 
signal in the globus pallidi (6-4A,6-4C) and more medially on 6-4C and 
substantia nigra (6-4B,6-4D). The degree of iron deposition is much more 
marked in patient 6 (the older child) compared to patient 4  
 
Figure 6-4A     Figure 6-4B 
   
Figure 6-4C     Figure 6-4D 
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Figure 6-5 
MR imaging: Axial T2-weighted sequences in 3 children within the cohort. The abnormal reduced signal in the globus pallidi 
increases in severity with increasing age 
 
6-5A         6-5B         6-5C   
Age 3.8 years      Age 5.9 years       Age 13.8 years   
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Three additional features were identified. 8 children showed reduced volume in 
the optic chiasm and optic nerves, suggesting optic pathway atrophy. Borderline 
optic atrophy was evident in three further children. Cerebral white matter 
changes were present in 7 of the 12 patients with imaging affording adequate 
assessment (Table 6-2). The posterior corpus callosum was almost universally 
abnormal, with a simple appearance to the splenium, which was thin, elongated, 
and slightly vertically orientated (Figure 6-6). 
 
Figure 6-6 
MR imaging: Sagittal T1-weighted sequence showing thin, elongated and 
vertical orientation of the splenium (posterior) corpus callosum (long arrow). 
Note marked atrophy of the vermis of the cerebellum (short arrow) 
Patient 4, age 2.3 years 
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Table 6-2 
Radiological findings in the cohort 
Patient Scan 
Type 
Age 
(years) 
Cerebellar 
Atrophy 
Cerebellar 
gliosis 
Low signal/ 
density 
globus 
pallidus 
Low signal/density  
substantia nigra/ 
subthalamic nuclei 
Cerebral 
white 
matter 
Optic 
pathway 
atrophy 
Corpus 
callosum 
1 CT 4.9 + + + I - I I 
 MR 7.4 + + + I I I I 
2 MR 4.0 + + + + H B B 
3 CT 1.9 + + - I - I I 
 MR 2.5 + + B - H B S 
 MR 5.3 + + + + H B S 
4 MR 2.3 + + - - - + S 
 MR 5.8 + + + + - + S 
5 MR 2.3 + + B - - - S 
 MR 3.3 + + + - H + S 
 MR 5.2 + + + B H A + S A 
6 MR 13.7 + + ++ ++ H A + S A 
7 MR 3.3 + + - B - + S 
8 MR 2.3 + + - B - + S 
9 MR 3.3 + + + I H A + S 
10 MR 6.0 + + + I A + S A 
11 MR 2.8 + + - - - - S 
12 MR 3.4 + + (-) - - B B 
 CT 6.1 + + + I A I I 
13 MR 3.8 + B + - - + S 
 
KEY 
+ Changes present   I Imaging quality or type not suitable to assess feature 
B Borderline changes    H High (mild) T2 MR signal in cerebral white matter 
- Changes absent   A Atrophy  
      S Simple splenium (posterior) corpus callosum
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6.5.3 Results of other investigations 
6.5.3.1 Neurophysiology and histology 
On EEG, widespread high amplitude fast activity (at 16 to 22 Hz) was seen in 
71.4% (5/7) of patients who had this investigation. EMG signs of denervation 
were seen in all seven children who had this investigation. Of these seven 
children, a distal axonal-type sensorimotor neuropathy was evident in 43% (3/7) 
of patients who had NCS. Absent or delayed VEP were seen in 7/8 children 
examined. Histological examination of sural nerve and skin tissue was 
undertaken in 4 patients. 3 children showed features of axonal swelling and 
spheroid body formation on skin biopsy. One patient had negative findings on 
both skin and sural nerve examination. 
6.5.3.2 Other investigations 
As all patients presented with neuroregression (associated with intercurrent 
illness in some cases), detailed investigation was undertaken (prior to 
diagnosis) to rule out an inborn error of metabolism. Children in this cohort had 
the following tests: blood glucose, lactate, amino acids, acid/base status, 
ammonia, CK, carnitine, acylcarnitine profile, very long chain fatty acids, uric 
acid, B12, folate, cholesterol, isoelectric focusing of transferrin, biotinidase, 
lysosomal enzymes; urine amino acids, organic acids, oligosaccharides, and 
mucopolysaccharide screen; CSF glucose, lactate, amino acids, and 
neurotransmitters. Neurometabolic investigations did not indicate the presence 
of a metabolic disorder. 
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6.5.4 Results of molecular genetic investigation 
Details of the genetic findings are reported in Table 6-3. 13 patients had 
missense mutations (9 of whom were homozygous for p.Lys545Thr). No clinical 
or radiological differences were apparent between p.Lys545Thr mutation cases 
and the rest.  
Table 6-3  
Mutations identified in the cohort 
Patient Ethnicity 
Parents 
Related 
Mutation(s) State 
Effect on 
protein product 
Mutation(s) 
reported 
1 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
2 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
3 
Pakistani 
 
No c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
4 
Pakistani 
 
No c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
5 
British 
Caucasian 
No c.2221C>T Heterozygous p.Arg741Trp 
Morgan et al.,
 
2006 
6 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
7 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
8 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
9 Arabic No 
c.719T>C 
c.1978C>A 
Compound 
heterozygote 
p.Leu240Pro 
p.Pro660Thr 
Kurian et al., 
2008 
10* 
Pakistani 
 
No c.109C>T Heterozygous p.Arg37X 
Morgan et al.,
 
2006 
11 
British 
Caucasian 
No 
c.1103C>A 
c.1417G>T 
Compound 
heterozygote 
p.Ala368Asp 
p.Glu473X 
Kurian et al., 
2008 
12 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
13 
Pakistani 
 
Yes c.1634A>C Homozygous p.Lys545Thr 
Morgan et al.,
 
2006 
14 
Pakistani 
 
Yes c.905T>G Homozygous p.Met302Arg 
Kurian et al., 
2008 
(*) Maternal DNA – one mutation detected. DNA on affected patient and father was not available 
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6.6 Discussion 
Infantile neuroaxonal dystrophy (INAD) was reported as a clinical entity almost 
50 years ago (Cowen & Olmstead, 1963) and cohorts of patients have been 
frequently reported (Aicardi and Castelein, 1979; Nardocci et al., 1999). Since 
gene identification, the term PLA2G6-associated neurodegeneration (PLAN) 
has been adopted to account for this subgroup of patients as well as the other 
different phenotypes associated with this gene.  
6.6.1 Clinical features of infantile PLAN 
In this chapter, detailed review of the clinical and radiologic features of 14 
cases has allowed delineation of this homogeneous infantile PLAN 
phenotype. Infantile PLAN is thus characterised by the onset of rapidly 
progressive psychomotor regression in children, with disease onset under 2 
years of age (Gregory et al., 2008; Kurian et al., 2008).  In this cohort, 
intercurrent illness triggered symptom presentation in some cases, thus 
mimicking the clinical presentation of a metabolic disorder. This finding 
suggests that it is important to include infantile PLAN in the differential 
diagnosis of inborn errors of metabolism. Gait disturbance and axial 
hypotonia as well as visual features (nystagmus, new-onset strabismus and 
optic atrophy) were also frequently reported in the early stages of disease. 
During the first decade, children develop a spastic tetraparesis with 
symmetrical pyramidal tract signs (initially with hyperreflexia and later with 
areflexia), spinal deformities and limb contractures. Bulbar dysfunction was 
evident in the majority of this cohort by 5 years of age. Extrapyramidal 
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features such as dystonia were also prominent with increasing age. Although 
not evident in this cohort, generalised seizures have also been frequently 
reported and in certain populations, may be an early disease feature (Wu et 
al., 2009). Over time, children demonstrated progressive neurological 
regression, worsening spasticity, ongoing cognitive decline and worsening 
visual impairment, resulting in a vegetative state. Death occurred around the 
end of the first decade and is usually secondary to cardiorespiratory 
complications, infection, malnutrition and rarely status dystonicus (Gregory et 
al., 2009). 
6.6.2 Radiological features of infantile PLAN 
This study also confirmed that features on MRI brain can aid diagnosis of 
infantile PLAN (Tanabe et al., 1993; Farina et al., 1999). Cerebellar atrophy is 
a universal feature and often the earliest sign on MRI (Gregory et al., 2008). 
In this cohort, cerebellar gliosis was also commonly present (increasing in 
severity with age, Kurian et al., 2008) but not all patients have this feature 
(Biancheri et al., 2007). Atrophy of the cerebellum is associated with 
secondary posterior corpus callosum abnormalities with evidence of a simple 
vertically orientated, thin elongated splenium. Many children (40-50%) also 
have evidence of brain iron accumulation with increased iron deposition in the 
globus pallidi (particularly in the medial aspect of the globus pallidus), dentate 
nuclei and substantia nigra (Gregory et al., 2009). In the described cohort of 
children, the iron accumulation also appeared to become increasingly severe 
with age (Kurian et al., 2008). There were also features of optic pathway 
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atrophy (reduced volume of the optic chiasm and optic nerves) and evidence 
of cerebral white matter changes.  
6.6.3 Features on neurological investigation of infantile PLAN 
Other investigations also aided diagnosis (Carrilho et al., 2008), such as 
characteristic high amplitude fast activity on EEG, denervation on EMG, distal 
axonal-type sensorimotor neuropathy on NCS and absent/delayed, reduced 
amplitude VEP. Histological features of axonal swelling and spheroid body 
formation are evident on skin, sural nerve, conjunctiva, rectal or muscle 
biopsy (Gregory et al., 2009). Dystrophic axons viewed by electron 
microscopy exhibit membranotubular profiles, mitochondrial aggregates and 
axons with increased diameter and a thinned membrane. As in one case in 
this cohort, negative biopsy results are commonly reported (Ramaekers et al., 
1987). Biopsy at an age prior to the development of pathologic changes or 
biopsy from a site where changes are not evident may both account for the 
absence of dystrophic axons in such patients (Morgan et al., 2006). Less than 
a third of in this cohort had histological tissue analysis as, in recent years, the 
availability of molecular genetic testing has eliminated the need for invasive 
biopsy in the majority of cases. 
6.6.4 Other PLAN phenotypes 
Since gene identification, PLA2G6 has been investigated in a number of 
neurological conditions and PLA2G6 mutations have been described in a 
further two ‗PLAN‘ phenotypes. 
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6.6.4.1 Childhood onset PLAN 
A subgroup of patients with childhood onset PLAN has been described 
(Gregory et al., 2008). This is much rarer than infantile PLAN and includes 
the condition previously described as Karak syndrome (Mubaidin et al., 
2003). To date, 8 cases have been reported (Morgan et al., 2006; Gregory et 
al., 2008). The clinical phenotype appears more heterogeneous than infantile 
PLAN but will be increasingly characterised as more atypical cases are 
recognised and diagnosed. Childhood onset PLAN has a later disease onset 
(1.5-6.5 years, mean age 4.4 years) and tends to present more insidiously 
with slower disease progression than that observed in infantile PLAN. Subtle 
gait abnormalities (instability and ataxia), dyspraxia and speech regression 
are common presenting features. Diminished social communication and peer 
interaction is particularly evident in this phenotype, with the result that some 
affected children have been misdiagnosed with autism prior to the onset of 
detectable neurological symptoms and signs (L. Cif, personal communication, 
2009). Over time, children develop optic atrophy, nystagmus, tetraparesis 
(with joint contractures) and seizures similar to children with infantile PLAN. 
However, other features of infantile PLAN (such as early truncal hypotonia 
and strabismus) have not been described in childhood PLAN. This phenotype 
shows considerable phenotypic overlap with adolescent/adult NBIA 
phenotypes. Extrapyramidal features (of dystonia and dysarthria) and 
neuropsychiatric disturbances (emotional lability, compulsivity, hyperactivity, 
reduced attention span, neurobehavioural disturbances) become major 
features later in the disease course, reminiscent of the clinical phenotype of 
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idiopathic NBIA and PKAN (Chapter 6.2). The lifespan of atypical PLAN is not 
currently determined. Cerebellar atrophy and gliosis may be evident in this 
group of patients. Brain iron accumulation is a consistent universal feature of 
childhood PLAN, involving both globus pallidus and substantia nigra. Fast 
rhythms of EEG have not been reported in childhood PLAN although some 
children may develop EEG changes consistent with an epileptic process. 
VEPs may be delayed with reduced amplitude. EMG/NCS and ERG are 
normal. Histopathological findings are identical to that described for classical 
PLAN. 
6.6.4.2 Adult onset PLAN 
PLA2G6 mutations have also recently been described in a third subgroup of 
patients with a phenotype of autosomal recessive dystonia-parkinsonism 
(Paisan-Ruiz et al., 2009; Sina et al., 2009). Such affected individuals with 
adult PLAN are from consanguineous kindreds and all have homozygous 
missense PLA2G6 mutations. To date, patients from 4 consanguineous 
kindreds with this adult PLAN phenotype have been described. Affected 
individuals are born following a normal pregnancy and had normal 
milestones. Symptom presentation occurs in late adolescence/early 
adulthood (age 18–26 years) with features of subacute dystonia-parkinsonism 
(facial hypomimia, generalised rigidity, cogwheeling, pill rolling resting tremor, 
bradykinesia and dystonia) associated with the evolution of pyramidal signs. 
Patients also develop eye movement abnormalities, including eye lid opening 
apraxia, blepharoclonus, square wave jerks in the primary position, jerky 
saccadic pursuit, supranuclear vertical gaze palsy and hypometric vertical 
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saccades. Rapid cognitive decline results in impaired intellectual function, 
visual memory and executive function. Personality changes are also reported. 
Cerebellar symptoms and signs are absent. All patients are initially 
responsive to dopaminergic therapy (L-dopa or dopamine agonists), although 
early development of dyskinesia has been reported. On radiological 
investigation, unlike infantile/ childhood PLAN, no cerebellar or basal ganglia 
abnormalities are noted. MRI brain scans are initially either normal, or show 
features of non-specific mild generalised volume loss or increased white 
matter signal intensity on T2 FLAIR around the frontal horns. A DaTSCAN 
showed markedly reduced uptake in both striata.  
 
The above discussion highlights the number of clinical similarities between 
the various forms of PKAN and PLAN. The different subgroups of PKAN and 
PLAN are compared and contrasted in Table 6-4 and 6-5. The key for Table 
6-4 and 6-5 is as follows:- 
   PLAN  
 PKAN  
++ Clinical feature commonly described in this phenotype 
 + Clinical feature sometimes described 
(+) Clinical feature only rarely described 
 - Clinical feature more commonly absent in this phenotype 
 L May be a late feature of disease 
 N Normal in majority of cases 
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Table 6-4 Comparison of the clinical features of PKAN and PLAN 
 
Clinical Feature Infantile PLAN Childhood PLAN Adult PLAN Classical PKAN Atypical PKAN 
Average age 
Presentation  
0.5–2 years 
Mean age 1.3 years 
1.5–6.5 years 
Mean age 4.4 years 
18-26 years 
0.5-12 years 
Mean age 3.4 years 
1-28 years 
Mean age 13.7 years 
Common Presenting 
Features 
Gait disturbance 
Psychomotor regression 
 
Gait disturbance 
Speech delay 
↓ social interaction 
Dystonia-
parkinsonsim 
Spasticity 
Gait/postural 
disturbance 
Dyspraxia 
Gait disturbance 
Speech disturbance 
Psychiatric symptoms 
Axial Hypotonia ++ - - - - 
Limb spasticity ++ ++ ++ + + 
Contractures/  
Spinal deformity 
++ ++ - + + 
Dystonia ++ ++ ++ ++ ++ 
Parkinsonism  - - ++ (+) (+) 
Bulbar Dysfunction ++ ++ ++ ++ + 
Cerebellar signs  
(ataxia, nystagmus) 
++ ++ - - - 
Squint  
++ - - - - 
Optic Atrophy ++ ++ - (+) - 
Retinitis pigmentosa - - - ++ + 
Neuropsychiatric 
Features 
- ++ ++ (+) ++ 
Seizures 
+    L +   L - - - 
Expected rate of disease 
progression  
Rapid -  Ambulation loss 
<5 years after  
presentation 
Slower Variable 
Rapid - Ambulation 
loss <15 years after  
presentation 
Slower. Ambulation 
loss 15-40 years after 
presentation 
Estimated life expectancy 
End of 1st decade                          
Mean age of death 9.1 yrs 
Undetermined Undetermined Variable Variable 
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Table 6-5 Comparison of the features of PKAN and PLAN on investigation 
 
 
Infantile PLAN Childhood PLAN Adult PLAN Classical PKAN Atypical PKAN 
RADIOLOGICAL FEATURES      
Cerebellar Atrophy 
 
++ + - - - 
Cerebellar Gliosis 
 
++ (+) - - - 
Brain iron in globus pallidus 
 
+ ++ - 
++ 
‗Eye-of-the-tiger‘ sign 
++ 
‗Eye-of-the-tiger‘ sign 
Brain iron in substantia nigra/ subthalamic 
nuclei 
+ ++ - ++ ++ 
Cerebral White matter changes 
 
+ (Atrophy) - + (Atrophy) - - 
Optic pathway atrophy 
 
++ + - - - 
Corpus callosum  abnormal 
 
++ (+) - - - 
NEUROLOGICAL INVESTIGATION      
EEG 
Fast rhythm 
Epileptiform changes 
No fast rhythm 
Epileptiform changes 
N N N 
EMG Denervation 
Denervation               
L 
N N N 
NCS 
Distal axonal sensory 
motor neuropathy 
L 
Distal axonal sensory 
motor neuropathy 
L 
N N N 
VEP 
Delayed 
Reduced amplitude 
Delayed 
Reduced amplitude L 
N N N 
ERG N N N ++  Retinopathy +  Retinopathy 
Skin/ Sural/ Rectal Nerve Biopsy 
Axonal swelling and 
spheroid bodies 
Axonal swelling and 
spheroid bodies 
N N N 
GENETIC INVESTIGATION      
Appropriate Genetic Investigation PLA2G6 PLA2G6 PLA2G6 PANK2 PANK2 
Chapter 6                                                                         PLA2G6-associated neurodegeneration (PLAN)  
 
236 
 
6.6.5 Postulated function of PLA2G6 
PLA2G6 encodes a calcium-independent phospholipase enzyme iPLA2-VIA 
which catalyzes the hydrolysis of glycerophospholipids at the sn-2 position 
generating a free fatty acid, usually arachidonic acid and a lysophospholipid 
(Balsinde and Balboa, 2005).The iPLA2-VIA protein is active as a tetramer 
with proposed roles in phospholipids metabolism, arachidonic acid release, 
and leukotriene and prostaglandin synthesis. Levels of phosphoditylcholine, 
abundant in mammalian cell membranes and essential in maintaining cell 
membrane integrity, are regulated by the opposing actions of 
CTP:cytidylylphosphocholine transferase and iPLA2-VIA (Tanaka et al., 
2004). Defects in iPLA2-VIA could lead to a relative abundance of membrane 
phosphoditylcholine and secondary structural abnormalities. Current evidence 
also suggests that iPLA2-VIA-derived lysophosphatidylcholine may play a 
prominent role in mediating the chemoattractant and recognition/engulfment 
signals that accompany the process of apoptotic cell death. iPLA2-VIA may 
also be involved in the control of arachidonic acid levels within cells, which 
may provide important signals for the onset of apoptosis. It may also 
contribute to the effective clearance of dying cells by circulating phagocytes 
(Balsinde et al., 2006). Defects in iPLA2-VIA thus cause abnormalities in cell 
membrane structure and affect apoptosis, which may underlie the axonal 
pathology and high brain iron seen in this disorder. Recently, PLA2G6 knock-
out mouse models have been developed which display several phenotypic 
features that are evident in the human phenotype (Shinzawa et al., 2008; 
Malik et al., 2008; Wada et al., 2009). Impaired phospholipid metabolism has 
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also been implicated in the pathogenesis of the other major NBIA disorder of 
childhood, PKAN (Gregory et al., 2005, Hayflick et al., 2006). It is thus 
possible that the phenotypic overlap seen in these conditions may be 
reflective of similarities in their underlying aetiologies. 
6.6.6 Genetic features of PLAN 
As illustrated by the findings in this cohort, the majority of PLA2G6 variants 
detected in PLAN are missense mutations but insertions, deletions, nonsense 
mutations and splice site mutations are also described (Gregory et al., 2008). 
The mutations reported in the literature to date are illustrated in Figure 6-7. In 
our cohort, despite extensive investigation only one mutation was identified 
(p.Arg741Trp) in patient 5. It is possible that the other mutation may be in a 
promoter region, embedded deep within an intronic sequence or a 
heterozygous deletion which would be undetected by standard direct 
sequencing methodology. Indeed recent local collaborative work I have 
undertaken has identified pathogenic copy number variants (detected by 
MLPA, multiplex ligation-dependent probe amplification) in infantile PLAN 
(Crompton et al., 2010). It is estimated that copy number variants account for 
up to 12.5% PLA2G6 mutations in PLAN. MLPA may thus be a useful 
technique (and adjunct to direct sequencing) to detect copy number variants 
in patients who show clinical features of PLAN but in whom both disease-
causing mutations are not identified on routine sequencing. 
Analysis of this cohort is further confirmation of the current observation that 
genotype is a relatively weak predictor of phenotype. Although no definitive 
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genotype-phenotype correlations are evident, it been proposed that patients 
with two null mutations are more likely to have infantile PLAN, while 
compound heterozygotes (for two missense mutations) are more likely to 
have childhood PLAN (Gregory et al., 2009). There also appears to be an 
increased proportion of missense PLA2G6 mutations (located towards the 3‘ 
end of the coding sequence) in atypical and adult onset PLAN. The variable 
phenotypic presentation of PLAN may depend on a combination of ‗allelic 
heterogeneity‘ (i.e. type of mutation and effect on protein function) as well as 
genetic and environmental modifier effects (Hayflick, 2009). 
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Figure 6-7 
Schematic representation of PLA2G6 protein structure (adapted from Balsinde & Balboa 2005, Morgan et al., 2006) and reported PLA2G6 mutations 
(Morgan et al., 2006, Kurian et al 2008, Gregory et al 2008, Carrilho et al 2008, Paisan Ruiz et al 2009, Sina et al 2009, Wu et al 2009, Crompton et 
al 2010). The protein consists of 7 ankyrin repeats (green), a proline-rich motif (dark blue) a glycine rich nucleotide binding site (brown), a lipase 
motif (red), a putative C-terminus calcium–dependent calmodulin binding site (purple) and three proposed caspase cleavage sites (orange). Numbers 
indicate amino acids. Missense mutations are indicated above the protein and deletions, duplications, nonsense, and splice site mutations are 
indicated below the protein. Mutations described in infantile PLAN (black), childhood PLAN (light blue) and adult PLAN (red) are illustrated 
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6.7 Conclusion 
Advances in molecular genetics have contributed to increased understanding 
and definition of NBIA disorders. In this chapter, analysis of this infantile PLAN 
cohort should facilitate the future identification of patients who are most likely to 
have a PLA2G6 mutation. Careful assessment of the natural history and 
radiologic features has allowed the proposal of clinical and radiologic criteria, 
which in conjunction with molecular genetic analysis can provide early definitive 
diagnosis of this neurodegenerative disorder. 
It is thus evident that the childhood NBIA disorders PKAN and PLAN are 
becoming increasingly well defined clinical syndromes with genetic 
aetiologies. However, there are a number of patients and families with NBIA 
syndromes (who are negative for PANK2 and PLA2G6 mutations) in whom a 
genetic aetiology has not been determined. Recently at the American Society 
of Human Genetics Annual Meeting (2009) Hartig et al., presented an 
abstract describing a cohort of Polish patients with mutations in a novel NBIA 
gene on chromosome 19 (MIN) which is postulated also to have a role in 
phospholipid metabolism. Hayflick et al., have also recently identified 
mutations in a novel gene for patients with radiological features of NBIA and 
pontocerebellar atrophy (Hayflick, personal communication, 2010). Childhood 
NBIA is thus clinically and genetically heterogeneous and it is extremely likely 
that in the future, more genes accounting for a number of these NBIA 
syndromes will be identified. 
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There are currently no curative treatments for NBIA disorders and therapeutic 
strategies focus on supportive measures (such as the medical and surgical 
management of spasticity, dystonia, seizures and nutrition) to improve patient 
quality of life. In the future, a detailed knowledge of the natural history of PLAN 
may help evaluate potential therapeutic interventions. Understanding the 
mechanisms of pathogenesis may additionally contribute to our understanding 
of more common neurodegenerative disorders with iron dyshomeostasis (such 
as Parkinson and Alzheimer disease, Zecca et al., 2004) as well as providing 
targets for neuroprotection strategies in this group of neurodegenerative 
disorders. 
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Appendix 1:  
See Chapter 4.2.2.4 
Pedigree file for multipoint linkage analysis   
 
Pedigree: A 
1  0 0 2 1 0 0 0 0 0 0 0 0  
2  0 0 1 1 0  0 0 0 0 0 0 0  
3  2 1 1 1 0 0 0 0 0 0 0 0  
4  0 0 2 1 0 0 0 0 0 0 0 0  
5  2 1 2 1 0 0 0 0 0 0 0 0  
6  0 0 1 1 0 0 0 0 0 0 0 0  
7  0 0 2 1 0 0 0 0 0 0 0 0  
8  3 4 1 1 0 0 0 0 0 0 0 0  
9  3 4 1 1 0 0 0 0 0 0 0 0  
10 3 4 2 1 0 0 0 0 0 0 0 0  
11 0 0 1 1 0 0 0 0 0 0 0 0  
12 0 0 2 1 0 0 0 0 0 0 0 0  
13 6 5 1 1 0 0 0 0 0 0 0 0  
14 8 7 2 1 0 0 0 0 0 0 0 0  
15 11 10 1 1 0 0 0 0 0 0 0 0  
16 0 0 2 1 0 0 0 0 0 0 0 0  
17 13 12 1 1 3 3 1 3 1 2 2 3  
18 13 12 2 1 0 0 0 0 0 0 0 0  
19 13 12 1 1 0 0 0 0 0 0 0 0  
20 13 12 1 1 0 0 0 0 0 0 0 0  
21 15 16 1 1 0 0 0 0 0 0 0 0  
22 15 16 1 1 0 0 0 0 0 0 0 0  
23 15 16 1 1 0 0 0 0 0 0 0 0  
24 0 0 2 1 0 0 0 0 0 0 0 0  
25 15 16 2 1 0 0 0 0 0 0 0 0  
26 22 14 1 1 0 0 0 0 0 0 0 0  
27 22 14 1 1 0 0 0 0 0 0 0 0  
28 22 14 2 1 2 3 1 4 1 1 2 3  
29 23 24 1 1 1 3 1 3 1 2 2 4  
30 23 24 2 1 0 0 0 0 0 0 0 0  
31 23 24 1 1 0 0 0 0 0 0 0 0  
32 23 24 1 1 0 0 0 0 0 0 0 0  
33 22 14 2 1 2 3 1 4 1 1 2 3  
34 29 28 1 2 3 3 1 1 1 1 2 2  
35 29 28 1 1 1 3 1 3 1 2 2 4  
36 17 33 2 2 3 3 1 1 1 1 2 2  
Pedigree: B 
37 0 0 2 1 0 0 0 0 0 0 0 0  
38 0 0 1 1 0 0 0 0 0 0 0 0  
39 0 0 1 1 0 0 0 0 0 0 0 0  
40 38 37 2 1 0 0 0 0 0 0 0 0  
41 0 0 2 1 0 0 0 0 0 0 0 0  
42 38 37 1 1 0 0 0 0 0 0 0 0  
43 39 40 2 1 0 0 0 0 0 0 0 0  
44 39 40 1 1 0 0 0 0 0 0 0 0  
45 39 40 1 1 0 0 0 0 0 0 0 0  
46 39 40 2 1 0 0 0 0 0 0 0 0  
47 0 0 1 1 0 0 0 0 0 0 0 0  
48 0 0 2 1 0 0 0 0 0 0 0 0  
49 42 41 1 1 0 0 0 0 0 0 0 0  
50 42 41 1 1 0 0 0 0 0 0 0 0  
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51 42 41 1 1 0 0 0 0 0 0 0 0  
52 42 41 2 1 0 0 0 0 0 0 0 0  
53 42 41 2 1 0 0 0 0 0 0 0 0  
54 42 41 1 1 0 0 0 0 0 0 0 0  
55 42 41 2 1 0 0 0 0 0 0 0 0  
56 42 41 2 1 0 0 0 0 0 0 0 0  
57 42 41 1 1 0 0 0 0 0 0 0 0  
58 47 46 1 1 0 0 0 0 0 0 0 0  
59 47 46 2 1 2 4 3 4 1 2 1 4  
60 49 48 1 1 3 4 3 4 1 2 1 4  
61 60 59 1 1 2 4 3 4 1 2 1 4  
62 60 59 2 2 4 4 4 4 2 2 4 4  
63 60 59 1 1 3 4 3 4 1 2 1 4 
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Appendix 2:  
See Chapter 4.2.3 and 5.2.3 
Functional investigation of mutant hDAT proteins 
Functional investigation of all SLC6A3 mutations that were predicted to result 
in an expressed protein was undertaken. Mutant constructs of hDAT were 
prepared from wild-type pCIN4-hDAT (gift from Dr. Jonathan A. Javitch, 
Columbia University, NY, USA) as the template for polymerase chain 
reaction (PCR) using the QuikChange® site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) with some modifications. 50ng of DNA 
template (pCIN4-hDAT) was mixed with a primer and its complementary 
primer (100ng each), 1µl dNTP mix, 2.5µl of 10X reaction buffer, and 1.25 
units of PfuTurbo DNA polymerase in a final volume of 25µl. The PCR 
conditions were an initial denaturation cycle (1 min, 95°C); 18 cycles of 
denaturation (30 sec, 95°C), annealing (1 min, 55°C), and extension (16 min, 
68°C); a final extension cycle (10 min, 68°C ); and termination at 4°C. PCR 
products were digested with 10 units of DpnI at 37°C for 1 hr to remove the 
parental strands. The digested DNA mixture was transformed into E. coli XL-
1 blue supercompetent cells by heat shock. Mutagenesis was verified by 
DNA sequence analysis (New York University, Skirball Institute of 
Biomolecular Medicine, DNA sequencing facility). The following primers and 
their complementary primers (IDT, Inc., Coralville, IA, USA) were used: 
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Mutant Primers (5’ to 3’) 
Val158Phe TC TTT TAC AAC TTC ATC ATT GCC TG 
Leu224Pro CGG GGC GTG CTG CAC CCC CAT CAG AGC CAC GGC 
Gly327Arg GGC GTG GGA TTC AGG GTC CTG ATC GCC TTC 
Leu368Gln GTCGTGTTCAGCTTTCAGGGATACATGGCCCAG 
Pro395Leu GATCTTCATTATCTACCTTGAGGCCATCGCTACCC 
Arg521Trp CCA GCC TGT ACT GGT GGCTGT GCT GGA AGC 
Pro529Leu TGG AAG CTC GTC TCC CTC TGC TTC CTC CTG TTC 
Pro554Leu GGC GCC TAC ATC TTC CTC GAC TGG GCC AAT GCA 
Gln439X - Gly327Arg CTG ATC GAC GAA TTC TAG CTC CTG CAC CGG CAT 
 
Culturing and transient transfection of HEK-293 cells with Lipofectamine 
2000, was carried out (Zhou et al., 2007). Uptake of [3H]dopamine into hDAT 
expressing cells was measured for 5 min at 21oC (Zhou et al., 2007) with 
high sodium, low potassium, glucose and tropolone containing buffer (Chen 
et al., 2004b). Nonspecific uptake was defined by 1μM CFT. For 
measurement of cocaine analogue binding, cells were incubated with 4nM 
[3H]CFT (Perkin Elmer) for 20 min at 21oC in 200μl of the same buffer used 
for the uptake assay. For saturation analysis, increasing concentrations of 
nonradioactive CFT (0.1-100nM) were included in assay. The procedures 
were as described by Chen and Reith (2007). Non-specific binding was 
defined with 1μM CFT. The dopamine concentration producing half-maximal 
transport velocity (Km), the maximal velocity (Vmax), the equilibrium 
dissociation constant (Kd) for [3H]CFT binding, and maximal binding (Bmax), 
were estimated with nonlinear regression fitting by Radlig software (KELL 
program, Biosoft, Cambridge, UK). The equilibrium dissociation constant (Ki) 
for inhibition of [3H]CFT binding was computed with the Cheng-Prusoff 
equation (Chen and Reith, 2007) from the concentration inhibiting binding by 
50% as estimated with logistic fitting of data by the ORIGIN software 
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(OriginLab Co., Northampton, MA). Comparisons of the mutants with wild-
type DAT were performed by one-way ANOVA followed by the Dunnett 
multiple comparisons test. Statistical significance was considered at P<0.05. 
DAT surface protein preparation by biotinylation and western blotting 
Cells transiently expressing wild-type and mutant hDAT and mock cells were 
processed as described previously (Chen and Reith, 2008) with minor 
changes.  Briefly, the cells were washed with cold PBS and incubated with 
Sulfo-NHS-SS-Biotin (1mg/mL PBS) for 60 min at 4°C, followed by incubation 
with 50mM glycine in PBS for 20 min and extensive wash. The washed cells 
were lysed in Mammalian Protein Extraction Reagents supplemented with 
protein inhibitor cocktail for 10 min at 21°C followed by 60 min at 4°C with 
vortexing at 5 min intervals. The lysate samples were centrifuged at 14 000 g 
for 15 min to remove cell debris. The biotinylated proteins were separated 
with immobilized monomeric NeutrAvidin and eluted with sodium dodecyl 
sulfate-polyacryl amide gel electrophoresis (SDS-PAGE) sample buffer. The 
total lysates and biotinylated proteins were resolved on 4%–12% Bis-tris 
NuPAGE gels (Invitrogen, Carlsbad, CA). DAT was probed with polyclonal 
anti-DAT antibody (0.3μg/mL) against the C-terminus of DAT (Millipore, 
Billerica, MA) followed by HRP-conjugated goat anti-rabbit antibody. 
Polyclonal anti--actin antibody (Sigma, St. Louis, MO) was used as an 
internal control for loading. The transporter signal was visualized with 
SuperSignal West Dura Extended Duration chemiluminescence substrate 
solution (Thermo Scientific, Rockford, IL).  
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Appendix 3:  
See Chapter 4.3.2.2 
Microsatellite marker analysis and exclusion of potential IPD loci on chromosome 7, 9 and 14 in family A  
 
Chromosome 
Region on SNP(bp) 
Marker Start physical 
Position (bp) 
End physical 
Position (bp) 
VI:3 
 
 VI:5  VII:1  VII:2  VI:4  IV:4  VII:3 
 
Chromosome 7 D7S817 32 102921 32 403079 
172 172 164 172 164 172 172 172 172 172 172 172 172 172 
32 000929 – D7S2211 33 602237 33 602615 
371 385 379 385 379 385 385 385 370 384 370 370 370 370 
34 201718 D7S2758 33 611477 33 611617 
138 138 138 138 138 138 138 138 138 138 138 138 138 138 
Chromosome 7 D7S678 43 247692 43 247865 
163 173 163 173 163 173 163 163 163 171 163 171 163 163 
42 521005- D7S2436 44 686503 44 686764 
262 262 262 262 262 262 262 262 262 262 262 262 262 262 
48 537723 D7S519 46 082558 46 082813 
265 276 265 267 265 267 265 265 265 276 265 276 265 265 
 D7S2561 47 359975 47 360192 
214 214 214 214 214 214 214 214 210 214 214 214 214 214 
Chromosome 9 D9S1817 33 849625 33 849887 
283 285 283 297 283 297 283 297 285 294 283 285 285 285 
(Spans centromere) D9S1791 36 383383 36 383557 
168 180 168 180 168 180 168 180 168 168 168 177 168 168 
32 229114 – D9S1874 37 212295 37 212493 
192 196 192 196 192 196 192 196 192 192 192 194 192 192 
73 854511 D9S2148 38 285718 38 285887 
149 166 149 166 149 166 149 166 149 153 153 166 153 153 
 D9S273 71 729255 71 729401 
216 220 210 216 210 216 210 216 212 216 210 212 212 212 
 D9S301 72 992540 72 992774 
206 231 206 206 206 206 206 206 219 231 227 231 231 231 
Chromosome 14 D14S1280 25 725631 25 725926 
289 295 291 295 291 295 295 295 287 294 287 298 287 287 
 D14S275 25 766620 25 766814 
155 157 151 157 151 157 157 157 149 155 151 155 155 155 
25 377656 – D14S608 27 919195 27 919400 
200 200 200 200 200 200 200 200 200 229 200 229 229 229 
36 301274 D14S70 33 528945 33 529156 
104 104 104 110 104 110 104 104 104 106 104 106 106 106 
 D14S599 33 723548 33 723631 
112 112 112 112 112 112 112 112 109 112 109 112 109 109 
